Publications

Journals

• Marin D; Ibrahim AR; Lucas C; Gerrard G; Wang L; Szydlo RM; Clark RE; Apperley JF; et alMilojkovic D; Bua M; Pavlu J; Paliompeis C; Reid A; Rezvani K; Goldman JM; Foroni L. (20 Jan 2012). Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. JOURNAL OF CLINICAL ONCOLOGY. 30:232-238. Author weblink DOI.
• Gerrard G; Mudge K; Foskett P; Stevens D; Alikian M; White HE; Cross NC; Apperley J; et alForoni L. (30 Mar 2012). Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: Innovation, automation, and harmonization. Am J Hematol. DOI.
• Neelakantan P; Marin D; Laffan M; Goldman J; Apperley J; Milojkovic D. (24 Apr 2012). Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy. Haematologica. DOI.
• Worel N; Apperley JF; Basak GW; Douglas KW; Gabriel IH; Geraldes C; Hübel K; Jaksic O; et alKoristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Duarte RF; Mohty M. (13 Mar 2012). European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization. Transfusion. DOI.
• Chaidos A; Patterson S; Szydlo R; Chaudhry MS; Dazzi F; Kanfer E; Macdonald D; Marin D; et alMilojkovic D; Pavlu J; Davis J; Rahemtulla A; Rezvani K; Goldman J; Roberts I; Apperley J; Karadimitris A. (27 Feb 2012). Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood. DOI.
• Alikian M; Gerrard G; Subramanian PG; Mudge K; Foskett P; Khorashad JS; Lim AC; Marin D; et alMilojkovic D; Reid A; Rezvani K; Goldman J; Apperley J; Foroni L. (Mar 2012). BCR-ABL1 kinase domain mutations: methodology and clinical evaluation. Am J Hematol. 87:298-304. DOI.
• Milojkovic D; Apperley JF; Gerrard G; Ibrahim AR; Szydlo R; Bua M; Reid A; Rezvani K; et alForoni L; Goldman J; Marin D. (23 Feb 2012). Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood. 119:1838-1843. DOI.
• Milojkovic D; Ibrahim A; Reid A; Foroni L; Apperley J; Marin D. (Mar 2012). Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation. Haematologica. 97:473-474. DOI.
• Hübel K; Fresen MM; Apperley JF; Basak GW; Douglas KW; Gabriel IH; Geraldes C; Jaksic O; et alKoristek Z; Kröger N; Lanza F; Lemoli RM; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF. (14 Nov 2011). European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant. DOI.
• le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; et alBaccarani M; Cortes J; Kantarjian HM. (11 Nov 2011). Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. DOI.
• Marin D; Ibrahim AR; Lucas C; Gerrard G; Wang L; Szydlo RM; Clark RE; Apperley JF; et alMilojkovic D; Bua M; Pavlu J; Paliompeis C; Reid A; Rezvani K; Goldman JM; Foroni L. (20 Jan 2012). Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 30:232-238. DOI.
• Auner HW; Pavlu J; Szydlo R; Giles C; Kanfer E; Macdonald D; Marin D; Milojkovic D; et alRezvani K; Goldman JM; Apperley JF; Landgren O; Rahemtulla A. (3 Nov 2011). Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. Br J Haematol. DOI.
• Malard F; Kröger N; Gabriel IH; Hübel K; Apperley JF; Basak GW; Douglas KW; Geraldes C; et alJaksic O; Koristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF. (Feb 2012). Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol Blood Marrow Transplant. 18:314-317. DOI.
• Basak GW; Wiktor-Jedrzejczak W; Apperley JF; Douglas KW; Gabriel IH; Geraldes C; Hübel K; Jaksic O; et alKoristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF. (10 Oct 2011). Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. Bone Marrow Transplant. DOI.
• Nicolini FE; Basak GW; Soverini S; Martinelli G; Mauro MJ; Müller MC; Hochhaus A; Chuah C; et alDufva IH; Rege-Cambrin G; Saglio G; Michallet M; Labussière H; Morisset S; Hayette S; Etienne G; Olavarria E; Zhou W; Peter S; Apperley JF; Cortes J. (17 Nov 2011). Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 118:5697-5700. DOI.
• Dignan FL; Greenblatt D; Cox M; Cavenagh J; Oakervee H; Apperley JF; Fielding AK; Pagliuca A; et alMufti G; Raj K; Marks DI; Amrolia P; Peniket A; Medd P; Potter MN; Shaw BE; Scarisbrick JJ. (19 Sep 2011). Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. Bone Marrow Transplant. DOI.
• Ibrahim AR; Clark RE; Holyoake TL; Byrne J; Shepherd P; Apperley JF; Milojkovic D; Szydlo R; et alGoldman J; Marin D. (Dec 2011). Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica. 96:1779-1782. DOI.
• Marin D; Gabriel IH; Ahmad S; Foroni L; de Lavallade H; Clark R; O'Brien S; Sergeant R; et alHedgley C; Milojkovic D; Khorashad JS; Bua M; Alsuliman A; Khoder A; Stringaris K; Cooper N; Davis J; Goldman JM; Apperley JF; Rezvani K. (Feb 2012). KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia. 26:296-302. DOI.
• Pavlu J; Auner HW; Ellis S; Szydlo RM; Giles C; Contento A; Rahemtulla A; Apperley JF; et alNaresh K; MacDonald DH; Kanfer EJ. (1 Jun 2011). LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre. HEMATOLOGICAL ONCOLOGY. 29:75-80. DOI.
• Babb A; Farah N; Lyons C; Lindsay K; Reddy N; Goldman J; Apperley JF; Salooja N. (Apr 2012). Uptake and outcome of assisted reproductive techniques in long-term survivors of SCT. Bone Marrow Transplant. 47:568-573. DOI.
• Rezvani K; Kanfer EJ; Marin D; Gabriel I; Rahemtulla A; Taylor A; Macdonald D; Dazzi F; et alMilojkovic D; Foroni L; Pavlu J; Sargent J; Le Dieu R; Goldman JM; Apperley J; Szydlo R. (Feb 2012). EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure. Biol Blood Marrow Transplant. 18:235-240. DOI.
• Ibrahim AR; Eliasson L; Apperley JF; Milojkovic D; Bua M; Szydlo R; Mahon F-X; Kozlowski K; et alPaliompeis C; Foroni L; Khorashad JS; Bazeos A; Molimard M; Reid A; Rezvani K; Gerrard G; Goldman J; Marin D. (7 Apr 2011). Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. BLOOD. 117:3733-3736. Author weblink DOI.
• Gratwohl A; Brand R; Niederwieser D; Baldomero H; Chabannon C; Cornelissen J; de Witte T; Ljungman P; et alMcDonald F; McGrath E; Passweg J; Peters C; Rocha V; Slaper-Cortenbach I; Sureda A; Tichelli A; Apperley J. (20 May 2011). Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol. 29:1980-1986. DOI.
• Auner HW; Mazzarella L; Cook L; Szydlo R; Saltarelli F; Pavlu J; Bua M; Giles C; et alApperley JF; Rahemtulla A. (1 Mar 2011). High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma. BONE MARROW TRANSPLANTATION. 46:364-367. Author weblink DOI.
• de Lavallade H; Garland P; Sekine T; Hoschler K; Marin D; Stringaris K; Loucaides E; Howe K; et alSzydlo R; Kanfer E; Macdonald D; Kelleher P; Cooper N; Khoder A; Gabriel IH; Milojkovic D; Pavlu J; Goldman JM; Apperley JF; Rezvani K. (1 Feb 2011). Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. 96:307-314. DOI.
• PATTERSON J; PRENTICE HG; GILMORE M; BLACKLOCK H; BRENNER MK; JANOSSY G; SKEGGS D; IVORY K; et alHOFFBRAND AV; APPERLEY J; GOLDMAN J; BURNETT A; GRIBBEN J; ALCORN M; PEARSON C; MCVICKERS I; HANN I; REID C; WARDLE D; BACIGALUPO A; ROBERTSON AG. (1 Jan 1985). ANALYSIS OF REJECTION IN HLA MATCHED T-DEPLETED BONE-MARROW TRANSPLANTS. EXPERIMENTAL HEMATOLOGY. 13:117-117.
• HOWS J; APPERLEY J; YIN J; HALE G; WALDMAN H; GOLDMAN J; GORDONSMITH E. (1 Jan 1985). T-CELL DEPLETION WITH CAMPATH-1 TO PREVENT GVHD. EXPERIMENTAL HEMATOLOGY. 13:114-114.
• Shaw BE; Apperley JF; Russell NH; Craddock C; Liakopoulou E; Potter MN; Wynn R; Gibson B; et alPearce RM; Kirkland K; Lee J; Madrigal JA; Cook G; Byrne JL. (Apr 2011). Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. Br J Haematol. 153:244-252. DOI.
• Chabannon C; Pamphilon D; Vermylen C; Gratwohl A; Niederwieser D; McGrath E; Lamers C; Lanza F; et alSlaper-Cortenbach I; Madrigal A; Apperley J. (Jan 2012). Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical outcome is improved when hematopoietic SCT is performed in a JACIE accredited program. Bone Marrow Transplant. 47:15-17. DOI.
• Chabannon C; Pamphilon D; Vermylen C; Gratwohl A; Niederwieser D; McGrath E; Lamers C; Lanza F; et alSlaper-Cortenbach I; Madrigal A; Apperley J. (Jul 2011). JACIE celebrates its 10-year anniversary with the demonstration of improved clinical outcome. Cytotherapy. 13:765-766. DOI.
• Schwarb H; May PC; Apperley J; Naresh KN. (Feb 2011). Bone marrow trephine biopsy findings in B acute lymphoblastic leukaemia of early precursor (Pro-B) subtype. Am J Hematol. 86:195-196. DOI.
• Garland P; Apperley J. (Feb 2011). Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia. Future Oncol. 7:201-218. DOI.
• Gratwohl A; Baldomero H; Schwendener A; Gratwohl M; Apperley J; Frauendorfer K; Niederwieser D. (Feb 2011). The EBMT activity survey 2008: impact of team size, team density and new trends. Bone Marrow Transplant. 46:174-191. DOI.
• Loren AW; Chow E; Jacobsohn DA; Gilleece M; Halter J; Joshi S; Wang Z; Sobocinski KA; et alGupta V; Hale GA; Marks DI; Stadtmauer EA; Apperley J; Cahn JY; Schouten HC; Lazarus HM; Savani BN; McCarthy PL; Jakubowski AA; Kamani NR; Hayes-Lattin B; Maziarz RT; Warwick AB; Sorror ML; Bolwell BJ; Socié G; Wingard JR; Rizzo JD; Majhail NS. (Feb 2011). Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 17:157-166. DOI.
• Hehlmann R; Grimwade D; Simonsson B; Apperley J; Baccarani M; Barbui T; Barosi G; Bassan R; et alBéné MC; Berger U; Büchner T; Burnett A; Cross NC; de Witte TJ; Döhner H; Dombret H; Einsele H; Engelich G; Foà R; Fonatsch C; Gökbuget N; Gluckman E; Gratwohl A; Guilhot F; Haferlach C; Haferlach T; Hallek M; Hasford J; Hochhaus A; Hoelzer D; Kiladjian JJ; Labar B; Ljungman P; Mansmann U; Niederwieser D; Ossenkoppele G; Ribera JM; Rieder H; Serve H; Schrotz-King P; Sanz MA; Saussele S; European LeukemiaNet. (Jan 2011). The European LeukemiaNet: achievements and perspectives. Haematologica. 96:156-162. DOI.
• Gerrard G; Mudge K; Stewart R; Foskett P; Stevens D; Khorashad JS; Szydlo R; Rezvani K; et alMarin D; Reid A; Apperley J; Goldman J; Foroni L. (Mar 2011). Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignancies. Am J Hematol. 86:313-315. DOI.
• Morris C; Drake M; Apperley J; Iacobelli S; van Biezen A; Bjorkstrand B; Goldschmidt H; Harousseau JL; et alMorgan G; de Witte T; Niederwieser D; Gahrton G; Myeloma Subcommittee of Chronic Leukaemia Working Party of EBMT. (Dec 2010). Efficacy and outcome of autologous transplantation in rare myelomas. Haematologica. 95:2126-2133. DOI.
• Apperley JF. (Jan 2011). Regulation of donor participation in research studies: is there another way?. Bone Marrow Transplant. 46:15-16. DOI.
• Stewart WA; Pearce R; Kirkland KE; Bloor A; Thomson K; Apperley J; McQuaker G; Marks DI; et alCraddock C; McCann S; Russell N; Cook G; Kottaridis PD; British Society for Blood and Marrow Transplantation. (Nov 2010). The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant. 45:1587-1593. DOI.
• de Lavallade H; Garland P; Sekine T; Hoschler K; Marin D; Stringaris K; Loucaides E; Howe K; et alSzydlo R; Kanfer E; Macdonald D; Kelleher P; Cooper N; Khoder A; Gabriel IH; Milojkovic D; Pavlu J; Goldman JM; Apperley JF; Rezvani K. (Feb 2011). Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 96:307-314. DOI.
• Pavlu J; Szydlo RM; Goldman JM; Apperley JF. (20 Jan 2011). Three decades of transplantation for chronic myeloid leukemia: what have we learned?. Blood. 117:755-763. DOI.
• Szydlo RM; Gabriel I; Olavarria E; Apperley J. (Oct 2010). Sign of the Zodiac as a predictor of survival for recipients of an allogeneic stem cell transplant for chronic myeloid leukaemia (CML): an artificial association. Transplant Proc. 42:3312-3315. DOI.
• Daghistani M; Marin D; Khorashad JS; Wang L; May PC; Paliompeis C; Milojkovic D; De Melo VA; et alGerrard G; Goldman JM; Apperley JF; Clark RE; Foroni L; Reid AG. (23 Dec 2010). EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. Blood. 116:6014-6017. DOI.
• Ibrahim AR; Paliompeis C; Bua M; Milojkovic D; Szydlo R; Khorashad JS; Foroni L; Reid A; et alde Lavallade H; Rezvani K; Dazzi F; Apperley JF; Goldman JM; Marin D. (16 Dec 2010). Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 116:5497-5500. DOI.
• Kuwabara A; Babb A; Ibrahim A; Milojkovic D; Apperley J; Bua M; Reid A; Foroni L; et alRezvani K; Goldman J; Marin D. (12 Aug 2010). Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood. 116:1014-1016. DOI.
• Garland P; de Lavallade H; Sekine T; Hoschler K; Sriskandan S; Patel P; Brett S; Stringaris K; et alLoucaides E; Howe K; Marin D; Kanfer E; Cooper N; Macdonald D; Rahemtulla A; Atkins M; Danga A; Milojkovic D; Gabriel I; Khoder A; Alsuliman A; Apperley J; Rezvani K. (May 2011). Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation. Biol Blood Marrow Transplant. 17:632-639. DOI.
• Pavlů J; Auner HW; Ellis S; Szydlo RM; Giles C; Contento A; Rahemtulla A; Apperley JF; et alNaresh K; MacDonald DH; Kanfer EJ. (Jun 2011). LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre. Hematol Oncol. 29:75-80. DOI.
• Auner HW; Mazzarella L; Cook L; Szydlo R; Saltarelli F; Pavlu J; Bua M; Giles C; et alApperley JF; Rahemtulla A. (Mar 2011). High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma. Bone Marrow Transplant. 46:364-367. DOI.
• Gabriel IH; Sergeant R; Szydlo R; Apperley JF; DeLavallade H; Alsuliman A; Khoder A; Marin D; et alKanfer E; Cooper N; Davis J; MacDonald D; Bua M; Foroni L; Giles C; Milojkovic D; Rahemtulla A; Rezvani K. (23 Sep 2010). Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood. 116:2033-2039. DOI.
• Frewer LJ; Coles D; van der Lans IA; Schroeder D; Champion K; Apperley JF. (Mar 2011). Impact of the European clinical trials directive on prospective academic clinical trials associated with BMT. Bone Marrow Transplant. 46:443-447. DOI.
• Apperley JF. (Jun 2010). Hematology. Imatinib--should we have more of a good thing?. Nat Rev Clin Oncol. 7:303-304. DOI.
• Shaughnessy PJ; Bolwell BJ; van Besien K; Mistrik M; Grigg A; Dodds A; Prince HM; Durrant S; et alIlhan O; Parenti D; Gallo J; Foss F; Apperley J; Zhang MJ; Horowitz MM; Abhyankar S. (Jun 2010). Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 45:1068-1076. DOI.
• Sobrinho-Simões M; Wilczek V; Score J; Cross NC; Apperley JF; Melo JV. (26 Aug 2010). In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood. 116:1329-1335. DOI.
• Bazeos A; Marin D; Reid AG; Gerrard G; Milojkovic D; May PC; de Lavallade H; Garland P; et alRezvani K; Apperley JF; Goldman JM; Foroni L; Khorashad JS. (Jun 2010). hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia. 24:1243-1245. DOI.
• Drake MB; Iacobelli S; van Biezen A; Morris C; Apperley JF; Niederwieser D; Björkstrand B; Gahrton G; et alEuropean Group for Blood and Marrow Transplantation and the European Leukemia Net. (May 2010). Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica. 95:804-809. DOI.
• Drake MB; Iacobelli S; van Biezen A; Morris C; Apperley JF; Niederwieser D; Bjorkstrand B; Gahrton G. (1 May 2010). Primary plasma cell leukemia and autologous stem cell transplantation. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. 95:804-809. DOI.
• Marin D; Bazeos A; Mahon FX; Eliasson L; Milojkovic D; Bua M; Apperley JF; Szydlo R; et alDesai R; Kozlowski K; Paliompeis C; Latham V; Foroni L; Molimard M; Reid A; Rezvani K; de Lavallade H; Guallar C; Goldman J; Khorashad JS. (10 May 2010). Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 28:2381-2388. DOI.
• Gratwohl A; Schwendener A; Baldomero H; Gratwohl M; Apperley J; Niederwieser D; Frauendorfer K. (Apr 2010). Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology. Haematologica. 95:637-643. DOI.
• Cordonnier C; Labopin M; Chesnel V; Ribaud P; Camara RDEL; Martino R; Ullmann AJ; Parkkali T; et alLocasciulli A; Yakouben K; Pauksens K; Bonnet E; Einsele H; Niederwieser D; Apperley J; Ljungman P. (24 Mar 2010). Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine. 28:2730-2734. DOI.
• Pavlů J; Kew AK; Taylor-Roberts B; Auner HW; Marin D; Olavarria E; Kanfer EJ; MacDonald DH; et alMilojkovic D; Rahemtulla A; Rezvani K; Goldman JM; Apperley JF; Szydlo RM. (20 May 2010). Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood. 115:4018-4020. DOI.
• Dickinson AM; Pearce KF; Norden J; O'Brien SG; Holler E; Bickeböller H; Balavarca Y; Rocha V; et alKolb HJ; Hromadnikova I; Sedlacek P; Niederwieser D; Brand R; Ruutu T; Apperley J; Szydlo R; Goulmy E; Siegert W; de Witte T; Gratwohl A. (Jun 2010). Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia. Haematologica. 95:922-927. DOI.
• Hidalgo-Curtis C; Apperley JF; Stark A; Jeng M; Gotlib J; Chase A; Cross NCP; Grand FH. (1 Mar 2010). Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms (vol 148, pg 268, 2010). BRITISH JOURNAL OF HAEMATOLOGY. 148:964-964. DOI.
• Vianello F; Villanova F; Tisato V; Lymperi S; Ho KK; Gomes AR; Marin D; Bonnet D; et alApperley J; Lam EW; Dazzi F. (Jul 2010). Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica. 95:1081-1089. DOI.
• Clare S; Mank A; Stone R; Davies M; Potting C; Apperley JF; Research Sub-committee of the EBMT Nurses Group. (Jan 2010). Management of related donor care: a European survey. Bone Marrow Transplant. 45:97-101. DOI.
• Shaw BE; Mayor NP; Russell NH; Apperley JF; Clark RE; Cornish J; Darbyshire P; Ethell ME; et alGoldman JM; Little AM; Mackinnon S; Marks DI; Pagliuca A; Thomson K; Marsh SG; Madrigal JA. (Jan 2010). Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia. 24:58-65. DOI.
• Hidalgo-Curtis C; Apperley JF; Stark A; Jeng M; Gotlib J; Chase A; Cross NCP; Grand FH. (1 Jan 2010). Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms. BRITISH JOURNAL OF HAEMATOLOGY. 148:268-273. Author weblink DOI.
• Mohty M; Apperley JF. (2010). Long-term physiological side effects after allogeneic bone marrow transplantation. Hematology Am Soc Hematol Educ Program. 2010:229-236. DOI.
• Frewer LJ; Coles D; Champion K; Demotes-Mainard J; Goetbuget N; Ihrig K; Klingmann I; Kubiak C; et alLejeune SA; McDonald F; Apperley J. (2010). Has the European Clinical Trials Directive been a success?. BMJ. 340:c1862.
• Nicolini FE; Mauro MJ; Martinelli G; Kim DW; Soverini S; Müller MC; Hochhaus A; Cortes J; et alChuah C; Dufva IH; Apperley JF; Yagasaki F; Pearson JD; Peter S; Sanz Rodriguez C; Preudhomme C; Giles F; Goldman JM; Zhou W. (17 Dec 2009). Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 114:5271-5278. DOI.
• Milojkovic D; Apperley J. (15 Dec 2009). Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia. Clin Cancer Res. 15:7519-7527. DOI.
• Baccarani M; Cortes J; Pane F; Niederwieser D; Saglio G; Apperley J; Cervantes F; Deininger M; et alGratwohl A; Guilhot F; Hochhaus A; Horowitz M; Hughes T; Kantarjian H; Larson R; Radich J; Simonsson B; Silver RT; Goldman J; Hehlmann R; European LeukemiaNet. (10 Dec 2009). Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 27:6041-6051. DOI.
• Bacigalupo A; Ballen K; Rizzo D; Giralt S; Lazarus H; Ho V; Apperley J; Slavin S; et alPasquini M; Sandmaier BM; Barrett J; Blaise D; Lowski R; Horowitz M. (Dec 2009). Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 15:1628-1633. DOI.
• Apperley J. (Nov 2009). Issues of imatinib and pregnancy outcome. J Natl Compr Canc Netw. 7:1050-1058.
• de Lavallade H; Finetti P; Carbuccia N; Khorashad JS; Charbonnier A; Foroni L; Apperley JF; Vey N; et alBertucci F; Birnbaum D; Mozziconacci MJ. (Feb 2010). A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leuk Res. 34:254-257. DOI.
• Gratwohl A; Stern M; Brand R; Apperley J; Baldomero H; de Witte T; Dini G; Rocha V; et alPassweg J; Sureda A; Tichelli A; Niederwieser D; European Group for Blood and Marrow Transplantation and the European Leukemia Net. (15 Oct 2009). Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 115:4715-4726. DOI.
• Milojkovic D; Nicholson E; Apperley JF; Holyoake TL; Shepherd P; Drummond MW; Szydlo R; Bua M; et alForoni L; Reid A; Khorashad JS; de Lavallade H; Rezvani K; Paliompeis C; Goldman JM; Marin D. (Feb 2010). Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 95:224-231. DOI.
• Uprichard J; Dazzi F; Apperley JF; Laffan MA. (1 Jan 2010). Haemopoietic stem cell transplantation induces tolerance to donor antigens but not to foreign FVIII peptides. HAEMOPHILIA. 16:143-147. Author weblink DOI.
• Apperley J. (Sep 2009). CML in pregnancy and childhood. Best Pract Res Clin Haematol. 22:455-474. DOI.
• Apperley JF; Cortes JE; Kim DW; Roy L; Roboz GJ; Rosti G; Bullorsky EO; Abruzzese E; et alHochhaus A; Heim D; de Souza CA; Larson RA; Lipton JH; Khoury HJ; Kim HJ; Sillaber C; Hughes TP; Erben P; Van Tornout J; Stone RM. (20 Jul 2009). Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol. 27:3472-3479. DOI.
• Khorashad JS; Wagner S; Greener L; Marin D; Reid A; Milojkovic D; Patel H; Willimott S; et alRezvani K; Gerrard G; Loaiza S; Davis J; Goldman J; Melo J; Apperley J; Foroni L. (Jun 2009). The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib. Haematologica. 94:861-864. DOI.
• Cordonnier C; Labopin M; Chesnel V; Ribaud P; De La Camara R; Martino R; Ullmann AJ; Parkkali T; et alLocasciulli A; Yakouben K; Pauksens K; Einsele H; Niederwieser D; Apperley J; Ljungman P; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. (15 May 2009). Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis. 48:1392-1401. DOI.
• Ciceri F; Bonini C; Stanghellini MTL; Bondanza A; Traversari C; Salomoni M; Turchetto L; Colombi S; et alBernardi M; Peccatori J; Pescarollo A; Servida P; Magnani Z; Perna SK; Valtolina V; Crippa F; Callegaro L; Spoldi E; Crocchiolo R; Fleischhauer K; Ponzoni M; Vago L; Rossini S; Santoro A; Todisco E; Apperley J; Olavarria E; Slavin S; Weissinger EM; Ganser A; Stadler M; Yannaki E; Fassas A; Anagnostopoulos A; Bregni M; Stampino CG; Bruzzi P; Bordignon C. (1 May 2009). Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. LANCET ONCOLOGY. 10:489-500. Author weblink DOI.
• Marin D; Khorashad JS; Foroni L; Milojkovic D; Szydlo R; Reid AG; Rezvani K; Bua M; et alGoldman JM; Apperley JF. (May 2009). Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?. Br J Haematol. 145:373-375. DOI.
• Flowers MED; Apperley JF; van BK; Elmaagacli A; Grigg A; Reddy V; Bacigalupo A; Kolb HJ; et alBouzas L; Michallet M; Prince HM; Knobler R; Parenti D; Gallo J; Greinix HT. (30 Apr 2009). A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease (vol 112, pg 2667, 2008). BLOOD. 113:4478-4478. Author weblink.
• Reid AG; De Melo VA; Elderfield K; Clark I; Marin D; Apperley J; Naresh KN. (Mar 2009). Phenotype of blasts in chronic myeloid leukemia in blastic phase-Analysis of bone marrow trephine biopsies and correlation with cytogenetics. Leuk Res. 33:418-425. DOI.
• Auner HW; Giles C; Pavlu J; Macdonald D; Kanfer E; Olavarria E; Apperley J; Rahemtulla A. (1 Feb 2009). Ethnicity and Myeloma: Experience of a Large UK Stem Cell Transplantation Center. CLINICAL LYMPHOMA & MYELOMA. 9:S84-S84. Author weblink.
• Morris T; Drake MB; Apperley JF; Iaccobelli S; Niederwieser D; van Biezen A; Bjorkstrand B; Gahrton G. (1 Feb 2009). Efficacy and Outcome of Autologous Transplantation in Rare Myelomas. CLINICAL LYMPHOMA & MYELOMA. 9:S27-S28. Author weblink.
• Walz C; Score J; Mix J; Cilloni D; Roche-Lestienne C; Yeh RF; Wiemels JL; Ottaviani E; et alErben P; Hochhaus A; Baccarani M; Grimwade D; Preudhomme C; Apperley J; Martinelli G; Saglio G; Cross NC; Reiter A; European LeukemiaNet. (Feb 2009). The molecular anatomy of the FIP1L1-PDGFRA fusion gene. Leukemia. 23:271-278. DOI.
• Gratwohl A; Baldomero H; Schwendener A; Rocha V; Apperley J; Frauendorfer K; Niederwieser D; Joint Accreditation Committee of the International Society for Cellular Therapy; et alEuropean Group for Blood and Marrow Transplantation. (Feb 2009). The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant. 43:275-291. DOI.
• Halter J; Kodera Y; Ispizua AU; Greinix HT; Schmitz N; Favre G; Baldomero H; Niederwieser D; et alApperley JF; Gratwohl A. (Jan 2009). Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica. 94:94-101. DOI.
• Pamphilon D; Apperley JF; Samson D; Slaper-Cortenbach I; McGrath E. (2009). JACIE accreditation in 2008: demonstrating excellence in stem cell transplantation. Hematol Oncol Stem Cell Ther. 2:311-319.
• Shaw BE; Mufti GJ; Mackinnon S; Cavenagh JD; Pearce RM; Towlson KE; Apperley JF; Chakraverty R; et alCraddock CF; Kazmi MA; Littlewood TJ; Milligan DW; Pagliuca A; Thomson KJ; Marks DI; Russell NH. (1 Dec 2008). Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. BONE MARROW TRANSPLANTATION. 42:783-789. Author weblink DOI.
• Marin D; Milojkovic D; Olavarria E; Khorashad JS; de lavallade H; Reid AG; Foroni L; Rezvani K; et alBua M; Dazzi F; Pavlu J; Klammer M; Kaeda JS; Goldman JM; Apperley JF. (1 Dec 2008). European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. BLOOD. 112:4437-4444. Author weblink DOI.
• Iacobelli S; Apperley J; Morris C. (Nov 2008). Assessment of the role of timing of second transplantation in multiple myeloma by multistate modeling. Exp Hematol. 36:1567-1571. DOI.
• Khorashad JS; de Lavallade H; Apperley JF; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; et alKaeda J; Goldman JM; Marin D. (10 Oct 2008). Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol. 26:4806-4813. DOI.
• Flowers ME; Apperley JF; van Besien K; Elmaagacli A; Grigg A; Reddy V; Bacigalupo A; Kolb HJ; et alBouzas L; Michallet M; Prince HM; Knobler R; Parenti D; Gallo J; Greinix HT. (1 Oct 2008). A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 112:2667-2674. DOI.
• Khorashad JS; De Melo VA; Fiegler H; Gerrard G; Marin D; Apperley JF; Goldman JM; Foroni L; et alReid AG. (1 Sep 2008). Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis. LEUKEMIA. 22:1806-1807. Author weblink DOI.
• Mohty M; Szydlo RM; Yong ASM; Apperley JF; Goldman JM; Melo JV. (1 Sep 2008). Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. BLOOD. 112:2163-2166. Author weblink DOI.
• Gabriel I; Chaidos A; Sorouri J; Dannie E; Davis J; Goldman J; Apperley J; Marin D. (Aug 2008). Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib. Leukemia. 22:1618-1619. DOI.
• Pai M; Zacharoulis D; Milicevic MN; Helmy S; Jiao LR; Levicar N; Tait P; Scott M; et alMarley SB; Jestice K; Glibetic M; Bansi D; Khan SA; Kyriakou D; Rountas C; Thillainayagam A; Nicholls JP; Jensen S; Apperley JF; Gordon MY; Habib NA. (Aug 2008). Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol. 103:1952-1958. DOI.
• de Lavallade H; Apperley JF; Khorashad JS; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; et alKaeda J; Goldman JM; Marin D. (10 Jul 2008). Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 26:3358-3363. DOI.
• Khorashad JS; Thelwell N; Milojkovic D; Marin D; Watson JA; Goldman JM; Apperley JF; Foroni L; et alReid AG. (1 Jul 2008). A new rapid and sensitive assay for detecting the T3151 BCR-ABL kinase domain mutation in chronic myeloid leukaemia. JOURNAL OF CLINICAL PATHOLOGY. 61:863-865. Author weblink DOI.
• Pye SM; Cortes J; Ault P; Hatfield A; Kantarjian H; Pilot R; Rosti G; Apperley JF. (15 Jun 2008). The effects of imatinib on pregnancy outcome. BLOOD. 111:5505-5508. Author weblink DOI.
• Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; et alCervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM. (Jun 2008). Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 22:1200-1206. DOI.
• de Lavallade H; Punnialingam S; Milojkovic D; Bua M; Khorashad JS; Gabriel IH; Chaidos A; Olavarria E; et alGoldman JM; Apperley JF; Marin D. (May 2008). Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 141:745-747. DOI.
• Abusedra A; Joshi R; Bybee A; Apperley JF; Wagner SD. (May 2008). V lambda genes in chronic lymphocytic leukaemia: highly skewed V gene segment usage with similar CDR3 sequences. Leukemia. 22:1073-1075. DOI.
• Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; et alHarlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG; Imatinib Target Exploration Consortium Study B2225. (1 May 2008). Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 14:2717-2725. DOI.
• De Melo VA; Milojkovic D; Marin D; Apperley JF; Nacheva EP; Reid AG. (15 Apr 2008). Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements. Cancer Genet Cytogenet. 182:111-115. DOI.
• Gratwohl A; Baldomero H; Frauendorfer K; Rocha V; Apperley J; Niederwieser D; Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT); European Group for Blood and Marrow Transplantation EBMT (JACIE). (Apr 2008). The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. Bone Marrow Transplant. 41:687-705. DOI.
• Gabriel I; Apperley J; Bower M; Chaidos A; Gazzard B; Giles C; Kew A; Nelson M; et alKanfer E. (19 Feb 2008). A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVBHIV-associated Hodgkins disease. AIDS. 22:539-540. Author weblink.
• Khorashad JS; Milojkovic D; Mehta P; Anand M; Ghorashian S; Reid AG; De Melo V; Babb A; et alde lavallade H; Olavarria E; Marin D; Goldman JM; Apperley JF; Kaeda JS. (15 Feb 2008). In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. BLOOD. 111:2378-2381. Author weblink DOI.
• le Coutre P; Ottmann OG; Giles F; Kim DW; Cortes J; Gattermann N; Apperley JF; Larson RA; et alAbruzzese E; O'Brien SG; Kuliczkowski K; Hochhaus A; Mahon FX; Saglio G; Gobbi M; Kwong YL; Baccarani M; Hughes T; Martinelli G; Radich JP; Zheng M; Shou Y; Kantarjian H. (15 Feb 2008). Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 111:1834-1839. DOI.
• De Melo V; Vetter M; Mazzullo H; Howard JD; Betts DR; Nacheva EP; Apperley JF; Reid AG. (13 Sep 2007). A simple FISH assay for the detection of 3q26 rearrangements in myeloid malignancy. Leukemia. Publisher weblink.
• Levicar N; Pai M; Habib NA; Tait P; Jiao LR; Marley SB; Davis J; Dazzi F; et alSmadja C; Jensen SL; Nicholls JP; Apperley JF; Gordon MY. (Feb 2008). Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+ cells in patients with chronic liver disease. Cell Prolif. 41 Suppl 1:115-125. DOI.
• Virgili A; Brazma D; Reid AG; Howard-Reeves J; Valgañón M; Chanalaris A; De Melo VA; Marin D; et alApperley JF; Grace C; Nacheva EP. (2008). FISH mapping of Philadelphia negative BCR/ABL1 positive CML. Mol Cytogenet. 1:14. DOI.
• Milojkovic D; Apperley J. (Jan 2008). State-of-the-art in the treatment of chronic myeloid leukaemia. Curr Opin Oncol. 20:112-121. DOI.
• Olavarria E; Siddique S; Griffiths MJ; Avery S; Byrne JL; Piper KP; Lennard AL; Pallan L; et alArrazi JM; Perz JB; O'Shea D; Goldman JM; Apperley JF; Craddock CF. (15 Dec 2007). Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood. 110:4614-4617. DOI.
• Apperley JF. (Dec 2007). Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 8:1116-1128. DOI.
• Gratwohl A; Baldomero H; Schwendener A; Gratwohl M; Apperley J; Niederwieser D; Frauendorfer K; Joint Accreditation Committee of the International Society for Cellular Therapy; et alEuropean Group for Blood and Marrow Transplantation; European Leukemia Net. (Dec 2007). Predictability of hematopoietic stem cell transplantation rates. Haematologica. 92:1679-1686. DOI.
• Apperley JF. (Nov 2007). Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 8:1018-1029. DOI.
• Perz JB; Szydo R; Sergeant R; Sanz J; O'Shea D; Khan T; Davey N; Loaiza S; et alDavis J; Apperley JF; Olavarria E. (1 Nov 2007). Impact of HLA class I and class II DNA high-resolution HLA typing on clinical outcome in adult unrelated stem cell transplantation after in vivo T-cell depletion with alemtuzumab. TRANSPLANT IMMUNOLOGY. 18:179-185. Author weblink DOI.
• Brazma D; Grace C; Howard J; Melo JV; Holyoke T; Apperley JF; Nacheva EP. (Nov 2007). Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression. Genes Chromosomes Cancer. 46:1039-1050. DOI.
• De Melo VA; Milojkovic D; Khorashad JS; Marin D; Goldman JM; Apperley JF; Reid AG. (15 Oct 2007). Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia. Blood. 110:3086-3087. DOI.
• Perz JB; Marin D; Szydlo RM; Giles C; Olavarria E; Williams G; Apperley JF. (1 Oct 2007). Incidence of hyperthyroidism after unrelated donor allogeneic stem cell transplantation. LEUKEMIA RESEARCH. 31:1433-1436. Author weblink DOI.
• de Lavallade H; Khorashad JS; Davis HP; Milojkovic D; Kaeda JS; Goldman JM; Apperley JF; Marin D. (1 Oct 2007). Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood. 110:2779-2780. DOI.
• Gabriel IH; Olavarria E; Jones RR; Whittaker S; Chaidos A; Apperley JF. (Aug 2007). Graft versus lymphoma effect after early relapse following reduced-intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides. Bone Marrow Transplant. 40:401-403. DOI.
• Bourhis J-H; Bouko Y; Koscielny S; Bakkus M; Greinix H; Derigs G; Salles G; Feremans W; et alApperley J; Samson D; Bjorkstrand B; Niederwieser D; Gahrton G; Pico J-L; Goldschmidt H. (1 Aug 2007). Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34(+) cell selection: long term follow-up of an EBMT phase III randomized study. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. 92:1083-1090. DOI.
• Knop S; Hebart H; Gratwohl A; Kliem C; Faul C; Holler E; Apperley J; Kolb HJ; et alSchaefer A; Niederwieser D; Einsele H. (Aug 2007). Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party. Leukemia. 21:1830-1833. DOI.
• Mohty M; Yong AS; Szydlo RM; Apperley JF; Melo JV. (1 Jul 2007). The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood. 110:380-383. DOI.
• Chaidos A; Kanfer E; Apperley JF. (Jun 2007). Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage. Best Pract Res Clin Haematol. 20:125-154. DOI.
• Pavlu J; Andreasson C; Chuah C; Kaeda J; Goldman JM; Apperley JF; Marin D. (Jun 2007). Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission. Br J Haematol. 137:423-428. DOI.
• Jovanovic JV; Score J; Waghorn K; Cilloni D; Gottardi E; Metzgeroth G; Erben P; Popp H; et alWalz C; Hochhaus A; Roche-Lestienne C; Preudhomme C; Solomon E; Apperley J; Rondoni M; Ottaviani E; Martinelli G; Brito-Babapulle F; Saglio G; Hehlmann R; Cross NC; Reiter A; Grimwade D. (1 Jun 2007). Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 109:4635-4640. DOI.
• Guilhot F; Apperley J; Kim DW; Bullorsky EO; Baccarani M; Roboz GJ; Amadori S; de Souza CA; et alLipton JH; Hochhaus A; Heim D; Larson RA; Branford S; Muller MC; Agarwal P; Gollerkeri A; Talpaz M. (15 May 2007). Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 109:4143-4150. DOI.
• Simula MP; Marktel S; Fozza C; Kaeda J; Szydlo RM; Nadal E; Bua M; Rahemtulla A; et alKanfer E; Marin D; Olavarria E; Goldman JM; Apperley JF; Dazzi F. (May 2007). Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia. 21:943-948. DOI.
• Elliot V; Marin D; Horncastle D; Elderfield K; Howard J; Apperley JF; Lampert IA; Naresh KN. (May 2007). Total CD34+ cells per 10 HPF in bone marrow trephines of patients with chronic myeloid leukaemia correlates with probability of complete cytogenetic response following imatinib treatment. Histopathology. 50:810-812. DOI.
• Crawley C; Iacobelli S; Björkstrand B; Apperley JF; Niederwieser D; Gahrton G. (15 Apr 2007). Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 109:3588-3594. DOI.
• Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; et alSaglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M. (15 Apr 2007). Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 109:3207-3213. DOI.
• Hochhaus A; Kantarjian HM; Baccarani M; Lipton JH; Apperley JF; Druker BJ; Facon T; Goldberg SL; et alCervantes F; Niederwieser D; Silver RT; Stone RM; Hughes TP; Muller MC; Ezzeddine R; Countouriotis AM; Shah NP. (15 Mar 2007). Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 109:2303-2309. DOI.
• Fozza C; Szydlo RM; Abdel-Rehim MM; Nadal E; Goldman JM; Apperley JF; Dazzi F. (Mar 2007). Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. Br J Haematol. 136:833-836. DOI.
• Nadal E; Garin M; Kaeda J; Apperley J; Lechler R; Dazzi F. (1 Mar 2007). Increased frequencies of CD4(+)CD25(high) T-regs correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. LEUKEMIA. 21:472-479. Author weblink DOI.
• Daikeler T; Kötter I; Bocelli Tyndall C; Apperley J; Attarbaschi A; Guardiola P; Gratwohl A; Jantunen E; et alMarmont A; Porretto F; Musso M; Maurer B; Rinaldi N; Saccardi R; Tyndall A; EBMT Autoimmune Diseases Working Party. (Feb 2007). Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature. Ann Rheum Dis. 66:202-207. DOI.
• Smith G; Olavarria E; Richards S; Apperley J; Carella A; Nierderweiser D; Olavarria E; Rowe J; et alTallman M; Hehlmann R; Hasford J; Berger U; Pfirrmann M; Goldman J; O'Brien S; Richards S; Smith G; Reiffers J; Fort M-P; Mahon F; Boque C; Sureda A. (1 Feb 2007). Autologous stem cell transplantation in chronic myeloid leukaemia: A meta-analysis of six randomized trials. CANCER TREATMENT REVIEWS. 33:39-47. DOI.
• David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; et alGrand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF. (1 Jan 2007). Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood. 109:61-64. DOI.
• Perz JB; Giles C; Szydlo R; O'Shea D; Sanz J; Chaidos A; Wagner S; Davis J; et alLoaiza S; Marin D; Apperley J; Olavarria E; Rahemtulla A; Lampert I; Naresh K; Samson D; MacDonald D; Kanfer EJ. (1 Jan 2007). LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. BONE MARROW TRANSPLANTATION. 39:41-47. Author weblink DOI.
• Weisdorf D; Apperley J; Courmelon P; Gorin N-C; Wingard J; Chao N. (1 Jan 2007). Radiation emergencies: Evaluation, management, and transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 13:103-106. DOI.
• Perz JB; Kristen AV; Rahemtulla A; Parameshwar J; Sack FU; Apperley JF; Goldschmidt H; Katus HA; et alDengler TJ. (Dec 2006). Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation. Clin Res Cardiol. 95:671-674. DOI.
• Anand M; Khorashad J; Marin D; Apperley JF; Goldman JM; Kaeda JS. (15 Oct 2006). Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele. Blood. 108:2881-2882. DOI.
• Gorin NC; Fliedner TM; Gourmelon P; Ganser A; Meineke V; Sirohi B; Powles R; Apperley J. (Oct 2006). Consensus conference on European preparedness for haematological and other medical management of mass radiation accidents. Ann Hematol. 85:671-679. DOI.
• Baccarani M; Saglio G; Goldman J; Hochhaus A; Simonsson B; Appelbaum F; Apperley J; Cervantes F; et alCortes J; Deininger M; Gratwohl A; Guilhot F; Horowitz M; Hughes T; Kantarjian H; Larson R; Niederwieser D; Silver R; Hehlmann R; European LeukemiaNet. (15 Sep 2006). Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 108:1809-1820. DOI.
• Apperley JF. (1 Aug 2006). Never say never again!. BLOOD. 108:786-787. Author weblink DOI.
• Perz JB; Khorashad JS; Marin D; Apperley JF; Olavarria E. (Aug 2006). Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia. Haematologica. 91:1145-1146.
• Greinix HT; Socié G; Bacigalupo A; Holler E; Edinger MG; Apperley JF; Schwarz T; Ullrich SE; et alAlbert ML; Knobler RM; Peritt D; Ferrara JL. (Aug 2006). Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant. 38:265-273. DOI.
• Bird JM; Fuge R; Sirohi B; Apperley JF; Hunter A; Snowden J; Mahendra P; Milligan D; et alByrne J; Littlewood T; Fegan C; McQuaker G; Pagliuca A; Johnson P; Rahemtulla A; Morris C; Marks DI; British Society of Blood and Marrow Transplantation. (Aug 2006). The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol. 134:385-390. DOI.
• GOLDMAN JM; APPERLEY JF; MARCUS RE; HOWS J; GORDONSMITH EC; REID CD; CATOVSKY D; GALTON DAG. (1 Jan 1985). BONE-MARROW TRANSPLANTATION FOR PATIENTS IN THE CHRONIC PHASE OF CHRONIC GRANULOCYTIC-LEUKEMIA - APPARENT LOW INCIDENCE OF RELAPSE WITHIN THE 1ST 2 YEARS POST-BMT. EXPERIMENTAL HEMATOLOGY. 13:14-15.
• Gordon MY; Levicar N; Pai M; Bachellier P; Dimarakis I; Al-Allaf F; M'Hamdi H; Thalji T; et alWelsh JP; Marley SB; Davies J; Dazzi F; Marelli-Berg F; Tait P; Playford R; Jiao L; Jensen S; Nicholls JP; Ayav A; Nohandani M; Farzaneh F; Gaken J; Dodge R; Alison M; Apperley JF; Lechler R; Habib NA. (Jul 2006). Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells. 24:1822-1830. DOI.
• Kaeda J; O'Shea D; Szydlo RM; Olavarria E; Dazzi F; Marin D; Saunders S; Khorashad JS; et alCross NC; Goldman JM; Apperley JF. (15 May 2006). Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood. 107:4171-4176. DOI.
• Perz JB; Rahemtulla A; Giles C; Szydlo RM; Davis J; Gopaul D; Gillmore J; Mathias CJ; et alHawkins PN; Apperley JF. (May 2006). Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis. Bone Marrow Transplant. 37:937-943. DOI.
• Duarte RF; Pamphilon D; Cornish J; Shaw BE; Samson D; Craddock C; Marks D; Mufti GJ; et alPowles RL; Apperley JF; Madrigal JA; Goldman JM. (May 2006). Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005. Bone Marrow Transplant. 37:901-908. DOI.
• Khorashad JS; Anand M; Marin D; Saunders S; Al-Jabary T; Iqbal A; Margerison S; Melo JV; et alGoldman JM; Apperley JF; Kaeda J. (Apr 2006). The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia. 20:658-663. DOI.
• O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; et alSamson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A. (Apr 2006). Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant. 37:731-737. DOI.
• Gratwohl A; Brand R; Apperley J; Crawley C; Ruutu T; Corradini P; Carreras E; Devergie A; et alGuglielmi C; Kolb HJ; Niederwieser D; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. (Apr 2006). Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 91:513-521.
• Ljungman P; Urbano-Ispizua A; Cavazzana-Calvo M; Demirer T; Dini G; Einsele H; Gratwohl A; Madrigal A; et alNiederwieser D; Passweg J; Rocha V; Saccardi R; Schouten H; Schmitz N; Socie G; Sureda A; Apperley J; European Group for Blood and Marrow. (Mar 2006). Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant. 37:439-449. DOI.
• Politou M; Karadimitris A; Terpos E; Kotsianidis I; Apperley JF; Rahemtulla A. (Feb 2006). No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. Leuk Res. 30:240-241. DOI.
• Apperley JF. (2006). Managing the patient with chronic myeloid leukemia through and after allogeneic stem cell transplantation. Hematology Am Soc Hematol Educ Program. 226-232. DOI.
• Yong AS; Szydlo RM; Goldman JM; Apperley JF; Melo JV. (1 Jan 2006). Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood. 107:205-212. DOI.
• Terpos E; Rezvani K; Basu S; Milne AE; Rose PE; Scott GL; Rahemtulla A; Samson D; et alApperley JF. (Nov 2005). Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol. 75:376-383. DOI.
• Crawley C; Szydlo R; Lalancette M; Bacigalupo A; Lange A; Brune M; Juliusson G; Nagler A; et alGratwohl A; Passweg J; Komarnicki M; Vitek A; Mayer J; Zander A; Sierra J; Rambaldi A; Ringden O; Niederwieser D; Apperley JF; Chronic Leukemia Working Party of the EBMT. (1 Nov 2005). Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 106:2969-2976. DOI.
• Xue SA; Gao LQ; Hart D; Gillmore R; Qasim W; Thrasher A; Apperley J; Engels B; et alUckert W; Morris E; Stauss H. (1 Nov 2005). Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. BLOOD. 106:3062-3067. Author weblink DOI.
• Elliot V; Marin D; Horncastle D; Elderfield K; Apperley JF; Lampert IA; Naresh K. (Aug 2005). Percentage of CD34 cells in a minimum 500-cell count in bone marrow trephines of patients with chronic myeloid leukaemia provides the best correlation with aspirate blast count. Br J Haematol. 130:460-461. DOI.
• al-Jurf M; Aranha F; Annassetti C; Apperley JF; Baynes R; Bensinger WI; Blaise D; Chaudhary MA; et alClarke M; Cornelissen JJ; Couban S; Cutler C; Djulbegovic B; Gyger M; Gratwohl A; Heldal D; Van der Holt B; Hozo I; Kuentz M; Kumar A; Lipton J; Matchamm J; Mohty M; Morton J; Panzarella T; Powles R; Richards SM; Sahovic E; Schmitz N; Simpson DR; Sirohi B; Soares HP; de Souza CA; Vigorito AC; Wheatley K. (1 Aug 2005). Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials. JOURNAL OF CLINICAL ONCOLOGY. 23:5074-5087. Author weblink DOI.
• Schultheis B; Szydlo R; Mahon FX; Apperley JF; Melo JV. (15 Jun 2005). Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. Blood. 105:4893-4894. DOI.
• Crawley C; Lalancette M; Szydlo R; Gilleece M; Peggs K; Mackinnon S; Juliusson G; Ahlberg L; et alNagler A; Shimoni A; Sureda A; Boiron JM; Einsele H; Chopra R; Carella A; Cavenagh J; Gratwohl A; Garban F; Zander A; Björkstrand B; Niederwieser D; Gahrton G; Apperley JF; Chromic Leukaemia Working Party of the EBMT. (1 Jun 2005). Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 105:4532-4539. DOI.
• Marin D; Kaeda JS; Andreasson C; Saunders SM; Bua M; Olavarria E; Goldman JM; Apperley JF. (1 May 2005). Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer. 103:1850-1855. DOI.
• Schmitz N; Beksac M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; et alSzerm J; Bradstock K; Buzyn A; Schlegelberger B; Matcham J; Gratwohl A. (May 2005). Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica. 90:643-648.
• Burton C; Morin D; Apperley J. (1 Apr 2005). Personalized medical treatment strategies for patients with chronic myeloid leukemia. EXPERT REVIEW OF ANTICANCER THERAPY. 5:343-353. Author weblink DOI.
• Marin D; Kaeda J; Szydlo R; Saunders S; Fleming A; Howard J; Andreasson C; Bua M; et alOlavarria E; Rahemtulla A; Dazzi F; Kanfer E; Goldman JM; Apperley JF. (Apr 2005). Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia. 19:507-512. DOI.
• Cremer FW; Bouko Y; Samson D; Apperley JF; Thielemans K; Van Camp B; Benner A; Goldschmidt H; et alMoos M; Bakkus MHC. (1 Mar 2005). Response to Owen and Rawstron. BRITISH JOURNAL OF HAEMATOLOGY. 128:733-734. Author weblink DOI.
• Gahrton G; Iacobelli S; Apperley J; Bandini G; Björkstrand B; Bladé J; Boiron JM; Cavo M; et alCornelissen J; Corradini P; Kröger N; Ljungman P; Michallet M; Russell NH; Samson D; Schattenberg A; Sirohi B; Verdonck LF; Volin L; Zander A; Niederwieser D. (Mar 2005). The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant. 35:609-617. DOI.
• Politou M; Naresh K; Terpos E; Crawley D; Lampert I; Apperley JF; Rahemtulla A. (2005). Anti-angiogenic effect of bortezomib in patients with multiple myeloma. Acta Haematol. 114:170-173. DOI.
• Ruutu T; Corradini P; Gratwohl A; Holler E; Apperley J; Dini G; Rocha V; Schmitz N; et alSocié G; Niederwieser D. (Jan 2005). Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 35:121-124. DOI.
• Passweg JR; Orchard K; Buergi A; Gratwohl A; Powles R; Goldman J; Apperley J; Mehta J. (Dec 2004). Autologous/syngeneic stem cell transplantation to treat refractory GvHD. Bone Marrow Transplant. 34:995-998. DOI.
• Gratwohl A; Baldomero H; Labar B; Apperley J; Urbano-Ispizua A; Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). (Dec 2004). Evolution of hematopoietic stem cell transplantation in Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey. Croat Med J. 45:689-694.
• Apperley J; Bain B. (15 Nov 2004). The FIP1L1-PDGFRA syndrome: a case of mistaken identity?. BLOOD. 104:2999-3000. Author weblink DOI.
• Apperley J. (Nov 2004). Just another cost increasing exercise (JACIE)?. Bone Marrow Transplant. 34:835-838. DOI.
• Bakkus MH; Bouko Y; Samson D; Apperley JF; Thielemans K; Van Camp B; Benner A; Goldschmidt H; et alMoos M; Cremer FW. (Sep 2004). Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol. 126:665-674. DOI.
• Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; et alRahemtulla A. (Sep 2004). Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 126:686-689. DOI.
• Terpos E; Politou M; Szydlo R; Nadal E; Avery S; Olavarria E; Kanfer E; Goldman JM; et alApperley JF; Rahemtulla A. (Aug 2004). Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia. 18:1420-1426. DOI.
• Radich JP; Olavarria E; Apperley JF. (1 Jun 2004). Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA. 18:685-+. Author weblink DOI.
• Avery S; Nadal E; Marin D; Olavarria E; Kaeda J; Vulliamy T; Brito Babapulle F; Goldman JM; et alApperley JF. (May 2004). Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib. Leuk Res. 28 Suppl 1:S75-S77. DOI.
• Marin D; Rahemtulla A; Olavarria E; Goldman J; Apperley J. (10 Apr 2004). Interactive web-based guidelines for chronic myeloid leukaemia. LANCET. 363:1239-1239. Author weblink DOI.
• Zino E; Frumento G; Marktel S; Sormani MP; Ficara F; Di Terlizzi S; Parodi AM; Sergeant R; et alMartinetti M; Bontadini A; Bonifazi F; Lisini D; Mazzi B; Rossini S; Servida P; Ciceri F; Bonini C; Lanino E; Bandini G; Locatelli F; Apperley J; Bacigalupo A; Ferrara GB; Bordignon C; Fleischhauer K. (15 Feb 2004). A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood. 103:1417-1424. DOI.
• Nadal E; Fowler A; Kanfer E; Apperley J; Goldman J; Dazzi F. (Feb 2004). Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Exp Hematol. 32:218-223. DOI.
• Russell NH; Szydlo R; McCann S; Potter MN; Craddock C; Towlson K; Apperley JF; British Society for Blood and Marrow Transplantation. (Feb 2004). The use of a national transplant registry to benchmark transplant outcome for patients undergoing autologous and allogeneic stem cell transplantation in the United Kingdom and Ireland. Br J Haematol. 124:499-503.
• Favre G; Beksaç M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; et alSzer J; Bradstock K; Buzyn A; Matcham J; Gratwohl A; Schmitz N; European Group for Blood and Marrow Transplantation (EBMT). (Nov 2003). Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant. 32:873-880. DOI.
• Terpos E; Politou M; Szydlo R; Goldman JM; Apperley JF; Rahemtulla A. (Oct 2003). Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol. 123:106-109.
• Marin D; Goldman JM; Olavarria E; Apperley JF. (1 Oct 2003). Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. BLOOD. 102:2702-2703. Author weblink DOI.
• Marin D; Marktel S; Szydlo R; Klein JP; Bua M; Foot N; Olavarria E; Shepherd P; et alKanfer E; Goldman JM; Apperley JF. (23 Aug 2003). Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. Lancet. 362:617-619. DOI.
• Seaton ED; Szydlo RM; Kanfer E; Apperley JF; Russell-Jones R. (15 Aug 2003). Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood. 102:1217-1223. DOI.
• Cwynarski K; Roberts IA; Iacobelli S; van Biezen A; Brand R; Devergie A; Vossen JM; Aljurf M; et alArcese W; Locatelli F; Dini G; Niethammer D; Niederwieser D; Apperley JF; Paediatric and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation. (15 Aug 2003). Stem cell transplantation for chronic myeloid leukemia in children. Blood. 102:1224-1231. DOI.
• Gordon MY; Marley SB; Apperley JF; Marin D; Kaeda J; Szydlo R; Goldman JM. (Aug 2003). Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons. Br J Haematol. 122:424-429.
• Terpos E; Szydlo R; Apperley JF; Hatjiharissi E; Politou M; Meletis J; Viniou N; Yataganas X; et alGoldman JM; Rahemtulla A. (1 Aug 2003). Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 102:1064-1069. DOI.
• Marin D; Marktel S; Bua M; Szydlo RM; Franceschino A; Nathan I; Foot N; Crawley C; et alNa Nakorn T; Olavarria E; Lennard A; Neylon A; O'Brien SG; Goldman JM; Apperley JF. (Aug 2003). Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia. 17:1448-1453. DOI.
• Goldman J; Apperley J; Kanfer E; Olavarria E; Marin D. (12 Jul 2003). Imatinib or transplant for chronic myeloid leukaemia?. Lancet. 362:172-173. DOI.
• Orlent H; Crawley C; Cwynarski K; Dina R; Apperley J. (1 Jul 2003). Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation. BONE MARROW TRANSPLANTATION. 32:115-117. Author weblink DOI.
• Kaeda J; Apperley J; Melo J; Cross N; Goldman J. (15 Jun 2003). Monitoring CML after nonmyeloablative transplantations: how negative is negative?. Blood. 101:5084. DOI.
• Goldman JM; Marin D; Olavarria E; Apperley JF. (Apr 2003). Clinical decisions for chronic myeloid leukemia in the imatinib era. Semin Hematol. 40:98-103. DOI.
• Bonini C; Grez M; Traversari C; Ciceri F; Marktel S; Ferrari G; Dinauer M; Sadat M; et alAiuti A; Deola S; Radrizzani M; Hagenbeek A; Apperley J; Ebeling S; Martens A; Kolb HJ; Weber M; Lotti F; Grande A; Weissinger E; Bueren JA; Lamana M; Falkenburg JH; Heemskerk MH; Austin T; Kornblau S; Marini F; Benati C; Magnani Z; Cazzaniga S; Toma S; Gallo-Stampino C; Introna M; Slavin S; Greenberg PD; Bregni M; Mavilio F; Bordignon C. (Apr 2003). Safety of retroviral gene marking with a truncated NGF receptor. Nat Med. 9:367-369. DOI.
• Marktel S; Marin D; Foot N; Szydlo R; Bua M; Karadimitris A; De Melo VA; Kotzampaltiris P; et alDazzi F; Rahemtulla A; Olavarria E; Apperley JF; Goldman JM. (Mar 2003). Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica. 88:260-267.
• Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; et alRahemtulla A. (Feb 2003). Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant. 31:163-170. DOI.
• Marin D; Marktel S; Foot N; Bua M; Goldman JM; Apperley JF. (Feb 2003). Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica. 88:227-229.
• Melo JV; Hughes TP; Apperley JF. (2003). Chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program. 132-152.
• Gratwohl A; Brand R; Apperley J; Biezen Av A; Bandini G; Devergie A; Schattenberg A; Frassoni F; et alGuglielmi C; Iacobelli S; Michallet M; Kolb HJ; Ruutu T; Niederwieser D; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (CLWP-EBMT). (1 Dec 2002). Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood. 100:3877-3886. DOI.
• Bellantuono I; Gao L; Parry S; Marley S; Dazzi F; Apperley J; Goldman JM; Stauss HJ. (15 Nov 2002). Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood. 100:3835-3837. DOI.
• Dazzi F; Szydlo RM; Apperley JF; Goldman JM. (1 Oct 2002). Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions. Blood. 100:2673-2674.
• Dazzi F; Szydlo RM; Apperley JF; Goldman JM. (1 Oct 2002). To the editor: Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions. BLOOD. 100:2673-2674. Author weblink DOI.
• Powles R; Apperley J. (19 Sep 2002). Major radiation exposure. N Engl J Med. 347:944-947.
• Powles R; Apperley J. (19 Sep 2002). Major radiation exposure. NEW ENGLAND JOURNAL OF MEDICINE. 347:945-945.
• Ruutu T; Hermans J; Niederwieser D; Gratwohl A; Kiehl M; Volin L; Bertz H; Ljungman P; et alSpence D; Verdonck LF; Prentice HG; Bosi A; Du Toit CE; Brinch L; Apperley JF; EBMT Chronic Leukaemia Working Party. (Sep 2002). Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 118:1112-1119.
• Marin D; Marktel S; Bua M; Armstrong L; Goldman JM; Apperley JF; Olavarria E. (Sep 2002). The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations. Haematologica. 87:979-988.
• Olavarria E; Reiffers J; Boque C; Sureda A; Meloni G; Michallet M; Clark RE; Blaise D; et alCarella AM; Cahn JY; Jouet JP; Rizzoli V; Van Biezen A; Gratwohl A; Goldman JM; Niederwieser D; Apperley JF. (Sep 2002). The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase. Br J Haematol. 118:762-770.
• Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; et alColombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM. (15 Aug 2002). Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 347:481-487. DOI.
• Schmitz N; Beksac M; Hasenclever D; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; et alApperley JF; Gorin NC; Szer J; Bradstock K; Buzyn A; Clark P; Borkett K; Gratwohl A; European Group for Blood and Marrow Transplantation. (1 Aug 2002). Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 100:761-767. DOI.
• Guglielmi C; Arcese W; Dazzi F; Brand R; Bunjes D; Verdonck LF; Schattenberg A; Kolb HJ; et alLjungman P; Devergie A; Bacigalupo A; Gomez M; Michallet M; Elmaagacli A; Gratwohl A; Apperley J; Niederwieser D. (15 Jul 2002). Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood. 100:397-405.
• Goldman J; Apperley J; Clark R; Green T; Holyoake T; O'Brien S; Shepherd P. (8 Jun 2002). Not so NICE for CML. Lancet. 359:2036. DOI.
• Goldman J; Apperley J; Clark R; Green T; Holyoake T; O'Brien S; Shepherd P. (8 Jun 2002). Not so NICE for CML. LANCET. 359:2036-2036. Author weblink DOI.
• Olavarria E; Craddock C; Dazzi F; Marin D; Marktel S; Apperley JF; Goldman JM. (15 May 2002). Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood. 99:3861-3862.
• Urbano-Ispizua A; Schmitz N; de Witte T; Frassoni F; Rosti G; Schrezenmeier H; Gluckman E; Friedrich W; et alCordonnier C; Socie G; Tyndall A; Niethammer D; Ljungman P; Gratwohl A; Apperley J; Niederwieser D; Bacigalupo A; European Group for Blood and Marrow Transplantation. (Apr 2002). Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant. 29:639-646. DOI.
• Wadhwa J; Szydlo RM; Apperley JF; Chase A; Bua M; Marin D; Olavarria E; Kanfer E; et alGoldman JM. (1 Apr 2002). Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood. 99:2304-2309.
• Urbano-Ispizua A; Schmitz N; de Witte T; Frassoni F; Rosti G; Schrezenmeier H; Gluckman E; Friedrich W; et alCordonnier C; Socie G; Tyndall A; Niethammer D; Ljungman P; Gratwohl A; Apperley J; Niederwieser D; Bacigalupo A. (1 Apr 2002). Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. BONE MARROW TRANSPLANTATION. 29:639-646. DOI.
• Cwynarski K; Craddock C; Cobbold M; Apperley J; Goldman J. (9 Mar 2002). Survival after bone-marrow transplantation. Lancet. 359:887-888. DOI.
• Bouko Y; Goldschmidt H; Feremans W; Bourhis J; Szydlo R; Greinix H; Pico J; Apperley J; et alGahrton G; Samson D. (1 Mar 2002). Oligoclonal reconstitution after autologous PBPCT in myeloma patients - Implications for assessment of remission status. BONE MARROW TRANSPLANTATION. 29:S102-S102. Author weblink.
• Karadimitris A; Fuller S; Szydlo R; Brooks P; Olavarria E; Rahemtulla A; Kanfer E; Apperley J; et alGoldman J. (1 Mar 2002). Impact of high resolution HLA typing on severe acute GVHD in chronic phase CML patients treated with unrelated donor bone marrow transplantation. BONE MARROW TRANSPLANTATION. 29:S40-S40. Author weblink.
• Hasserjian RP; Boecklin F; Parker S; Chase A; Dhar S; Zaiac M; Olavarria E; Lampert I; et alHenry K; Apperley JF; Goldman JM. (Mar 2002). ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol. 117:360-367. DOI.
• Davis JG; Garin M; Marktel S; Miller A; Elliston D; Melo JV; Apperley JF. (1 Mar 2002). Clinical scale production of HSV-tk/LNGFR transduced allogeneic T-lymphocytes for treatment of leukemic relapse after allogeneic stem cell transplantation. BONE MARROW TRANSPLANTATION. 29:S42-S42. Author weblink.
• Drake M; Morris C; Hagman A; Bjorkstrand B; Gahrton G; Apperley J. (1 Mar 2002). Transplantation in plasma cell leukemia. BONE MARROW TRANSPLANTATION. 29:S11-S11.
• Gahrton G; Apperley J; Bacigalupo A; Bjorkstrand B; Blade J; Cavo M; Cornelissen J; De Laurenzi A; et alFacon T; Hagman A; Ljungman P; Michallet M; Niederwieser D; Powles R; Reiffers J; Russell N; Samson D; Schaefer U; Schattenberg A; Tura S; Verdonck L; Vernant J; Willemze R; Volin L. (1 Mar 2002). An update of allogeneic transplantation with peripheral blood stem cells (PBSCT) as compared to bone marrow (BMT) in multiple myeloma. BONE MARROW TRANSPLANTATION. 29:S13-S13.
• Guglielmi C; Arcese W; Dazzi F; Bunjes D; Verdonck L; Schattenberg A; Kolb H; Ljungman P; et alDevergie A; Bacigalupo A; Urbano-Ispizua A; Michallet M; Elmaagacli A; Gratwohl A; Apperley J; Niederwieser D. (1 Mar 2002). Donor Lymphocyte Infusion for relapsed chronic myelogenous leukemia - The effect of its method of administration In separate risk groups. BONE MARROW TRANSPLANTATION. 29:S30-S31.
• Ruutu T; Apperley J; Corradini P; Gratwohl A; Aschan J; Hertenstein B; Holler E; Niederwieser D. (1 Mar 2002). Intrathecal prophylaxis in allogeneic hematopoietic stem cell transplantation for malignant blood diseases. BONE MARROW TRANSPLANTATION. 29:S31-S31.
• Bakkus M; Everaert T; Bouko Y; Lipinsky E; Samson D; Apperley J; Thielemans K; Van Camp B; et alGoldschmidt H; Moos M; Cremer F. (1 Mar 2002). Post-transplantation tumor load in the bone marrow assessed by quantitative ASO-PCR as a prognostic parameter in multiple myeloma (an EBMT/GMMG joint study). BONE MARROW TRANSPLANTATION. 29:S32-S32.
• Marks D; Lush R; Chakrabarti S; Fuller S; Parker A; Clark F; Yin J; Vandenberghe E; et alMarsh J; Littlewood T; Smith G; Culligan D; Apperley J. (1 Mar 2002). The toxicity and medium term efficacy of donor lymphocyte infusions (DLI) given after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (SCT). BONE MARROW TRANSPLANTATION. 29:S59-S59.
• Cwynarski K; Roberts I; Brand R; van Biezen A; Vossen W; Arcese W; Bazarbashi S; Slavin S; et alWachowiak J; Niethammer D; Niederwieser D; Apperley J. (1 Mar 2002). Allogeneic SCT for adult type CML (AT-CML) in children. BONE MARROW TRANSPLANTATION. 29:S161-S161.
• Sauce D; Bodinier M; Garin M; Petracca B; Tonnelier N; Duperrier A; Melo JV; Apperley JF; et alFerrand C; Hervé P; Lang F; Tiberghien P; Robinet E. (15 Feb 2002). Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood. 99:1165-1173.
• Hasserjian RP; Chase A; Olavarria E; Lampert I; Henry K; Apperley JF; Goldman JM. (1 Jan 2002). Comparison of the effects of ST1571 (GLEEVEC) versus interferon-alpha on the bone marrow of CML patients. LABORATORY INVESTIGATION. 82:243A-244A. Author weblink.
• Hasserjian RP; Chase A; Dhar S; Olavarria E; Lampert I; Henry K; Apperley JF; Goldman JM. (1 Jan 2002). Histologic and cytogenetic relapse and progression in CML patients treated with STI571 (GLEEVEC). MODERN PATHOLOGY. 15:244A-244A. Author weblink.
• Hasserjian RP; Chase A; Olavarria E; Lampert I; Henry K; Apperley JF; Goldman JM. (1 Jan 2002). Comparison of the effects of STI571 (GLEEVEC) versus interferon-alpha on the bone marrow of CML patients. MODERN PATHOLOGY. 15:243A-244A. Author weblink.
• Terpos E; Apperley J; Samson D; Rahemtulla A. (2002). Management of multiple myeloma. Haema. 5:21-35.
• Hasserjian RP; Chase A; Dhar S; Olavarria E; Lampert I; Henry K; Apperley JF; Goldman JM. (1 Jan 2002). Histologic and cytogenetic relapse and progression in CML patients treated with STI571 (GLEEVEC). LABORATORY INVESTIGATION. 82:244A-244A. Author weblink.
• de Witte T; Pikkemaat F; Hermans J; van Biezen A; Mackinnan S; Cornelissen J; Gratwohl A; Delforge M; et alIriondo A; Kuentz M; Harousseau J; Fauser A; Wandt H; Runde V; Niederwieser D; Apperley J; EBMT, CLWP-MDS subcommittee. (Dec 2001). Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation. Leukemia. 15:1878-1884.
• Gillmore JD; Apperley JF; Lachmann HJ; Barrett AJ; Madhoo S; Pepys MB; Hawkins PN. (1 Dec 2001). Combination chemotherapy for systemic AL amyloidosis. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS. 8:72-73. Author weblink.
• Mughal TI; Yong A; Szydlo RM; Dazzi F; Olavarria E; van Rhee F; Kaeda J; Cross NC; et alCraddock C; Kanfer E; Apperley J; Goldman JM. (Dec 2001). Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol. 115:569-574.
• Guglielmi C; Arcese W; Dazzi F; Bunjes D; Verdonck LF; Schattenberg A; Kolb HJ; Ljungman P; et alDevergie A; Bacigalupo A; Gomez M; Michallet M; Elmaagacli A; Gratwohl A; Apperley J; Niederwieser D. (16 Nov 2001). Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: The first dose decides outcome. BLOOD. 98:727A-727A. Author weblink.
• Sauce D; Garin MI; Bodinier M; Duperrier A; Melo JV; Apperley JF; Ferrand C; Herve P; et alLang F; Cahn JY; Tiberghien P; Robinet E. (16 Nov 2001). Neomycine phosphotransferase/G418-based selection, to the difference of membrane marker (Delta LNGFR)-based selection, impairs the anti-EBV potential of retrovirally-transduced human gene-modified T cells. BLOOD. 98:406B-406B. Author weblink.
• Lin F; Chase A; O'Brien SG; Saunders SM; Lennard AL; McLean RA; Marin D; Cross NCP; et alOlavarria E; Apperley JF; Goldman JM; Kaeda JS. (16 Nov 2001). Response of chronic phase CML patients to STI571 therapy assessd by quantitative real time PCR. BLOOD. 98:614A-614A. Author weblink.
• Bakkus MH; Everaert T; Bouko Y; Lipinski E; Samson D; Apperley JF; Thielemans K; Van Camp B; et alGoldschmidt H; Moos M; Cremer F. (16 Nov 2001). Post-transplantation tumor load in the bone marrow assessed by quantitative ASO-PCR as a prognostic parameter in multiple myeloma (an EBMT/GMMG joint study). BLOOD. 98:295B-295B. Author weblink.
• Yong ASM; Szydlo RM; Roberts IAG; Apperley JF; Goldman JM. (16 Nov 2001). Secondary malignancies after allogeneic stem cell transplantation for chronic myeloid leukemia: A single institution analysis of 608 patients. BLOOD. 98:373B-373B. Author weblink.
• Marin D; Bua M; Marktel S; Chase A; Armstrong L; Udom C; Olavarria E; Apperley JF; et alGoldman JM. (16 Nov 2001). The chromosomal complexity score (CCS) as a predictive factor for response of patients with CML in accelerated phase to treatment with STI571. BLOOD. 98:262B-262B. Author weblink.
• Olavarria E; Giles C; Addada J; MacDonald I; Fuller S; Gilleece M; Rahemtulla A; Apperley JF; et alGoldman JM; Samson D; Kanfer E. (16 Nov 2001). Reduced intensity conditioning stem cell transplantation with LACE: Long-term follow-up. BLOOD. 98:379B-379B. Author weblink.
• Marin D; Bua M; Marktel S; Chase A; Udom C; Armstrong L; Gilleece MH; Olavarria E; et alGoldman JM; Apperley JF. (16 Nov 2001). The combination of cytogenetic response after 6 months treatment with STI571 and the presence of cytopenias in patients with CML in chronic phase resistant to or intolerant of interferon-alfa defines four different prognostic groups. BLOOD. 98:846A-846A. Author weblink.
• Marktel S; Bua M; Marin D; Chase A; Udom C; Armstrong L; Apperley JF; Olavarria E; et alGoldman JM. (16 Nov 2001). Emergence of additional chromosomal abnormalities following treatment with STI571 (imatinib mesylate) for Philadelphia positive chronic myeloid leukemia in chronic phase. BLOOD. 98:617A-617A. Author weblink.
• Wadhwa J; Szydlo RM; Apperley JF; Chase A; Bua M; Marin D; Olavarria E; Kanfer E; et alGoldman JM. (16 Nov 2001). Treatment options for blastic transformation of chronic myeloid leukemia and factors impacting on duration of survival. BLOOD. 98:349A-349A. Author weblink.
• Apperley JF; Schultheis B; Chase A; Steer J; Bain B; Dimitrijevic S; Marin D; Olavarria E; et alCross N; Russell-Jones R; Melo J; Goldman J. (16 Nov 2001). Chronic Myeloproliferative diseases with t(5;12) and a PDGFRB fusion gene: Complete cytogenetic remissions on STI571. BLOOD. 98:726A-726A. Author weblink.
• Elliston DJ; Garrett E; Melo JV; Apperley JF. (16 Nov 2001). Efficient marking of CML perpheral blood CD34+cells and their subsets, using two different packaging line systems. BLOOD. 98:403B-403B. Author weblink.
• Bouko Y; Goldschmidt H; Feremans W; Bourhis JH; Greinix H; Pico JL; Apperley J; Gahrton G; et alSamson D. (16 Nov 2001). Oligoclonal reconstitution after high dose therapy with PBPCT in myeloma patients: Implications for assessment of remission status. BLOOD. 98:158A-158A.
• Gratwohl A; Brand R; Van Biezen A; Apperley J; Bandini G; Devergie A; Frassoni F; Guglielmi C; et alMichallet M; Kolb H; Ruutu T; Niederwieser D. (16 Nov 2001). A time interval > 12 months from diagnosis to transplant is associated with increased acute graft-versus-host disease in patients transplanted for chronic myeloid leukemia. BLOOD. 98:660A-660A.
• Cwynarski K; Roberts IAG; Brand R; van Biezen A; Slavin S; Vossen J; Wachowiak J; Niethammer D; et alApperley J. (16 Nov 2001). Stem cell transplantation for chronic myeloid leukemia in children. BLOOD. 98:814A-814A.
• Michallet M; Brand R; Dreger P; Millighan D; Esteve J; Kimby E; Nicolini F; Apperley J; et alvan Biezen A; Niederwieser D. (16 Nov 2001). Analysis of prognostic factors on the outcome of autologous and allogeneic stem cell transplantations (SCT) for chronic lymphocytic leukemia (CLL). BLOOD. 98:859A-860A.
• Cwynarski K; Goulding R; Pocock C; Dazzi F; Craddock C; Kaeda J; Olavarria E; Kanfer E; et alApperley J; Lawler M; Goldman JM. (Sep 2001). Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions. Bone Marrow Transplant. 28:581-586. DOI.
• Olavarria E; Child F; Woolford A; Whittaker SJ; Davis JG; McDonald C; Chilcott S; Spittle M; et alGrieve RJ; Stewart S; Apperley JF; Russell-Jones R. (Sep 2001). T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol. 114:624-631.
• Russell-Jones R; Child F; Olavarria E; Whittaker S; Spittle M; Apperley J. (Sep 2001). Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival. Ann N Y Acad Sci. 941:147-154.
• Chalmers D; Ferrand C; Apperley JF; Melo JV; Ebeling S; Newton I; Duperrier A; Hagenbeek A; et alGarrett E; Tiberghien P; Garin M. (Aug 2001). Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. Mol Ther. 4:146-148. DOI.
• Salooja N; Szydlo RM; Socie G; Rio B; Chatterjee R; Ljungman P; Van Lint MT; Powles R; et alJackson G; Hinterberger-Fischer M; Kolb HJ; Apperley JF; Late Effects Working Party of the European Group for Blood and Marrow Transplantation. (28 Jul 2001). Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet. 358:271-276.
• Clark RE; Hermans J; Madrigal A; Nachbaur D; Kropshofer G; Gratwohl A; Apperley J; Niederwieser D; et alChronic Leukaemia Working Party of the European Group of Blood and Bone Marrow Transplantation. (Jul 2001). HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia. Br J Haematol. 114:36-41.
• Pocock CF; Lucas GF; Giles C; Vassiliou G; Cwynarski K; Rezvani K; Apperley JF; Goldman JM. (May 2001). Immune neutropenia associated with anti-human neutrophil antigen-2a (NB1) antibodies following unrelated donor stem cell transplantation for chronic myeloid leukaemia: perpetuation by granulocyte colony-stimulating factor. Br J Haematol. 113:483-485.
• Rivas C; Miller AR; Collado M; Lam EW; Apperley JF; Melo JV. (May 2001). BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir. Mol Ther. 3:642-652. DOI.
• Gahrton G; Svensson H; Cavo M; Apperley J; Bacigalupo A; Bjorkstrand B; Blade J; Cornelissen J; et alde Laurenzi A; Facon T; Ljungman P; Michallet M; Niederwieser D; Powles R; Reiffers J; Russell NH; Samson D; Schaefer UW; Schattenberg A; Tura S; Verdonck LF; Vernant JP; Willemze R; Volin L. (1 Apr 2001). Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. BRITISH JOURNAL OF HAEMATOLOGY. 113:209-216. DOI.
• Olavarria E; Kanfer E; Szydlo R; Kaeda J; Rezvani K; Cwynarski K; Pocock C; Dazzi F; et alCraddock C; Apperley JF; Cross NC; Goldman JM. (15 Mar 2001). Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 97:1560-1565.
• Rezvani K; Lawler M; Goulding R; Kaedar J; Dazzi F; Domingo E; Pocock C; Johnston R; et alGardiner N; McCann SR; Craddock C; Apperley J; Goldman J. (1 Mar 2001). Myeloid and Lymphoid chimerism in long-term survivors post SCT for CML-CP: the presence of recipient hematopoiesis is not predictive of relapse and correlates with lower GvHD risk. BONE MARROW TRANSPLANTATION. 27:S28-S28. Author weblink.
• Lalancette M; Michallet M; Szydlo R; Rezvani K; Mackinnon S; Blaise D; Finke J; Slavin S; et alAlessandrino EP; Niederwieser D; Frassoni F; Apperley J. (1 Mar 2001). The importance of patient selection in non-myeloablative stem cell transplant (NMSCT) for acute and chronic leukaemia, myelodysplastic syndrome, and myeloma. BONE MARROW TRANSPLANTATION. 27:S277-S277. Author weblink.
• Lalancette M; Rezvani K; Szydlo R; Mayer J; Blaise D; Zander A; Michallet M; Slavin S; et alFrassoni F; Niederwieser D; Apperley J. (1 Mar 2001). Favorable outcome of non-myeloablative stem cell transplant (NMSCT) for chronic myeloid leukaemias (CML) in first chronic phase: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). BONE MARROW TRANSPLANTATION. 27:S279-S279. Author weblink.
• Rezvani K; Lalancette M; Szydlo R; Blaise D; Slavin S; Alessandrino P; Michallet M; Niederwieser D; et alApperley J; Frassoni F. (1 Mar 2001). Non-Myeloablative Stem Cell Transplantation (NMSCT) in AML, ALL and MDS: disappointing outcome for patients with advanced phase disease. BONE MARROW TRANSPLANTATION. 27:S279-S279. Author weblink.
• Lalancette M; Rezvani K; Szydlo R; Mackinnon S; Juliusson G; Michallet M; Slavin S; Frassoni F; et alNiederwieser D; Gahrton G; Apperley J. (1 Mar 2001). Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: the European Group for Blood and Marrow Transplantation (EBMT) experience. BONE MARROW TRANSPLANTATION. 27:S279-S280. Author weblink.
• Björkstrand B; Svensson H; Goldschmidt H; Ljungman P; Apperley J; Mandelli F; Marcus R; Boogaerts M; et alAlegre A; Remes K; Cornelissen JJ; Bladé J; Lenhoff S; Iriondo A; Carlson K; Volin L; Littlewood T; Goldstone AH; San Miguel J; Schattenberg A; Gahrton G. (Mar 2001). Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 27:511-515. DOI.
• Cwynarski K; Ainsworth J; Cobbold M; Wagner S; Mahendra P; Apperley J; Goldman J; Craddock C; et alMoss PA. (1 Mar 2001). Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 97:1232-1240.
• Michallet M; Brand R; Dreger P; Milligan DW; Esteve J; Kimby E; Gratwohl A; Apperley J; et alVan Biezen A; Niederwieser D. (1 Mar 2001). Prognostic factors for survival after autologous and allogeneic stem cell transplantation for Chronic Lymphocytic Leukemia (CLL): The EBMT experience. BONE MARROW TRANSPLANTATION. 27:S31-S31.
• Guglielmi C; Apperley J; Arcese W; Bacigalupo A; Bunjes D; Dazzi D; Ljungman P; Michallet M; et alSchattenberg A; Verdonck LF; Kolb H; Niederwieser D. (1 Mar 2001). Dose schedule of donor lymphocyte transfusion is associated with survival of patients who relapse after transplant for Ph plus CML. BONE MARROW TRANSPLANTATION. 27:S31-S31.
• Bourhis JH; Bouko Y; Greinix H; Derigs G; Salles G; Feremans W; Bakkus M; Samson D; et alGahrton G; Pico JL; Goldschmidt H; Apperley J. (1 Mar 2001). A reappraisal of the benefits and the safety of CD34+selection in patients with myeloma: a phase III randomized study of the EBMT. BONE MARROW TRANSPLANTATION. 27:S31-S32.
• Gahrton G; Svensson H; Cavo M; Apperley J; Bacigalupo A; Bjorkstrand B; Blade J; Cornelisson J; et alde Laurenzi A; Facon T; Hagman A; Ljungman P; Michallet M; Niederwieser D; Powles R; Reiffers J; Russell N; Samson D; Schaefer U; Schattenberg A; Tura S; Verdonck L; Vernant J; Willemze R; Volin L. (1 Mar 2001). Allogeneic peripheral blood stem cell transplantation (PBSCT) compared to bone marrow transplantation (BMT) in multiple myeloma. BONE MARROW TRANSPLANTATION. 27:S39-S39.
• Bakkus MHC; Everaert T; Bouko Y; Samson D; Thielemans K; Bourhis JH; Pico J; Goldschmidt H; et alVan Camp B; Apperley J. (1 Mar 2001). Long-term follow-up of the randomised phase III study of the EBMT of tumour cell depletion by CD34 selection in multiple myeloma patients: does quantitative MRD analysis have a predictive value?. BONE MARROW TRANSPLANTATION. 27:S39-S40.
• Bjorkstrand B; Hagman A; Ljungman P; Reiffers J; Goldschmidt H; Mandelli F; Ferrant A; Apperley J; et alApperley J; Barbui T; Remes K; Volin L; Coser P; Marcus R; Vernant J; Majolino I; Iriondo A; Boogaerts M; Rodeghiero F; Sureda A; Alegre A; Alessandrino P; Gahrton G. (1 Mar 2001). Autologous stem cell transplantation in multiple myeloma: the 2000 EBMT registry update. BONE MARROW TRANSPLANTATION. 27:S40-S40.
• Elizaga J; Olavarria E; Apperley J; Goldman J; Ward K. (1 Feb 2001). Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment. Clin Infect Dis. 32:413-418. DOI.
• Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G. (2001). Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy. 3:261-267. DOI.
• Gratwohl A; Herman J; Neiderwieser D; van Biezen A; van Houwelingen HC; Apperley JF; Chronic Leukaemia Working Party of the EBMT. (2001). Female donors influence transplant related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. Hematol J. 2:363-370.
• Garin MI; Garrett E; Tiberghien P; Apperley JF; Chalmers D; Melo JV; Ferrand C. (1 Jan 2001). Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood. 97:122-129.
• Pocock CF; Szydlo RM; Davis JD; de la FJ; Craddock C; Cwynarski K; Olavarria E; Rezvani K; et alKanfer E; Apperley JF; Goldman JM. (2001). Stem cell transplantation for chronic myeloid leukemia: the role of infused marrow cell dose. Hematol J. 2:265-272.
• Pocock C; Szydlo R; Davis J; de La Fuente J; Craddock C; Cwynarski K; Olavarria E; Rezvani K; et alKanfer E; Apperley J; Goldman J. (2001). Stem cell transplantation for chronic myeloid leukaemia: the role of infused marrow cell dose. Hematol J. 2:265-272. DOI.
• Craddock C; Szydlo RM; Dazzi F; Olavarria E; Cwynarski K; Yong A; Brookes P; de la Fuente J; et alKanfer E; Apperley JF; Goldman JM. (Jan 2001). Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol. 112:228-236.
• Craddock C; Bardy P; Kreiter S; Johnston R; Apperley J; Marks D; Huber C; Kolbe K; et alGoulding R; Lawler M; Goldman J; Hughes T; Derigs G. (Dec 2000). Short Report: Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. Br J Haematol. 111:797-800.
• Boecklin F; Hasserjian RP; Olavarria E; Armstrong L; Mulvanny M; Eades A; Chase A; Bua M; et alZaiac M; Apperley J; Goldman JM. (16 Nov 2000). Anti-fibrogenic effect of the tyrosine kinase inhibitor STI-571 on bone marrow fibrosis in chronic myeloid leukemia. BLOOD. 96:734A-734A. Author weblink.
• Lalancette M; Michallet M; Szydlo R; Rezvani K; Mackinnon S; Blaise D; Finke J; Slavin S; et alAlessandrino EP; Niederwieser D; Frassoni F; Gahrton G; Apperley J. (16 Nov 2000). The importance of patient selection in non-myeloablative stem cell transplant (NMSCT) for acute and chronic leukemia, myelodysplastic syndrome, and myeloma. BLOOD. 96:199A-199A. Author weblink.
• Bakkus M; Bouko Y; Everaert T; Samson D; Thielemans K; Bourhis JH; Pico J; Goldschmidt H; et alApperley J. (16 Nov 2000). Tumor cell depletion by CD34 selection in multiple myeloma patients: A randomised phase III study of the EBMT. BLOOD. 96:583A-+. Author weblink.
• de la Fuente J; Pocock CF; Szydlo RM; Davis JG; Craddock C; Cwynarski K; Olavarria E; Rezvani K; et alKanfer E; Apperley JF; Goldman JM. (16 Nov 2000). Impact of marrow cell dose on the outcome of stem cell allografts for the treatment of chronic myeloid leukaemia: Improved survival in unrelated donor allografts receiving a high marrow cell dose (> 3.65x10(3)/kg). BLOOD. 96:554A-+. Author weblink.
• Hasserjian RP; Boecklin F; Parker S; Grover S; Dhar S; Zaiac M; Olavarria E; Lampert IA; et alApperley J; Goldman JM. (16 Nov 2000). Effects of STI571 on bone marrow morphology in patients with CML: A longitudinal study of 49 patients. BLOOD. 96:735A-735A. Author weblink.
• Rezvani K; Lalancette M; Szydlo R; Mackinnon S; Blaise D; Slavin S; Alessandrino EP; Michallet M; et alNiederwieser N; Apperley J; Frassoni F. (16 Nov 2000). Non-myeloablative stem cell transplant (NMSCT) in AML, ALL, and MDS: Disappointing outcome for patients with advanced phase disease. BLOOD. 96:479A-479A. Author weblink.
• Garin MI; Garrett E; Tiberghien P; Apperley JF; Chalmers D; Melo JV; Ferrand C. (16 Nov 2000). In vivo expression of Herpes simplex virus thymidine kinase gene in human T-lymphocytes transduced with retroviral vectors. BLOOD. 96:802A-802A. Author weblink.
• Chalmers DE; Ferrand C; Apperley J; Melo J; Newton I; Duperrier A; Tiberghien P; Garin M. (16 Nov 2000). Non-degenerate third base change eliminates the production of truncated non functional message from the Herpes Simplex thymidine kinase gene. BLOOD. 96:377B-377B. Author weblink.
• Rezvani K; Lawler M; Goulding R; Kaedar J; Dazzi F; Domingo E; Pocock C; Johnston R; et alGardiner N; McCann S; Craddock C; Apperley J; Goldman J. (16 Nov 2000). Myeloid and lymphoid chimerism in long-term survivors post SCT for CML-CP: The presence of recipient hematopoiesis is not predictive of relapse and correlates with lower GVHD risk. BLOOD. 96:479A-479A. Author weblink.
• Sauce D; Bodinier M; Garin M; Petracca B; Duperrier A; Tonnelier N; Lang F; Apperley J; et alFerrand C; Herve P; Tiberghien P; Robinet E. (16 Nov 2000). Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-EBV response through both culture-dependent and gene transfer-dependent mechanisms. BLOOD. 96:845A-845A. Author weblink.
• Guglielmi C; Apperley J; Arcese W; Bunjes D; Dazzi F; Schattenberg A; Verdonck LF; Niederwieser D; et alKolb HJ. (16 Nov 2000). Risk assessment in patients with Ph plus CML treated with donor lymphocyte transfusion at relapse after allogeneic stem cell transplant. BLOOD. 96:545A-545A. Author weblink.
• Olavarria E; Reiffers J; Boque C; Sureda A; Capria S; Michallet M; Clark R; Blaise D; et alCarella A; Cahn JY; Jouet JP; Rizzoli V; Niederwieser D; Apperley J. (16 Nov 2000). The cytogenetic response on interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukemia in chronic phase. BLOOD. 96:842A-842A. Author weblink.
• Lalancette M; Rezvani K; Szydlo R; Mackinnon S; Juliusson G; Michallet M; Slavin S; Frassoni F; et alNiederwieser D; Gahrton G; Apperley J. (16 Nov 2000). Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: The EBMT experience. BLOOD. 96:204A-204A. Author weblink.
• Lalancette M; Rezvani K; Szydlo R; Mayer J; Blaise D; Zander A; Michallet M; Slavin S; et alFrassoni F; Gahrton G; Niederwieser D; Apperley J. (16 Nov 2000). Favorable outcome of non-myeloablative stem cell transplant (NMSCT) for chronic myeloid leukaemia (CML) in first chronic phase: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). BLOOD. 96:545A-545A. Author weblink.
• Mughal TI; Yong A; Szydlo RM; Kaeda J; Cross NCP; Craddock C; Kanfer E; Apperley JF; et alGoldman JM. (16 Nov 2000). RT-PCR studies in patients with chronic myeloid leukemia (CML) in remission 5 years after allogeneic stem cell transplant (SCT) define rise of subsequent relapse. BLOOD. 96:141A-141A. Author weblink.
• Rezvani K; Rahemtulla A; Cummins M; Cwynarski K; Gilleece M; Szydlo R; Kanfer E; Apperley J; et alGoldman J; Dazzi F. (16 Nov 2000). Donor lymphocyte infusions (DLI) for CML: Factors influencing the effective cell dose and implications for the definition of refractoriness. BLOOD. 96:195A-195A. Author weblink.
• Olavarria E; Boecklin E; Rezvani K; Vulliamy T; Zaiac M; Parker S; Chase A; Mulvanny M; et alArmstrong L; Rahemtulla A; Kanfer E; Apperley J; Goldman J. (16 Nov 2000). STI-571 induces mixed chimerism in patients relapsing in blastic transformation after allogeneic stem cell transplantation for chronic myeloid leukemia. BLOOD. 96:471A-471A. Author weblink.
• Apperley JF; Brand R; Gratwohl A; Hermans J; Niederwieser D; Frassoni F. (16 Nov 2000). Is center size an accurate surrogate marker of quality of patient care in stem cell transplant units?. BLOOD. 96:846A-846A. Author weblink.
• Goldschmidt H; Bouko Y; Bourhis JH; Greinix H; Salles G; Derigs G; Feremans W; Hegenbart U; et alBakkus M; Samson D; Gahrton G; Pico JL; Apperley J. (16 Nov 2000). CD34+selected PBPCT results in an increased infective risk without prolongation of event free survival in newly diagnosed myeloma: A randomised study from the EBMT. BLOOD. 96:558A-+.
• Gratwohl A; Brand R; Apperley J; Biezen AV; Devergie A; deWitte T; Frassoni F; Guglielmi C; et alMichallet M; Kolb H; Ruutu T; Niederwieser D. (16 Nov 2000). Prognostic relevance of acute graft-versus-host disease (AGvHD) on outcome in patients transplanted with HLA-identical sibling transplants for chronic myeloid leukemia (CML) in first chronic phase. BLOOD. 96:193A-193A.
• Michallet M; Brand R; Dreger P; Millighan D; Esteve J; Kimby E; Apperley J; Van Biezen A; et alNiederwieser D. (16 Nov 2000). Allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): Results and prognostic factors for survival after transplantation. Analysis from EBMT registry. BLOOD. 96:205A-205A.
• Schmitz N; Beksac M; Hasenclever D; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; et alApperley J; Gorin N; Szer J; Bradstock K; Varet B; Clark P; Borkett K; Gratwohl A. (16 Nov 2000). A randomised study from the European Group for Blood and Marrow Transplantation comparing allogeneic transplantation of filgrastim-mobilised peripheral blood progenitor cells with bone marrow transplantation in 350 patients (pts) with leukemia. BLOOD. 96:481A-481A.
• Olavarria E; Hassan M; Eades A; Nilsson C; Timms A; Matthews J; Craddock C; Kanfer E; et alApperley J; Goldman J. (1 Nov 2000). A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. LEUKEMIA. 14:1954-1959. Author weblink DOI.
• Dazzi F; Szydlo RM; Cross NCP; Craddock C; Kaeda J; Kanfer E; Cwynarski K; Olavarria E; et alYong A; Apperley JF; Goldman JM. (15 Oct 2000). Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. BLOOD. 96:2612-2616.
• Dazzi F; Szydlo RM; Cross NC; Craddock C; Kaeda J; Kanfer E; Cwynarski K; Olavarria E; et alYong A; Apperley JF; Goldman JM. (15 Oct 2000). Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 96:2712-2716.
• de Witte T; Hermans J; Vossen J; Bacigalupo A; Meloni G; Jacobsen N; Ruutu T; Ljungman P; et alGratwohl A; Runde V; Niederwieser D; van Biezen A; Devergie A; Cornelissen J; Jouet JP; Arnold R; Apperley J. (Sep 2000). Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 110:620-630.
• Craddock C; Szydlo RM; Klein JP; Dazzi F; Olavarria E; van Rhee F; Pocock C; Cwynarski K; et alApperley JF; Goldman JM. (1 Jul 2000). Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood. 96:86-90.
• Kalotychou V; Rombos Y; Apperley J. (1 Jul 2000). Amifostine protects normal pluripotent peripheral blood stem cells against the toxicity of Idarubicin. EXPERIMENTAL HEMATOLOGY. 28:123-123. DOI.
• Olavarria E; Parker S; Craddock C; Philpott N; Tiniakou M; Chase A; Kanfer E; Apperley JF; et alGoldman JM. (Jun 2000). Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilization. Haematologica. 85:647-652.
• Rivas C; Chandler P; Melo JV; Simpson E; Apperley JF. (Jun 2000). Absence of in vitro or in vivo bystander effects in a thymidine kinase-transduced murine T lymphoma. Cancer Gene Ther. 7:954-962. DOI.
• Guglielmi C; Arcese W; Hermans J; Bacigalupo A; Bandini G; Bunjes D; Carreras E; Devergie A; et alFrassoni F; Goldman J; Gratwohl A; Kolb HJ; Iori AP; Niederwieser D; Prentice HG; de Witte T; Apperley J. (1 Jun 2000). Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 95:3328-3334.
• Guglielmi C; Arcese W; Hermans J; Bacigalupo A; Bandini G; Bunjes D; Carreras E; Devergie A; et alFrassoni F; Goldman J; Gratwohl A; Kolb HJ; Iori AP; Niederwieser D; Prentice HG; de Witte E; Apperley J. (1 Jun 2000). Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. BLOOD. 95:3328-3334.
• Posthuma EF; Falkenburg JH; Apperley JF; Gratwohl A; Hertenstein B; Schipper RF; Oudshoorn M; Biezen JH; et alHermans J; Willemze R; Roosnek E; Niederwieser D. (May 2000). HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. Leukemia. 14:859-862.
• Posthuma EFM; Falkenburg JHF; Apperley JF; Gratwohl A; Hertenstein B; Schipper RF; Oudshoorn M; von Biezen JH; et alHermans J; Willemze R; Roosnek E; Niederwieser D. (1 May 2000). HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). LEUKEMIA. 14:859-862. Author weblink DOI.
• Michallet M; Thiébaut A; Dreger P; Remes K; Milpied N; Santini G; Hamon M; Björkstrand B; et alKimby E; Belhabri A; Tanguy ML; Apperley JF. (Mar 2000). Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol. 108:595-601.
• Olavarria E; Kanfer E; Szydlo R; O'Brien S; Craddock C; Apperley J; Goldman J. (Mar 2000). High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience. Br J Haematol. 108:769-777.
• Garin MI; Apperley JF; Melo JV. (Feb 2000). Ex vivo expansion and characterisation of CD34+ cells derived from chronic myeloid leukaemia bone marrow and peripheral blood, and from normal bone marrow and mobilised peripheral blood. Eur J Haematol. 64:85-92.
• Karadag A; Oyajobi BO; Apperley JF; Russell RG; Croucher PI. (Feb 2000). Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts. Br J Haematol. 108:383-390.
• Garrett E; Miller AR; Goldman JM; Apperley JF; Melo JV. (5 Jan 2000). Characterization of recombination events leading to the production of an ecotropic replication-competent retrovirus in a GP+envAM12-derived producer cell line. Virology. 266:170-179. DOI.
• Dazzi F; Szydlo RM; Craddock C; Cross NC; Kaeda J; Chase A; Olavarria E; van Rhee F; et alKanfer E; Apperley JF; Goldman JM. (1 Jan 2000). Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 95:67-71.
• Gratwohl A; van Biezen A; Hermans J; Apperley J. (2000). Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 6:211-213.
• Gratwohl A; van Biezen A; Hermans J; Apperley J. (1 Jan 2000). Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 6:211-212. DOI.
• Kolb HJ; Socié G; Duell T; Van Lint MT; Tichelli A; Apperley JF; Nekolla E; Ljungman P; et alJacobsen N; van Weel M; Wick R; Weiss M; Prentice HG. (16 Nov 1999). Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med. 131:738-744.
• Kolb HJ; Socie G; Duell T; Van Lint MT; Tichelli A; Apperley JF; Nekolla E; Ljungman P; et alJacobsen N; van Weel M; Wick R; Weiss M; Prentice HG. (16 Nov 1999). Malignant neoplasms in long-term survivors of bone marrow transplantation. ANNALS OF INTERNAL MEDICINE. 131:738-+. Author weblink.
• Olavarria E; Kaeda J; Carnicero F; Szydlo R; Cross N; Dazzi F; Rezvani K; Johnston R; et alCwynarski K; Craddock C; Kanfer E; Apperley J; Goldman J. (15 Nov 1999). Early detection of BCR/ABL transcripts by RT-PCR predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. BLOOD. 94:632A-632A. Author weblink.
• Orchard KH; Cooper M; Mehta A; Potter M; Wijdenes J; Borchardt P; Quadri S; Goldman J; et alSamson D; Apperley J; Buscombe J; Hilson A; Myers M; Amlot P; Begent R; Prentice HG. (15 Nov 1999). Targeted radiotherapy for patients with multiple myeloma: Results of pre-clinical evaluation of candidate antibodies. BLOOD. 94:302B-302B. Author weblink.
• Olavarria E; Craddock C; Philpott N; Tiniakou M; Chase A; Parker S; Kanfer E; Apperley J; et alGoldman J. (15 Nov 1999). Immunologic characterization of peripheral blood progenitor cell (PBPC) grafts mobilized with or without chemotherapy (CT) in addition to hematopoietic growth factors (GF). BLOOD. 94:329A-329A. Author weblink.
• Olavarria E; Szydlo R; Cwynarski K; Pocock C; Kanfer E; Apperley J; Craddock C; Goldman J. (15 Nov 1999). Busulfan alone provides adequate cytoreduction for second allogeneic stem cell transplants (SCT) in patients with chronic myeloid leukemia (CML) in relapse. BLOOD. 94:166A-166A. Author weblink.
• Miller ARM; Rivas C; Chandler P; Simpson E; Melo JV; Apperley JF. (15 Nov 1999). Development of an immune response to the truncated low affinity nerve growth factor receptor in mice. BLOOD. 94:414B-414B. Author weblink.
• Cwynarski K; Rebello P; Eades A; Craddock C; Kanfer E; Goldman J; Apperley J; Hale G. (15 Nov 1999). Serum levels of CAMPATH-1H in recipients of unrelated bone marrow transplants. BLOOD. 94:366B-366B. Author weblink.
• Rivas C; Miller ARM; Collado M; Lam EWF; Apperley JF; Melo JV. (15 Nov 1999). Induction of apoptosis using the HSV-tk/ganciclovir system in BCR-ABL expressing cells. BLOOD. 94:104A-104A. Author weblink.
• Dazzi F; Cwynarski K; Craddock C; Szydlo R; Kanfer E; Olavarria E; Apperley JF; Goldman JM. (15 Nov 1999). Factors influencing acute GVHD after donor lymphocyte infusion. BLOOD. 94:669A-669A. Author weblink.
• Garrett E; Staal FJ; Goldman JM; Melo JV; Apperley JF. (15 Nov 1999). Efficient cell surface marking of CML CD34(+) cells using two different forms of the Delta LNGFR gene. BLOOD. 94:410B-410B. Author weblink.
• Pocock C; Craddock C; Szydlo R; Klein J; Dazzi F; Olavarria E; Cwynarski K; Apperley J; et alGoldman J. (15 Nov 1999). 'Current leukemia free survival': A novel method for assessing results of allogeneic stem cell transplantation for CML that takes account of the impact of donor lymphocyte infusions in the treatment of relapse. BLOOD. 94:161A-161A. Author weblink.
• Frassoni F; Niedewieser D; Gratwohl A; van Biezen A; Soracco M; Beelen D; Gluckman E; Arcese W; et alAlessandrino EP; Jacobsen N; Tangun Y; Bacigalupo A; Goldman JM; Apperley JF. (15 Nov 1999). Long-term disease-free (PCR-negative) survival after identical twin transplant in chronic myeloid leukemia: Graft-versus-tumor or reduction of leukemic burden?. BLOOD. 94:641A-641A. Author weblink.
• Cwynarski K; Craddock C; Dazzi F; Szydlo R; Olavarria E; Kaeda J; Apperley J; Goldman J. (15 Nov 1999). T-cell depletion plus adoptive immunotherapy with donor lymphocyte infusions as a strategy to treat patients with chronic myeloid leukemia undergoing stem cell transplantation from volunteer unrelated donors. BLOOD. 94:567A-567A. Author weblink.
• Cwynarski K; Dazzi F; Cross NCP; Yong A; Craddock C; Kaeda J; Olavarria E; Kanfer E; et alApperley JF; Goldman JM. (15 Nov 1999). Response to donor lymphocyte infusions (DLI) of patients with CML in relapse after allografting: A long-term follow-up study using RT-PCR. BLOOD. 94:669A-669A. Author weblink.
• Olavarria E; Craddock C; Philpott N; Tiniakou M; Chase A; Parker S; Kanfer E; Apperley J; et alGoldman J. (15 Nov 1999). Collection of philadelphia negative progenitor cells from interferon responsive patients with chronic myeloid leukemia. Effect of G-CSF mobilisation. BLOOD. 94:329A-329A. Author weblink.
• Michallet M; Hermans J; Dreger P; Kimby E; Bandini G; Esteve J; Van Biezen A; Gratwhol A; et alNiederwieser D; Bilger K; Apperley J. (15 Nov 1999). Allotransplants and autotransplants in chronic lymphocytic leukemia (CLL) in Europe. BLOOD. 94:165A-165A.
• Craddock C; Hughes T; Johnston R; Kreiter S; Bardy P; Apperley J; Goldman J; Derigs G. (15 Nov 1999). Engraftment of T depleted allogeneic peripheral blood stem cells using a non-myeloablative conditioning regimen. BLOOD. 94:394A-394A.
• Cwynarski K; Ainsworth J; Wagner S; Mahendra P; Apperley J; Goldman J; Craddock C; Moss P. (15 Nov 1999). Direct quantitation of cytomegalovirus specific T-cell reconstitution after allogeneic bone marrow transplantation using HLA-peptide tetramers. BLOOD. 94:395A-395A.
• Guglielmi C; Arcese W; Hermans J; Bacigalupo A; Bandini G; Bunjes D; Carreras E; Devergie A; et alFrassoni F; Goldman J; Gratwohl A; Kolb HJ; Iori AP; Niederwieser D; Prentice HG; de Witte T; Apperley J. (15 Nov 1999). Risk assessment in patients with Ph plus CML at first relapse after allogeneic stem cell transplant. BLOOD. 94:640A-640A.
• Bjorkstrand BT; Svensson H; Goldschmidt H; Ljungman PT; Apperley J; Remes K; Marcus R; Barbui T; et alAlegre A; Majolino I; Carlson K; Boogaerts M; Coser P; Iriondo A; Sureda A; Lenhoff S; de Laurenzi A; Blade J; Ferrant A; Goldstone AH; Gahrton G. (15 Nov 1999). 5489 autotransplants in multiple myeloma - A registry study from the European group for blood and marrow transplantation (EBMT). BLOOD. 94:714A-714A.
• Garrett E; Garin MI; Miller AR; Goldman JM; Melo JV; Apperley JF. (Nov 1999). Enhanced retroviral gene transfer into CML and normal bone marrow, and CML and mobilized peripheral blood CD34+ cells using the recombinant fibronectin fragment CH-296. Br J Haematol. 107:401-408.
• Gahrton G; Svensson H; Björkstrand B; Apperley J; Carlson K; Cavo M; Ferrant A; Fouillard L; et alGratecos N; Gratwohl A; Guilhot F; Lambertenghi Deliliers G; Ljungman P; Masszi T; Milligan DW; Powles RL; Reiffers J; Samson JD; Stoppa AM; Vernant JP; Volin L; Wallvik J. (Oct 1999). Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 24:741-745. DOI.
• Gahrton G; Svensson H; Bjorkstrand B; Apperley J; Carlson K; Cavo M; Ferrant A; Fouillard L; et alGratecos N; Gratwohl A; Guilhot F; Deliliers GL; Ljungman P; Masszi T; Milligan DW; Powles RL; Reiffers J; Samson JD; Stoppa AM; Vernant JP; Volin L; Wallvik J. (1 Oct 1999). Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. BONE MARROW TRANSPLANTATION. 24:741-745. DOI.
• Apperley JF. (1 Sep 1999). Bone marrow transplantation for multiple myeloma. EUROPEAN JOURNAL OF CANCER. 35:S304-S304. Author weblink DOI.
• Gooding RP; Bybee A; Cooke F; Little A; Marsh SG; Coelho E; Gupta D; Samson D; et alApperley JF. (Sep 1999). Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia. Br J Haematol. 106:669-681.
• McCann S; Apperley J; Cohen A; Kolb HJ. (28 Aug 1999). Late effects of transplantation. Gerard Socie, for the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 354:778.
• McCann S; Apperley J; Cohen A; Kolb HJ; Socie G. (28 Aug 1999). Late effects of transplantation. LANCET. 354:778-778. DOI.
• Boiron JM; Cahn JY; Meloni G; Carlo-Stella C; Bandini G; Reman O; Milpied N; Apperley J; et alReiffers J. (Aug 1999). Chronic myeloid leukemia in first chronic phase not responding to alpha-interferon: outcome and prognostic factors after autologous transplantation. EBMT Working Party on Chronic Leukemias. Bone Marrow Transplant. 24:259-264. DOI.
• Boiron JM; Cahn JY; Meloni G; Carlo-Stella C; Bandini G; Reman O; Milpied N; Apperley J; et alReiffers J. (1 Aug 1999). Chronic myeloid leukemia in first chronic phase not responding to alpha-interferon: outcome and prognostic factors after autologous transplantation. BONE MARROW TRANSPLANTATION. 24:259-264. DOI.
• Posthuma EFM; Falkenburg JHF; Apperley JF; Gratwohl A; Roosnek E; Hertenstein B; Schipper RF; Schreuder GMT; et alD'Amaro J; Oudshoorn M; von Biezen JH; Hermans J; Willemze R; Niederwieser D. (1 Jun 1999). HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. BLOOD. 93:3863-3865. Author weblink.
• Posthuma EF; Falkenburg JH; Apperley JF; Gratwohl A; Roosnek E; Hertenstein B; Schipper RF; Schreuder GM; et alD'Amaro J; Oudshoorn M; van Biezen JH; Hermans J; Willemze R; Niederwieser D. (1 Jun 1999). HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood. 93:3863-3865.
• Cohen A; Duell T; Socie G; van Lint MT; Weiss M; Tichelli A; Rovelli A; Apperley JF; et alLjungman P; Kolb HJ. (1 May 1999). Nutritional status and growth after bone marrow transplantation (BMT) during childhood: EBMT Late-Effects Working Party retrospective data. BONE MARROW TRANSPLANTATION. 23:1043-1047. Author weblink DOI.
• Cohen A; Duell T; Socié G; van Lint MT; Weiss M; Tichelli A; Rovelli A; Apperley JF; et alLjungman P; Kolb HJ. (May 1999). Nutritional status and growth after bone marrow transplantation (BMT) during childhood: EBMT Late-Effects Working Party retrospective data. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 23:1043-1047. DOI.
• Gillmore JD; Apperley JF; Pepys MB; Hawkins PN. (1 May 1999). High dose chemotherapy for systemic AL amyloidosis. KIDNEY INTERNATIONAL. 55:2103-2103. Author weblink.
• Child FJ; Ratnavel R; Watkins P; Samson D; Apperley J; Ball J; Taylor P; Russell-Jones R. (May 1999). Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant. 23:881-887. DOI.
• Cooke F; Bakkus M; Thielemans K; Pico JL; Apperley JF; Samson D. (Apr 1999). Use of quantitative ASO-PCR to predict relapse in multiple myeloma. Br J Haematol. 105:317-319.
• Olavarria E; Craddock C; Cwynarski K; Timms A; Eades A; Kanfer E; Apperley J; Goldman JM. (1 Apr 1999). A multiple-dose phase I pharmacokinetic study of intravenous busulfan as myeloablation prior to bone marrow transplantation. BRITISH JOURNAL OF HAEMATOLOGY. 105:55-55.
• Craddock C; Kreiter S; Johnston R; Olavarria E; Cwynarski K; Kanfer E; Apperley J; Derigs G; et alGoldman J. (1 Apr 1999). Engraftment of T depleted allogeneic peripheral blood stem cells using a non-myeloablative conditioning regimen. BRITISH JOURNAL OF HAEMATOLOGY. 105:60-60. Author weblink.
• Cwynarski K; Yong ASM; Szydlo RM; Apperley JF. (1 Apr 1999). Thyroid and gonadotrophin function following allogeneic BMT in men. BRITISH JOURNAL OF HAEMATOLOGY. 105:55-55. Author weblink.
• Craddock C; Dazzi F; Szydlo R; Cwynarski K; Olavarria E; Brookes P; Kanfer E; Apperley J; et alGoldman J. (1 Apr 1999). Impact of donor leucocyte infusions on outcome after T cell depleted volunteer unrelated donor (VUD) bone marrow transplantation in patients with CML. BRITISH JOURNAL OF HAEMATOLOGY. 105:32-32. Author weblink.
• Stocchi R; Szydlo R; Craddock C; Kanfer E; Apperley JF; Goldman JM; Ward KN. (Apr 1999). A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation. Bone Marrow Transplant. 23:705-709. DOI.
• Cwynarski K; Roberts IAG; van Biezen A; Niethammer D; Apperley J. (1 Apr 1999). BMT for children with adult type chronic myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY. 105:66-66.
• Olavarria E; Timms A; Eates A; Kanfer E; Craddock C; Apperley J; Goldman J. (1 Mar 1999). A phase I pharmacokinetic study of an intravenous preparation of busulphan as cytoreduction before transplant for patients with leukaemia. BONE MARROW TRANSPLANTATION. 23:S76-S76. Author weblink.
• Yong ASM; Cwynarski K; Szydlo RM; Apperley JF. (1 Mar 1999). Thyroid and gonadotrophin function following allogeneic BMT in men. BONE MARROW TRANSPLANTATION. 23:S131-S131. Author weblink.
• Dazzi F; Craddock C; Szydlo R; Kaeda J; Kanfer E; Cross NCP; Apperley J; Goldman JM. (1 Mar 1999). Donor lymphocyte infusion (DLI) for relapse of chronic myeloid leukemia (CML) after allogeneic stem cell transplant (SCT): Factors influencing the effective cell dose (ECD). BONE MARROW TRANSPLANTATION. 23:S43-S43. Author weblink.
• Michallet M; Van Biezen A; Bandini G; Carreras E; Cornelissen JJ; Dreger P; Einsele H; Gratwhol A; et alKimby E; Niederwieser D; Apperley J. (1 Mar 1999). Allotransplants and autotransplants in chronic lymphocytic leukemia (CLL). BONE MARROW TRANSPLANTATION. 23:S53-S53.
• Guglielmi C; Arcese W; Hermans J; Gratwohl A; Kolb HJ; Niederwieser D; Apperley J. (1 Mar 1999). Risk assessment in patients with Ph+CML at first relapse after allogeneic BMT. An EBMT retrospective analysis. BONE MARROW TRANSPLANTATION. 23:S59-S59.
• Bjorkstrand B; Svensson H; Goldschmidt H; Ljungman P; Apperley J; Remes K; Marcus R; Barbui T; et alSureda A; Lenhoff S; de Laurenzi A; Blade J; Ferrant A; Goldstone AH; Gahrton G. (1 Mar 1999). Autologous stem cell transplantation (ASCT) in multiple myeloma (MM) - The 1999 EBMT registry update. BONE MARROW TRANSPLANTATION. 23:S133-S133.
• Gahrton G; Svensson H; Cavo M; Apperley J; Bacigalupo A; Bjorkstrand B; Blade J; de Laurenzi A; et alde Vries T; Ljungman P; Michallet M; Reiffers J; Russell NH; Samson D; Schaefer UW; Schattenberg A; Thierry F; Verdonck LF; Vernant JP; Volin L. (1 Mar 1999). Prognostic influence of the type of graft in allogeneic transplantation for multiple myeloma. BONE MARROW TRANSPLANTATION. 23:S134-S134.
• Arnold R; Hermans J; De Witte T; van Biezen A; Jacobsen N; Runde V; Gratwohl A; Apperley J. (1 Mar 1999). Unrelated bone marrow transplantation compared with autologous transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: An EBMT survey. BONE MARROW TRANSPLANTATION. 23:S152-S152.
• Pikkemaat F; De Witte T; van Biezen A; Hermans J; Mackinnan S; Cornelissen J; Gratwohl A; Boogaerts M; et alIriondo A; Kuentz M; Harousseau J; Fauser A; Wandt H; Niederwieser D; Apperley J. (1 Mar 1999). Transplantation with nonidentical donors for myelodysplastic syndrome and secondary acute myeloid leukemia. BONE MARROW TRANSPLANTATION. 23:S153-S153.
• Runde V; de Witte T; van Biezen A; Hermans J; Arnold R; Locatelli F; Gratwohl A; Apperley J. (1 Mar 1999). Allogeneic stem cell transplantation (SCT) from HLA-identical siblings in patients with myelodysplasia or secondary acute myeloid leukemia. BONE MARROW TRANSPLANTATION. 23:S153-S153.
• de Witte T; van Biezen A; Hermans J; Laporte JP; Meloni G; Tura S; Holowiecki J; Boogaerts M; et alMarcus R; Mauri SB; Cahn JY; Diez-Martin JL; Niederwieser D; Gratwohl A; Apperley J. (1 Mar 1999). Prognostic factors in autologous stem cell transplantation (ASCT) for patients with MDS and AML following MDS. BONE MARROW TRANSPLANTATION. 23:S154-S154.
• Gratwohl A; Hermans J; de Elvira CR; Ljungman P; Gorin NC; Frassoni F; Apperley J; Rosti G; et alGahrton G; Goldstone AH; Schmitz N; Schrezenmeier H; Friedrich W; Niethammer D; Bacigalupo A. (1 Mar 1999). Outcome of blood and marrow transplants in Europe. BONE MARROW TRANSPLANTATION. 23:S184-S184.
• Apperley JF; Croucher PI. (Feb 1999). Bisphosphonates in multiple myeloma. Pathol Biol (Paris). 47:178-181.
• Sati HI; Greaves M; Apperley JF; Russell RG; Croucher PI. (Feb 1999). Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma. Br J Haematol. 104:350-357.
• Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF. (Jan 1999). Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Haematologica. 84:71-79.
• Gupta D; Bybee A; Cooke F; Giles C; Davis JG; McDonald C; Armitage SE; McGuigan D; et alLyttelton MP; Kanfer EJ; Apperley JF; Samson D. (Jan 1999). CD34+-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome. Br J Haematol. 104:166-177.
• Croucher PI; Apperley JF. (Dec 1998). Bone disease in multiple myeloma. Br J Haematol. 103:902-910.
• Shipman CM; Rogers MJ; Apperley JF; Graham R; Russell G; Croucher PI. (Dec 1998). Anti-tumour activity of bisphosphonates in human myeloma cells. Leuk Lymphoma. 32:129-138. DOI.
• Dazzi F; Craddock C; Szydlo R; Kaeda J; Montefusco V; Kanfer E; Cross NCP; Apperley J; et alGoldman JM. (15 Nov 1998). Adoptive immunotherapy with donor lymphocytes for relapse of chronic myeloid leukemia (CML) after allogeneic stem cell transplant (SCT): Factor influencing the effective cell dose (ECD). BLOOD. 92:494A-494A. Author weblink.
• Abusedra A; Bybee A; Laffan M; Apperley JF. (15 Nov 1998). Detection and characterisation of clonal immunoglobulin gene rearrangements in AL amyloidosis. BLOOD. 92:262A-262A. Author weblink.
• Craddock C; Szydlo R; Ward K; Brookes P; McKinty B; de la Fuente J; Olavarria E; Yong A; et alCwynarski K; Kanfer E; Apperley J; Goldman J. (15 Nov 1998). Outcome after T depleted volunteer unrelated donor (VUD) transplantation in CML: The case for patient specific GVHD prophylaxis. BLOOD. 92:143A-143A. Author weblink.
• Olavarria E; Craddock C; Cwynarski K; Yong ASM; Hassan M; Matthews J; Timms A; Eades A; et alApperley JF; Kanfer E; Goldman JM. (15 Nov 1998). A multiple-dose phase I pharmacokinetic study of intravenous busulfan as myeloablation prior to bone marrow transplantation. BLOOD. 92:684A-684A. Author weblink.
• Craddock C; Dazzi F; Szydlo RM; Olavarria E; Cross NCP; van Rhee F; Kanfer E; Apperley JF; et alGoldman JM. (15 Nov 1998). Donor lymphocyte infusions produce durable molecular remission in patients who relapse after allografting for CML in chronic phase: The consequent need to reassess the definition of leukemia free survival. BLOOD. 92:654A-654A. Author weblink.
• Garrett E; Miller ARM; Chong H; Vile RG; Goldman JM; Apperley JF; Melo JV. (15 Nov 1998). Characterisation of a replication competent retrovirus present in a GP+envAM12-derived producer cell line. BLOOD. 92:470A-470A. Author weblink.
• Garrett E; Miller ARM; Goldman JM; Melo JV; Apperley JF. (15 Nov 1998). Enhanced gene transfer into CML and normal bone marrow, and CML and mobilised peripheral blood CD34+ cells, using the recombinant fibronectin fragment CH-296. BLOOD. 92:377B-377B. Author weblink.
• Carreras E; Bertz H; Arcese W; Vernant JP; Tomas JF; Hagglund H; Bandini G; Esperou H; et alRussell J; de la Rubia J; Di Girolamo G; Demuynck H; Hartmann O; Clausen J; Ruutu T; Leblond V; Iriondo A; Bosi A; Ben-Bassat I; Koza V; Gratwohl A; Apperley JF. (15 Nov 1998). Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European group for blood and marrow transplantation. BLOOD. 92:3599-3604.
• Kolb HJ; Schmid C; Muth A; Humann M; Ledderose G; Holler E; Munker R; Niederwieser D; et alApperley JF. (15 Nov 1998). Donor cell transfusion for the treatment of recur-adoptive immunotherapy using donor cells and GM-CSF for recurrent acute leukemia and acute phase CML after allogeneic marrow transplantation. BLOOD. 92:344B-344B. Author weblink.
• Garin MI; Miller ARM; Goldman JM; Melo JV; Apperley JF. (15 Nov 1998). Characterization of retroviral-mediated gene transfer of HSV-TK and low affinity nerve growth factor receptor (LNGFR) in human T-cell lines. BLOOD. 92:377B-377B. Author weblink.
• Dazzi F; Szydlo RM; Craddock C; Olavarria E; Kaeda J; van Rhee F; Cross NCP; Apperley JF; et alGoldman JM. (15 Nov 1998). Adoptive immunotherapy for patients who relapse after allografting for chronic myeloid leukemia: A comparison of two regimens for donor lymphocyte infusion. BLOOD. 92:653A-653A. Author weblink.
• Carreras E; Bertz H; Arcese W; Vernant JP; Tomás JF; Hagglund H; Bandini G; Esperou H; et alRussell J; de la Rubia J; Di Girolamo G; Demuynck H; Hartmann O; Clausen J; Ruutu T; Leblond V; Iriondo A; Bosi A; Ben-Bassat I; Koza V; Gratwohl A; Apperley JF. (15 Nov 1998). Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood. 92:3599-3604.
• Arnold R; Hermans J; De Witte T; van Biezen A; Jacobsen N; Runde V; Gratwohl A; Apperley J. (15 Nov 1998). Unrelated bone marrow transplantation compared with autologous transplantation inpatients with myelodysplastic syndromes and secondary acute myeloid leukemia: An EMBT survey. BLOOD. 92:142A-142A.
• Gratwohl A; Hermans J; van Biezen A; van Houwelingen H; Niederwieser D; Apperley J. (15 Nov 1998). Delayed and divergent effects of anti-HY minor histocompatibility antigen reactivity after allogeneic BMT for CML. BLOOD. 92:320A-320A.
• De Witte T; Suciu S; Verhoef G; Labar B; Archimbaud E; Aul C; Selleslag D; Ferrant A; et alWijermans P; Mandelli F; Amadori S; Jehn U; Muus P; DeMuynck H; Dardenne M; Zittoun R; Willemze R; Gratwohl A; Apperley J. (15 Nov 1998). Intensive chemotherapy followed by stem cell transplantation for patients with poor-risk mds and secondary AML (sAML). BLOOD. 92:714A-714A.
• Apperley JF. (Nov 1998). Hematopoietic stem cell transplantation in chronic myeloid leukemia. Curr Opin Hematol. 5:445-453.
• Gratwohl A; Hermans J; Goldman JM; Arcese W; Carreras E; Devergie A; Frassoni F; Gahrton G; et alKolb H; Niederwieser D; Ruutu T; Vernant JP; de Witte T; Apperley J. (3 Oct 1998). Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. LANCET. 352:1087-1092. Author weblink DOI.
• Gratwohl A; Hermans J; Goldman JM; Arcese W; Carreras E; Devergie A; Frassoni F; Gahrton G; et alKolb HJ; Niederwieser D; Ruutu T; Vernant JP; de Witte T; Apperley J. (3 Oct 1998). Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 352:1087-1092.
• Apperley JF; Dazzi F; Craddock C; Goldman JM. (Oct 1998). Immunotherapy for chronic myeloid leukaemia. Hematol Cell Ther. 40:229-232.
• Duguid JKM; Gesinde MO; Green RHA; Kinsey SE; Oscier DG; Potock D; Russell NH; Smith JG; et alKelsey PR; Bruce M; Chapman J; Duguid JKM; Knowles SM; Murphy MF; Williamson LM; Wood JK; Smith JG; Davies JM; Apperley JF; Gauly PS; Gozzard D; Kinsey S; Oscier DG. (1 Oct 1998). Guidelines for the clinical use of blood cell separators. CLINICAL AND LABORATORY HAEMATOLOGY. 20:265-278. Author weblink.
• Kanfer EJ; McGuigan D; Samson D; Abboudi Z; Abrahamson G; Apperley JF; Chilcott S; Craddock C; et alDavis J; MacDonald C; Macdonald D; Olavarria E; Philpott N; Rustin GJ; Seckl MJ; Sekhar M; Stern S; Newlands ES. (Oct 1998). High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels. Br J Cancer. 78:928-932.
• Ruutu T; Hermans J; van Biezen A; Niederwieser D; Gratwohl A; Apperley JF. (Sep 1998). How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 22:614-615. DOI.
• Ruutu T; Hermans J; van Biezen A; Niederwieser D; Gratwohl A; Apperley JF. (1 Sep 1998). How should corticosteroids be used in the treatment of acute GVHD?. BONE MARROW TRANSPLANTATION. 22:614-615. Author weblink DOI.
• Bladé J; Samson D; Reece D; Apperley J; Björkstrand B; Gahrton G; Gertz M; Giralt S; et alJagannath S; Vesole D. (Sep 1998). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 102:1115-1123.
• Olavarria E; Murphy K; Dazzi F; Craddock C; Philpott NJ; Apperley JF; Kanfer E; Goldman JM. (1 Jul 1998). Low incidence of GVHD using donor lymphocyte infusions (DLI) with an escalating dose protocol. BRITISH JOURNAL OF HAEMATOLOGY. 102:86-86. Author weblink.
• Capelli D; Szydlo RM; Savage DG; Apperley JF; Goldman JW. (1 Jul 1998). Prognostic factors influencing early transplant related mortality (TRM) after allogeneic bone marrow transplantation with HLA-identical sibling donors for chronic myeloid leukaemia (CML). BRITISH JOURNAL OF HAEMATOLOGY. 102:318-318. Author weblink.
• Bybee A; Cooke F; Gupta D; Davies J; Apperley JF; Samson D. (1 Jul 1998). Cd34+-selected peripheral blood progenitor cell (PBPC) transplant in patients with multiple myeloma: Tumour cell contamination and outcome. BRITISH JOURNAL OF HAEMATOLOGY. 102:7-7. Author weblink.
• Dazzi F; Kaeda J; Kanfer E; Apperley JF; Goldman JM. (1 Jul 1998). Interleukin-2 may induce complete remission in patients who respond only partially to donor lymphocyte infusion (DLI) for relapse following allogeneic bone marrow transplantation. BRITISH JOURNAL OF HAEMATOLOGY. 102:287-287. Author weblink.
• Apperley JF. (1 Jul 1998). The role of matched unrelated donor transplants in the management of malignancy. BRITISH JOURNAL OF HAEMATOLOGY. 102:272-272. Author weblink.
• Posthuma EFM; Falkenburg JHF; Apperley JF; Gratwohl A; Schipper RF; Schreuder GMT; D'Amaro J; Biezen JHV; et alHermans J; Willemze R; Niederwieser D. (1 Jul 1998). HLA-DR4 and HLA-DR15 lower the risk of the acquisition of chronic myeloid leukemia (CML). BRITISH JOURNAL OF HAEMATOLOGY. 102:284-284. Author weblink.
• Abusedra A; Bybee A; Laffan M; Apperley JF. (1 Jul 1998). PCR analysis of V lambda gene usage in B cell disorders. BRITISH JOURNAL OF HAEMATOLOGY. 102:278-279.
• Michallet M; Van Biezen A; Bandini G; Carreras E; Cornelissen JJ; Dreger P; Einsele H; Gratwohl A; et alKimby E; Niedwieser D; Apperley J. (1 Jul 1998). Hematopoietic stem cell transplantations for chronic lymphocytic leukemia (CLL). BRITISH JOURNAL OF HAEMATOLOGY. 102:151-151.
• De Witte T; Suciu S; Verhoef G; Labar B; Archimbaud E; Aul C; Selleslag D; Ferrant A; et alWijermans P; Mandelli F; Amadori S; Jehn U; Muus P; DeMuynck H; Dardenne M; Zittoun R; Willemze R; Gratwohl A; Apperley J. (1 Jul 1998). Autologous stem cell transplantation (ASCT) for patients with poor risk MDS and secundary AML (sAML). BRITISH JOURNAL OF HAEMATOLOGY. 102:282-282.
• Arnold R; de Witte T; van Biezen A; Hermans J; Jacobsen N; Runde V; Gratwohl A; Apperley JF. (1 Jun 1998). Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. BONE MARROW TRANSPLANTATION. 21:1213-1216. Author weblink DOI.
• Arnold R; de Witte T; van Biezen A; Hermans J; Jacobsen N; Runde V; Gratwohl A; Apperley JF. (Jun 1998). Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant. 21:1213-1216. DOI.
• Olavarria E; Murphy K; Dazzi F; Craddock C; Philpott NJ; Apperley JF; Kanfer E; Goldman JM. (1 May 1998). Low incidence of GVHD using donor lymphocyte infusion (DLI) with an escalating dose protocol. BRITISH JOURNAL OF HAEMATOLOGY. 101:69-69. Author weblink.
• Kanfer EJ; McGuigan D; Samson D; Apperley JF; Craddock C; Davis J; Olavarria E; Stern S; et alNewlands ES. (1 May 1998). High-dose etoposide with granulocyte colony-stimulating-factor for mobilisation of peripheral blood progenitor cells: Efficacy and toxicity at three dose levels. BRITISH JOURNAL OF HAEMATOLOGY. 101:91-91. Author weblink.
• van Rhee F; Savage D; Blackwell J; Orchard K; Dazzi F; Lin F; Chase A; Bungey J; et alCross NC; Apperley J; Szydlo R; Goldman JM. (May 1998). Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant. 21:1055-1061. DOI.
• Schmitz N; Bacigalupo A; Hasenclever D; Nagler A; Gluckman E; Clark P; Bourquelot P; Greinix H; et alFrickhofen N; Ringdén O; Zander A; Apperley JF; Gorin C; Borkett K; Schwab G; Goebel M; Russell NH; Gratwohl A. (May 1998). Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 21:995-1003.
• Sati HI; Apperley JF; Greaves M; Lawry J; Gooding R; Russell RG; Croucher PI. (May 1998). Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Br J Haematol. 101:287-295.
• Craddock C; Szydlo R; Ward K; Yong A; Brookes P; Kanfer E; Apperley J; Goldman J. (1 May 1998). Impact of recipient CMV status on outcome after T-depleted volunteer unrelated donor (VUD) transplantation for CML. BRITISH JOURNAL OF HAEMATOLOGY. 101:69-69. Author weblink.
• Apperley JF; Gilmore J; Haynes A; Lim S; Marcus R; Schey S; Hawkins P. (1 May 1998). Autografting for AL amyloidosis: Recommendations for patient selection. BRITISH JOURNAL OF HAEMATOLOGY. 101:96-96. Author weblink.
• Ward KN; Elizaga J; Murphy KM; Philpott NJ; Apperley JF; Goldman JM. (1 Mar 1998). Six year survey of Parainfluenza virus (PIV) infection in bone marrow transplant (BMT) patients: Relevance of rapid diagnosis. BONE MARROW TRANSPLANTATION. 21:S155-S155.
• Frassoni F; van Biezen A; Gluckman E; Goldman JM; Arcese W; Alessandrino P; Apperley JF. (1 Mar 1998). Identical twin transplant for CML-preliminary EBMT survey: High relapse rate but excellent overall survival. BONE MARROW TRANSPLANTATION. 21:S86-S86. Author weblink.
• Davis JG; Russell-Jones R; Stewart S; Apperley JF. (1 Mar 1998). Positive/negative immunomagnetic selection in an autograft for T-cell lymphoma: A single case report. BONE MARROW TRANSPLANTATION. 21:S19-S19. Author weblink.
• Cullis JO; Duncombe AS; Dudley JM; Lumley HS; Apperley JF; Smith AG. (Mar 1998). Acute leukaemia in Jehovah's Witnesses. Br J Haematol. 100:664-668.
• Dazzi F; Raanani P; van Rhee F; Szydlo R; Olavarria E; Kaeda J; Apperley JF; Cross NCP; et alGoldman JM. (1 Mar 1998). Donor lymphocyte infusion (DLI) for relapse of CML after allo-BMT: Comparison of two regimens. BONE MARROW TRANSPLANTATION. 21:S70-S70. Author weblink.
• Roberts IAG; Niethammer D; van Biezen A; Apperley JF. (1 Mar 1998). Outcome of transplant for children with adult type CML (ACTML). BONE MARROW TRANSPLANTATION. 21:S85-S85. Author weblink.
• Apperley JF; Gilmore J; Haynes A; Lim S; Marcus R; Schey S; Hawkins P. (1 Mar 1998). Autografting for AL amyloidosis: Recommendations for patient selection. BONE MARROW TRANSPLANTATION. 21:S212-S212. Author weblink.
• Kaeda JS; Dazzi F; Baker P; Raanani P; Kanfer E; Apperley JF; Cross NCP; Goldman JM. (1 Mar 1998). Escalating doses of DLI identify a subset of CML patients in relapse after allografting in whom only a partial or transient response is achieved. BONE MARROW TRANSPLANTATION. 21:S71-S71. Author weblink.
• Stocchi R; Szydlo RM; Craddock C; Ward KN; Apperley JF; Goldman JM. (1 Mar 1998). A comparison of prophylactic versus preemptive ganciclovir to prevent cytomegalovirus (CMV) disease after volunteer unrelated donor (VUD) bone marrow transplant (BMT) for chronic myeloid leukemia (CML). BONE MARROW TRANSPLANTATION. 21:S141-S141. Author weblink.
• Capelli D; Szydlo RM; Savage DG; Apperley J; Goldman JM. (1 Mar 1998). Transplant related mortality (TRM) following allogeneic bmt for chronic myeloid leukaemia (CML) patients aged over 45. BONE MARROW TRANSPLANTATION. 21:S86-S86. Author weblink.
• Craddock C; Szydlo RM; Ward K; Yong A; Kanfer E; Apperley J; Goldman JM. (1 Mar 1998). Impact of recipient CMV status on outcome after T-depleted VUD transplantation for CML. BONE MARROW TRANSPLANTATION. 21:S33-S33. Author weblink.
• De Witte T; van Biezen A; Hermans J; Suciu S; Dardenne M; Labar B; Archimbaud E; Aul C; et alSelleslag D; Ferrant A; Meloni G; Mauri SB; Carella A; Laporte J; DeMuynck H; Niederwieser D; Gratwohl A; Apperley J. (1 Mar 1998). Autologous stem cell transplantation (ASCT) for patients with myelodysplastic syndrome and secundary acute myeloid leukemia. BONE MARROW TRANSPLANTATION. 21:S10-S10.
• Michallet M; van Biezen A; Bandini G; Carreras E; Cornelissen JJ; Dreger P; Einsele H; Gratwhol A; et alKimby E; Niederwieser D; Apperley J. (1 Mar 1998). Hematopoietic stem cell transplantations for chronic lymphocytic leukemia (CLL). BONE MARROW TRANSPLANTATION. 21:S77-S77.
• Arcese W; Apperley J. (1 Mar 1998). Second bone marrow transplantation for hematologic relapse of chronic myeloid leukemia: An EBMT retrospective analysis. BONE MARROW TRANSPLANTATION. 21:S82-S82.
• Guardiola P; Anderson JE; Bandini B; Runde V; Bacigalupo A; Cornelissen JJ; Ruutu T; Ljungman P; et alvan Biezen A; Apperley J; de Witte T; Gluckman E. (1 Mar 1998). Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. An EBMT/F. Hutchinson CRC/SFGM collaborative study. BONE MARROW TRANSPLANTATION. 21:S83-S83.
• Child FJ; Ratnaval R; Samson D; Apperley J; Russell-Jones R. (1 Mar 1998). An open study to compare PUVA and extracorporeal photophoresis (ECP) in the treatment of cutaneous chronic GVHD. BONE MARROW TRANSPLANTATION. 21:S121-S121.
• Gahrton G; Tura S; Svensson H; Ljungman P; Blade J; Bjorkstrand B; Cavo M; Facon T; et alGratwohl A; Cornelissen JJ; De Laurenzi A; Van Lint M; Michallet M; Nikoskelainen J; Reiffers J; Samson D; Schattenberg A; Verdonck L; Volin L; Apperley J. (1 Mar 1998). Allogeneic bone marrow transplantation in multiple myeloma. BONE MARROW TRANSPLANTATION. 21:S204-S204.
• Bjorkstrand B; Svensson H; Ljungman P; Apperley J; Goldschmidt H; Remes K; Alegre A; Marcus R; et alCarlson K; Coser P; Sureda A; Barbui T; Goldstone AH; Blade J; Volin L; Boogaerts M; Lenhoff S; Majolino I; Samson D; de Laurenzi A; San Miguel JF; Gahrton G. (1 Mar 1998). Autologous stem cell transplantation in multiple myeloma - The 1998 EBMT registry update. BONE MARROW TRANSPLANTATION. 21:S208-S208.
• Bjorkstrand B; Svensson H; Ljungman P; Apperley J; Remes K; Alegre A; Marcus R; Carlson K; et alCoser P; Sureda A; Barbui T; Goldstone AH; Blade J; Volin L; Boogaerts M; Lenhoff S; Majolino I; Samson D; de Laurenzi A; San Miguel JF; Gahrton G. (1 Mar 1998). Alpha-interferon treatment after autologous stem cell transplantation in multiple myeloma - A retrospective case-matched analysis. BONE MARROW TRANSPLANTATION. 21:S208-S208.
• De Witte T; van Biezen A; Hermans J; Suciu S; Dardenne M; Labar B; Archimbaud E; Aul C; et alSelleslag D; Ferrant A; Meloni G; Mauri SB; Carella A; Laporte J; DeMuynck H; Niederwieser D; Gratwohl A; Apperley J. (1 Mar 1998). Autologous stem cell transplantation (ASCT) for patients with myelodysplastic syndrome and secundary acute myeloid leukemia, on behalf of the MDS study group of the EBMT CLWP and the EORTC-LCG. BONE MARROW TRANSPLANTATION. 21:S214-S214.
• Runde V; De Witte T; Van Biezen A; Hermans J; Arnold R; Locatelli F; Gratwohl A; Apperley J. (1 Mar 1998). Transplantation of blood or marrow stem cells (BMT) from HLA-identical siblings in patients with myelodysplastic syndromes (MDS) or secondary myeloid leukemia (sAML). BONE MARROW TRANSPLANTATION. 21:S215-S215.
• Locatelli F; Giorgiani G; van Biezen A; Hermans J; Runde V; Apperley J; de Witte T. (1 Mar 1998). Bone marrow transplantation (BMT) for children with myelodysplastic syndrome: An EBMT registry analysis. BONE MARROW TRANSPLANTATION. 21:S215-S215.
• Runde V; de Witte T; Arnold R; Gratwohl A; Hermans J; van Biezen A; Niederwieser D; Labopin M; et alWalter-Noel MP; Bacigalupo A; Jacobsen N; Ljungman P; Carreras E; Kolb HJ; Aul C; Apperley J. (Feb 1998). Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 21:255-261. DOI.
• Runde V; de Witte T; Arnold R; Gratwohl A; Hermans J; Van Biezen A; Niederwieser D; Labopin M; et alWalter-Noel MP; Bacigalupo A; Jacobsen N; Ljungman P; Carreras E; Kolb HJ; Aul C; Apperley J. (1 Feb 1998). Bone marrow transplantation from HLA identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. BONE MARROW TRANSPLANTATION. 21:255-261. DOI.
• Craddock C; Szydlo R; Olavarria E; Dazzi F; VanRhee F; Apperley J; Goldman J. (15 Nov 1997). Leukemia free survival after allogeneic transplantation for chronic myeloid leukemia: Effect of reclassifying responders to donor lymphocyte infusion as ''currently free of leukemia''. BLOOD. 90:4449-4449. Author weblink.
• Posthuma EFM; Falkenburg JHF; Apperley JF; Jeannet M; Schipper RF; Schreuder GMT; DAmaro J; vonBiezen JH; et alHermans J; Willemze R; Niederwieser D. (15 Nov 1997). HLA-A3 and HLA-B8 may protect against acquiring chronic myeloid leukemia (CML). BLOOD. 90:1102-1102. Author weblink.
• Raanani P; Dazzi F; Sohal J; Szydlo RM; vanRhee F; Reiter A; Lin F; Apperley JF; et alGoldman JM; Cross NCP. (15 Nov 1997). The incidence, kinetics and durability of response to donor leukocyte transfusions for CML patients who relapse after BMT. BLOOD. 90:2443-2443. Author weblink.
• Gooding RP; Bybee A; Cooke F; Samson D; Apperley JF. (15 Nov 1997). Reverse transcribed polymerase chain reaction [RT-PCR] amplification of cytokine transcripts in single myeloma cells: Reproducibility of results. BLOOD. 90:4092-4092. Author weblink.
• Olavarria E; Dazzi F; Craddock C; Murphy KM; Philpott NJ; Kanfer E; Apperley JF; Goldman JM. (15 Nov 1997). Donor lymphocyte infusions (DLI) for treatment of CML in relapse after allogeneic BMT: Low incidence of GVHD using an escalation dose protocol. BLOOD. 90:2621-2621. Author weblink.
• Kolb HJ; Menzel H; Holler E; Verdonck L; Bunjes D; Schattenberg A; Apperley JF; Ljungman P; et alJacobsen N; Ferrant A. (15 Nov 1997). Donor cell transfusion for the treatment of recurrent leukemia after allogeneic bone marrow transplantation. BLOOD. 90:2434-2434. Author weblink.
• Orchard K; Giles C; Apperley J; Goldman JM; Kanfer EJ; Samson D. (15 Nov 1997). LACE (lomustine, ara-C, cyclophosphamide and etoposide): An effective conditioning regimen for autologous and allogeneic transplantation with minimal toxicity. BLOOD. 90:1855-1855. Author weblink.
• Dazzi F; Raanani P; vanRhee F; Olavarria E; Murphy KM; Philpott NJ; Apperley JF; Cross NCP; et alGoldman JM. (15 Nov 1997). Responses to donor lymphocyte infusion (DLI) in CML patients in relapse after BMT may be partial and transient: Further evidence for a dose-reponse effect. BLOOD. 90:2307-2307. Author weblink.
• De Witte T; Van Biezen A; Hermans J; Labopin M; Runde V; Or R; Meloni G; Mauri SB; et alCarella A; Apperley J; Gratwohl A; Laporte JP. (15 Nov 1997). Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood. 90:3853-3857.
• Capelli D; Szydlo RM; Savage DG; Apperley J; Goldman JM. (15 Nov 1997). Bone marrow transplantation for chronic myeloid leukemia in patients over 45 yrs of age: A multivariate study to determine prognostic factors for survival. BLOOD. 90:1007-1007.
• Bjorkstrand B; Svensson K; Ljungman P; Apperley J; Goldschmidt H; Remes K; Alegre A; Marcus R; et alCarlson K; Coser P; Sureda A; Barbui T; Goldstone AH; Blade J; Volin L; Boogaerts M; Lenhoff S; Majolino I; Samson D; deLaurenzi A; Caballero D; Gahrton G. (15 Nov 1997). 2522 autotransplants in multiple myeloma - A registry study from the European group for blood and marrow transplantation (EBMT). BLOOD. 90:1862-1862.
• DeWitte T; Suciu S; Verhoef G; Labar B; Archimbaud E; Aul C; Selleslag D; Ferrant A; et alWijermans P; Mandelli F; Amadori S; Jehn U; Muus P; DeMuynck H; Dardenne M; Zittoun R; Willemze R; Gratwohl A; Apperley J. (15 Nov 1997). Autologous stem cell transplantation for patients with poor risk MDS and secondary AML (sAML). A joint study of the EORTC, EBMT, SAKK and GIMEMA leukemia groups. BLOOD. 90:2594-2594.
• DeWitte T; VanBiezen A; Hermans J; Labopin M; Runde V; Or R; Meloni G; Mauri SB; et alCarella A; Apperley J; Gratwohl A; Laporte JP. (15 Nov 1997). Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. BLOOD. 90:3853-3857.
• Savage DG; Szydlo RM; Chase A; Apperley JF; Goldman JM. (Oct 1997). Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol. 99:30-35.
• van Rhee F; Szydlo RM; Hermans J; Devergie A; Frassoni F; Arcese W; de Witte T; Kolb HJ; et alNiederwiser D; Jacobsen N; Gahrton G; Bandini G; Carreras E; Bacigalupo A; Michallet M; Ruutu T; Reiffers J; Goldman JM; Apperley J; Gratwohl A. (Oct 1997). Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 20:553-560. DOI.
• Shipman CM; Rogers MJ; Apperley JF; Russell RG; Croucher PI. (Sep 1997). Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 98:665-672.
• Pfeiffer S; Gooding RP; Apperley JF; Goldschmidt H; Samson D. (Sep 1997). Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. Br J Haematol. 98:973-982.
• Devergie A; Apperley JF; Labopin M; Madrigal A; Jacobsen N; Carreras E; Prentice HG; Jouet JP; et alKolb HJ; Herstenstein B; Bacigalupo A; Evensen SA; Ljungman P; deWitte T; Reiffers J; Nagler A; Clark RE; Goldman JM; Gratwohl A. (1 Jul 1997). European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. BONE MARROW TRANSPLANTATION. 20:11-19. Author weblink DOI.
• Devergie A; Apperley JF; Labopin M; Madrigal A; Jacobsen N; Carreras E; Prentice HG; Jouet JP; et alKolb HJ; Herstenstein B; Bacigalupo A; Evensen SA; Ljungman P; de Witte T; Reiffers J; Nagler A; Clark RE; Goldman JM; Gratwohl A. (Jul 1997). European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 20:11-19. DOI.
• Carella AM; Frassoni F; Melo J; Sawyers C; Eaves C; Eaves A; Apperley J; Tura S; et alHehlmann R; Reiffers J; Lerma E; Goldman J. (Jul 1997). New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica. 82:478-495.
• Ang HA; Apperley JF; Ward KN. (15 Jun 1997). Persistence of antibody to human parvovirus B19 after allogeneic bone marrow transplantation: role of prior recipient immunity. Blood. 89:4646-4651.
• Speiser DE; Hermans J; van Biezen A; Starobinski M; Jeannet M; Jacobsen N; Niederwieser D; Gratwohl A; et alApperley JF. (Jun 1997). Haploidentical family member transplants for patients with chronic myeloid leukaemia: a report of the Chronic Leukaemia Working Party of off European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 19:1197-1203. DOI.
• Scott MA; Apperley JF; Bloxham DM; Jestice HK; John S; Marcus RE; Gordon MY. (May 1997). Biological properties of peripheral blood progenitor cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor. Br J Haematol. 97:474-480.
• Pfeiffer S; Samson D; Apperley J; Gooding R. (May 1997). Ex vivo generation and function of dendritic cells in multiple myeloma. Biochem Soc Trans. 25:364S.
• Pfeiffer S; Samson D; Apperley J; Gooding R. (1 May 1997). Ex vivo generation and function of dendritic cells in multiple myeloma. BIOCHEMICAL SOCIETY TRANSACTIONS. 25:S364-S364.
• Ruutu T; Niederwieser D; Gratwohl A; Apperley JF. (Apr 1997). A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant. 19:759-764. DOI.
• Ruutu T; Niederwieser D; Gratwohl A; Apperley JF. (1 Apr 1997). A survey of the prophylaxis and treatment of acute GVHD in Europe: A report of the European Group for Blood and Marrow Transplantation (EBMT). BONE MARROW TRANSPLANTATION. 19:759-764. Author weblink DOI.
• Chen FE; Owen I; Savage D; Roberts I; Apperley J; Goldman JM; Laffan M. (1 Mar 1997). Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant. BONE MARROW TRANSPLANTATION. 19:491-495. Author weblink DOI.
• Duell T; van Lint MT; Ljungman P; Tichelli A; Socié G; Apperley JF; Weiss M; Cohen A; et alNekolla E; Kolb HJ. (1 Feb 1997). Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med. 126:184-192.
• Duell T; vanLint MT; Ljungman P; Tichelli A; Socie G; Apperley JF; Weiss M; Cohen A; et alNekolla E; Kolb HJ. (1 Feb 1997). Health and functional status of long-term survivors of bone marrow transplantation. ANNALS OF INTERNAL MEDICINE. 126:184-&. Author weblink.
• Savage DG; Taylor P; Blackwell J; Chen F; Szydlo RM; Rule SA; Spencer A; Apperley JF; et alGoldman JM. (Jan 1997). Paranasal sinusitis following allogeneic bone marrow transplant. Bone Marrow Transplant. 19:55-59. DOI.
• Björkstrand BB; Ljungman P; Svensson H; Hermans J; Alegre A; Apperley J; Bladé J; Carlson K; et alCavo M; Ferrant A; Goldstone AH; de Laurenzi A; Majolino I; Marcus R; Prentice HG; Remes K; Samson D; Sureda A; Verdonck LF; Volin L; Gahrton G. (15 Dec 1996). Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 88:4711-4718.
• Ringdén O; Hermans J; Labopin M; Apperley J; Gorin NC; Gratwohl A. (Dec 1996). The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Leuk Lymphoma. 24:71-79. DOI.
• Ringden O; Hermans J; Labopin M; Apperley J; Gorin NC; Gratwohl A. (1 Dec 1996). The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. LEUKEMIA & LYMPHOMA. 24:71-79. DOI.
• Gratwohl A; Hermans J; vonBiezen A; Arcese W; Debusscher L; Ernst P; Ferrant A; Frassoni F; et alGahrton G; Iriondo A; Kolb HJ; Link H; Niederwieser D; Ruutu T; Schattenberg A; Schmitz N; Siegert W; TorresGomez A; Vernant JP; Zwaan FE; Apperley J. (1 Dec 1996). Splenic irradiation before bone marrow transplantation for chronic myeloid leukemia. BRITISH JOURNAL OF HAEMATOLOGY. 95:494-500. DOI.
• vanRhee F; Savage D; Blackwell J; Orchard K; Szydlo R; Apperley JF; Goldman JM. (15 Nov 1996). Donor lymphocyte transfusion (DLI) for relapse of CML post BMT: Higher cell doses induce more rapid responses. BLOOD. 88:2714-2714. Author weblink.
• Garin MI; Apperley J; Melo JV. (15 Nov 1996). Ex vivo expansion of human hemopoietic cells from normal bone marrow and peripheral blood from CML patients. BLOOD. 88:2419-2419. Author weblink.
• OBrien SG; Apperley JF; Szydlo R; Spencer A; Rule SA; Savage D; Blackwell J; Orchard K; et alChase A; Hawkins TE; Goldman JM. (15 Nov 1996). High dose busulfan alone as cytoreduction before autografting for chronic myeloid leukemia - A feasibility study. BLOOD. 88:3528-3528. Author weblink.
• vanRhee F; Savage D; Blackwell J; Orchard K; Szydlo R; Apperley JF; Goldman JM. (15 Nov 1996). Comparison of lymphocyte transfusion from volunteer unrelated and sibling donors for release of CML post BMT. BLOOD. 88:1022-1022. Author weblink.
• Boiron JM; Cahn JY; CarloStella C; Bandini G; Meloni G; Reman O; Carreras E; Michallet M; et alDeLaurenzi A; Milpied N; Granena A; Faberes C; Apperley J; Reiffers J. (15 Nov 1996). Autologous stem cell transplantation (ASCT) for patients with chronic myeloid leukemia (CML) in first chronic phase (CP1) not responding to alpha-interferon (IFN). BLOOD. 88:492-492.
• Pfeiffer S; Samson D; Apperley J; Gooding R. (15 Nov 1996). Ex vivo generation and function of dendritic cells in multiple myeloma. BLOOD. 88:1556-1556.
• Carreras E; Bertz H; Vernant JP; Tomas JF; Hagglund H; Bandini G; Esperou H; Rusell J; et aldelaRubia J; DiGirolamo G; Cleeren M; Hartmann O; Ruutu T; Leblond V; Iriondo A; Bosi A; BenBassat I; Koza V; Gratwohl A; Apperley J. (15 Nov 1996). Incidence of hepatic veno-occlusive disease (VOD) after BMT in Europe: A prospective cohort study of the EBMT. BLOOD. 88:1647-1647.
• Orchard K; Blackwell J; Chase A; Kaeda J; Goldman JM; Apperley J. (15 Nov 1996). Autologous peripheral blood cell transplantation as treatment of severe life-threatening GVHD. BLOOD. 88:1673-1673.
• DeWitte; Suciu S; Boogaerts M; Labar B; Archimbaud E; Aul C; Selleslag D; Ferrant A; et alWeijermans P; Mandelli F; Amadori S; Jehn U; Muus P; DeMuynck H; Dardenne M; Willemze R; Gratwohl A; Apperley J. (15 Nov 1996). The influence of cytogenetic abnormalities on treatment outcome after intensive antileukemic therapy for patients with high risk MDS and AML following MDS. BLOOD. 88:1806-1806.
• Mattijssen V; DeWitte; Suciu S; Boogaerts M; Labar B; Archimbaud E; Aul C; Selleslag D; et alFerrant A; Weijermans P; Mandelli F; Amadori S; Jehn U; Muus P; DeMuynck H; Dardenne M; Willemze R; Gratwohl A; Apperley J. (15 Nov 1996). The prognostic impact of the presence of an HLA-identical donor on patients with high risk MDS and AML following MDS treated with an intensive antileukemic regimen. BLOOD. 88:1908-1908.
• Pfeiffer S; Samson D; Apperley J; Gooding R. (1 Nov 1996). Ex vivo generation and function of dendritic cells in multiple myeloma. IMMUNOLOGY. 89:II363-II363.
• Nawawi H; Samson D; Apperley J; Girgis SI. (1 Oct 1996). Biochemical bone markers in patients with multiple myeloma. JOURNAL OF BONE AND MINERAL RESEARCH. 11:P11-P11. Author weblink.
• Gratwohl A; Gorin C; Apperley J; Goldstone A; Rosti G; Bacigalupo A; Gluckman E; Fischer A; et alLjungman P; Kolb HJ; Niethammer D. (1 Oct 1996). The European Group for Blood and Marrow Transplantation (EBMT): A report from the President and the Chairmen of the Working Parties. BONE MARROW TRANSPLANTATION. 18:677-691. Author weblink.
• Nawawi H; Samson D; Apperley J; Girgis S. (30 Sep 1996). Biochemical bone markers in patients with multiple myeloma. Clin Chim Acta. 253:61-77.
• Rule SA; Savage DG; O'Brien SG; Orchard K; McDonald C; Davidson J; Matthey F; Reilly JT; et alBardhan G; Miller E; Cranfield T; Apperley JF; Goldman JM. (Sep 1996). Intermediate-dose busulphan before autografting for advanced-phase chronic myeloid leukaemia. Br J Haematol. 94:694-698.
• McKie N; Dallas DJ; Edwards T; Apperley JF; Russell RGG; Croucher PI. (1 Sep 1996). Cloning of a novel membrane-linked metalloproteinase from human myeloma cells. BIOCHEMICAL JOURNAL. 318:459-462. Author weblink.
• Gratwohl A; Hermans J; Schmitz N; Gorin NC; Apperley J; Goldstone AH; Rosti G; Gahrton G; et alBacigalupo A. (1 Aug 1996). Blood and marrow stem cell transplants in Europe. EXPERIMENTAL HEMATOLOGY. 24:656-656.
• DeWitte T; Suciu S; Boogaerts M; Labar B; Archimbaud E; Aul C; Selleslag D; Ferrant A; et alWeijermans P; Mandelli F; Amadori S; Muus P; DeMuynck H; Dardenne M; Willemze R; Gratwohl A; Apperley J. (1 Aug 1996). Intensive antileukemic therapy including stem cell transplantation (SCT) for high risk MDS and AML following MDS (sAML) in patients <60 years. A joint study of the EORTC and the EBMT leukemia groups. EXPERIMENTAL HEMATOLOGY. 24:678-678.
• Croucher PI; Dallas DJ; Edwards T; Apperley JF; Russell RGG; McKie N. (1 Jun 1996). Expression of a novel membrane-linked metallo-disintegrin from human myeloma cells. BRITISH JOURNAL OF HAEMATOLOGY. 93:485-485. Author weblink.
• Sati HIA; Greaves M; Apperley JF; Russell RGG; Croucher P. (1 Jun 1996). Demonstration of TNF alpha mRMA expression in neoplastic plasma cells using dual colour fluorescence in situ hybridisation. BRITISH JOURNAL OF HAEMATOLOGY. 93:484-484. Author weblink.
• OBrien SG; Spencer A; Rule S; Hawkins T; Savage D; Apperley JF; Chase AJ; McDonald C; et alDavidson RJ; Goldman JM. (1 Jun 1996). Chronic phase CML autografting using PBPCs mobilised by intermediate-dose chemotherapy - An update of the Hammersmith experience. BRITISH JOURNAL OF HAEMATOLOGY. 93:278-278. Author weblink.
• Gupta D; Lyttelton MP; Elliott CJ; Bybee A; Armitage S; McGuigan D; Apperley JF; Kanfer EJ; et alSamson D. (1 Jun 1996). CD34+ selected peripheral blood progenitor cell transplantation after high-dose melphalan and TBI in multiple myeloma: Feasibility, toxicity and tumour cell contamination. BRITISH JOURNAL OF HAEMATOLOGY. 93:1144-1144. Author weblink.
• Gooding R; Bybee A; Gupta D; Cooke F; Coelho E; Samson DM; Apperley JF. (1 Jun 1996). Phenotypic and molecular characterisation of putative human myeloma cell lines. BRITISH JOURNAL OF HAEMATOLOGY. 93:487-487. Author weblink.
• OBrien SG; Spencer A; Rule S; Hawkins T; Savage D; Apperley JF; Chase AJ; McDonald C; et alDavidson RJ; Goldman JM. (1 Apr 1996). Chronic phase cml autografting using PBPCs mobilised by intermediate-dose chemotherapy an update of the Hammersmith experienc. BRITISH JOURNAL OF HAEMATOLOGY. 93:4-4. Author weblink.
• Sati HIA; Greaves M; Apperley JF; Russell RGG; Croucher P. (1 Apr 1996). Demonstration of TNF alpha expression by clonal plasma cells using a novel dual colour fluorescent in situ hybridisation technique. BRITISH JOURNAL OF HAEMATOLOGY. 93:212-212. Author weblink.
• Gooding R; Coelho E; Bybee A; Dupta D; Cooke F; Samson DM; Apperley JF. (1 Apr 1996). Phenotypic and molecular characterisation of putative human myeloma cell lines. BRITISH JOURNAL OF HAEMATOLOGY. 93:312-312. Author weblink.
• Croucher PI; Dallas DJ; Edwards T; Apperley JF; Russel RGG; McKie N. (1 Apr 1996). Cloning of a novel membrane-linked metallodisintegrin from human myeloma cells. BRITISH JOURNAL OF HAEMATOLOGY. 93:307-307. Author weblink.
• Scott MA; Apperley JF; Jestice HK; Bloxham DM; Marcus RE; Gordon MY. (15 Dec 1995). Plastic-adherent progenitor cells in mobilized peripheral blood progenitor cell collections. Blood. 86:4468-4473.
• Apperley JF; Rio B; Ljungman P; Kolb HJ. (15 Nov 1995). Outcome of conceptions in recipients of autologous and allogeneic transplantation. BLOOD. 86:1584-1584. Author weblink.
• Kolb HJ; Duell T; Socie G; VanLint MT; Carreras E; Tichelli A; Ljungman P; Jacobsen N; et alApperley JF; Hertenstein B; Weiss M; Nekolla E; Goldstone AH. (15 Nov 1995). New malignancies in patients surviving more than 5 years after marrow transplantation. BLOOD. 86:1825-1825. Author weblink.
• Arnold R; DeWitte T; vanBiezen A; Hermans J; Jacobsen N; Runde V; Vossen J; Willemze R; et alSamson D; Gratwohl A; Apperley J. (15 Nov 1995). MUD BMT in MDS/sAML: An EBMT survey. BLOOD. 86:368-368.
• Runde V; deWitte T; Arnold R; Gratwohl A; Hermans J; vanBiezen A; Niederwieser D; Labopin M; et alWalterNoel MP; Bacigalupo A; Jacobsen N; Gahrton G; Carreras E; Kolb HJ; Aul C; Apperley J. (15 Nov 1995). Bone marrow transplantation from HLA-identical siblings as first line treatment in patients with myelodysplastic syndromes or secondary acute myelogenous leukemia: A European survey. BLOOD. 86:369-369.
• Boogaerts MA; Demuynck H; DeWitte T; Suciu S; Labar B; Archimbaud E; Runde V; Selleslag D; et alZittoun R; Lelie JVD; Muus P; Dardenne M; Willemze R; Gratwohl A; Apperley J. (15 Nov 1995). Repopulation after autologous bone marrow versus peripheral blood progenitor cell transplantation in younger patients with high risk myelodysplastic syndromes in complete remission after intensified induction therapy. A joint EORTC/EBMT study. BLOOD. 86:392-392.
• Lin F; Ward KN; Apperley J; Goldman JM; Cross NCP. (15 Nov 1995). Comparison of PCR amplification of immediate early (IE) and pp65 genomic DNA or cDNA for detection of cytomegalovirus in peripheral blood leukocytes. BLOOD. 86:899-899.
• DeWitte T; Suciu S; Boogaerts M; Labar B; Archimbaud E; Runde V; Selleslag D; Zittoun R; et alVanderLelie J; Muus P; DeMuynck H; Dardenne M; Willemze R; Gratwohl A; Apperley J. (15 Nov 1995). Intensive remission-induction chemotherapy followed by autologous or allogeneic stem cell transplantation (SCT) for high risk MDS and AML secondary to MDS (SAML) in patients <60 years, a joint study of the eortc LCG and the EBMT. BLOOD. 86:2458-2458.
• Gratwohl A; Hermans J; Pearce R; Gorin NC; Apperley J; deWitte T; Gahrton G; Schmitz N; et alPhilip T; Rosti G; Goldstone A; Ernst P; Bacigalupo A. (15 Nov 1995). Haematopoietic precursor cell transplants - Main risk factors. BLOOD. 86:2460-2460.
• Scott MA; Ager S; Apperley JF; Jestice HK; Bloxham DM; Boraks P; Mahendra P; Marcus RE. (Nov 1995). Peripheral blood progenitor cell harvesting in multiple myeloma and malignant lymphoma. Leuk Lymphoma. 19:479-484. DOI.
• DEWITTE T; VANBIEZEN A; LABOPIN M; HERMANS J; RUNDE V; OBERG G; OR R; GRATWOHL A; et alNIEDERWIESER D; MELONI G; MORGAN G; APPERLEY J; VERNANT J; KOLB H; VOSSEN J; LJUNGMAN P; FERRANT A; ARNOLD R; CAHN J; BACIGALUPO A; FIBBE W; GORIN N. (1 Aug 1995). AUTOLOGOUS BMT FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID-LEUKEMIA FOLLOWING MDS (SAML) - A REPORT FROM THE CHRONIC AND ACUTE-LEUKEMIA WORKING PARTIES OF THE EBMT. EXPERIMENTAL HEMATOLOGY. 23:904-904.
• Gratwohl A; Hermans J; Apperley J; Arcese W; Bacigalupo A; Bandini G; di Bartolomeo P; Boogaerts M; et alBosi A; Carreras E. (15 Jul 1995). Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood. 86:813-818.
• GRATWOHL A; HERMANS J; APPERLEY J; ARCESE W; BACIGALUPO A; BANDINI G; DIBARTOLOMEO P; BOOGAERTS M; et alBOSI A; CARRERAS E; DEVERGIE A; FERRANT A; FIBBE WE; FRASSONI F; GAHRTON G; GOLDMAN J; IRIONDO A; JACOBSEN N; KOLB HJ; LINK H; MICHALLET M; PRENTICE HG; REIFFERS J; VONRHEE F; RUUTU T; SCHWAIGHOFER H; VERNANT JP; DEWITTE T; NIEDERWIESER D. (15 Jul 1995). ACUTE GRAFT-VERSUS-HOST DISEASE - GRADE AND OUTCOME IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA. BLOOD. 86:813-818.
• Apperley JF; Reddy N. (Jun 1995). Mechanism and management of treatment-related gonadal failure in recipients of high dose chemoradiotherapy. Blood Rev. 9:93-116.
• RULE SAJ; OBRIEN SG; SPENCER A; APPERLEY J; GOLDMAN JM. (1 Apr 1995). BONE-MARROW TRANSPLANTATION - REVIEW ARTICLES MUST ACCURATELY REFLECT CURRENT PRACTICE. BRITISH MEDICAL JOURNAL. 310:874-874. Author weblink.
• Healy LE; Nirsimloo N; Scott M; Apperley JF; Gordon MY. (Dec 1994). In vitro proliferation by cells mobilized into the peripheral blood for collection and autologous transplantation. Exp Hematol. 22:1278-1282.
• Goldring MB; Birkhead JR; Suen LF; Yamin R; Mizuno S; Glowacki J; Arbiser JL; Apperley JF. (Dec 1994). Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes. J Clin Invest. 94:2307-2316. DOI.
• DEVERGIE A; LABOPIN M; APPERLEY J; CARRERAS E; PRENTICE G; HERSTENSTEIN B; REIFFERS J; MICHALLET M; et alJACOBSEN N; JOUET JP; GOLDMAN J; VANBIEZEN A; GRATWOHL A. (15 Nov 1994). EUROPEAN RESULTS OF 357 MATCHED UNRELATED DONOR (MUD) TRANSPLANTS FOR CHRONIC MYELOID-LEUKEMIA (CML) - IMPACT OF HLAD SUBTYPES ANALYSIS. BLOOD. 84:A537-A537.
• GRATWOHL A; HERMANS J; APPERLEY J; ARCESE W; BACIGULAPO A; BANDINI G; BOOGAERTS M; BOSI A; et alCARRERAS E; DEVERGIE A; FERRANT A; FIBBE WE; FRASSONI F; GAHRTON G; GOLDMAN J; IRIONDO A; JACOBSEN N; LINK H; KOLB HJ; MICHALLET M; PRENTICE HG; REIFFERS J; VANRHEE F; RUUTU T; TORLONTANO G; SCHWEIKOFER H; VERNANT JP; DEWITTE T; NIEDERWIESER D. (15 Nov 1994). ACUTE GRAFT-VERSUS-HOST DISEASE - GRADE AND OUTCOME IN PATIENTS WITH CML. BLOOD. 84:A539-A539.
• Bird JM; Bloxham D; Samson D; Marcus RE; Russell NH; Kelsey SM; Newland AC; Apperley JF. (Sep 1994). Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol. 88:110-116.
• APPERLEY JF. (1 Aug 1994). UMBILICAL-CORD BLOOD PROGENITOR-CELL TRANSPLANTATION. BONE MARROW TRANSPLANTATION. 14:187-196. Author weblink.
• SCOTT MA; APPERLEY JF; MARCUS RE; GORDON MY. (1 Aug 1994). PLASTIC-ADHERENT PROGENITOR CELLS ISOLATED FROM BONE-MARROW, VENOUS-BLOOD AND PERIPHERAL-BLOOD STEM-CELL HARVESTS. EXPERIMENTAL HEMATOLOGY. 22:757-757. Author weblink.
• GORDON MY; LEWIS JL; APPERLEY JF; GOLDMAN JM; SCOTT M; MARCUS R; BLACKETT NM. (1 Aug 1994). PRIMITIVE PROGENITOR CELLS IN NORMAL HUMAN BONE-MARROW, PERIPHERAL-BLOOD PROGENITOR-CELL HARVESTS, UMBILICAL-CORD BLOOD AND CHRONIC MYELOID-LEUKEMIA DISPLAY KINETIC DIFFERENCES IN RENEWAL AND GENERATION OF GRANULOCYTE-MACROPHAGE COLONY-FORMING CELLS. EXPERIMENTAL HEMATOLOGY. 22:789-789. Author weblink.
• Apperley JF. (Aug 1994). Umbilical cord blood progenitor cell transplantation. The International Conference Workshop on Cord Blood Transplantation, Indianapolis, November 1993. Bone Marrow Transplant. 14:187-196.
• DEVERGIE A; LABOPIN M; APPERLEY J; CARRERAS E; PRENTICE G; HERSTENSTEIN B; REIFFERS J; MICHALLET M; et alJACOBSEN N; JOUET JP; GOLDMAN J; VANBIEZEN A; GRATWOHL A. (1 Aug 1994). MATCHED UNRELATED DONOR (MUD) TRANSPLANT FOR CHRONIC MYELOID-LEUKEMIA (CML) IN EUROPE - REPORT OF 299 CASES AND ANALYSIS OF PROGNOSIS FACTORS. EXPERIMENTAL HEMATOLOGY. 22:715-715.
• Atkinson HG; Apperley JF; Dawson K; Goldman JM; Winston RM. (16 Jul 1994). Successful pregnancy after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Lancet. 344:199.
• ATKINSON HG; APPERLEY JF; DAWSON K; GOLDMAN JM; WINSTON RML. (16 Jul 1994). SUCCESSFUL PREGNANCY AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA. LANCET. 344:199-199. Author weblink DOI.
• Reiffers J; Goldman J; Meloni G; Cahn JY; Faberes C; Apperley J. (1994). Autologous transplantation in chronic myelogenous leukemia: European results: Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant. 14 Suppl 3:S51-S54.
• ARCESE W; GOLDMAN JM; DARCANGELO E; SCHATTENBERG A; NARDI A; APPERLEY JF; FRASSONI F; AVERSA F; et alPRENTICE HG; LJUNGMAN P; FERRANT A; MAROSI C; SAYER H; NIEDERWIESER D; ARNOLD R; BANDINI G; CARRERAS E; PARKER A; FRAPPAZ D; MANDELLI F; GRATWOHL A. (15 Nov 1993). OUTCOME FOR PATIENTS WHO RELAPSE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA. BLOOD. 82:3211-3219. Author weblink.
• BIRD JM; BLOXHAM D; RUSSELL NH; SAMSON D; APPERLEY JF. (15 Nov 1993). DETECTION OF CLONALLY REARRANGED CELLS IN PBSC HARVESTS IN MULTIPLE-MYELOMA BY IMMUNOGLOBULIN GENE FINGERPRINTING. BLOOD. 82:A265-A265. Author weblink.
• Arcese W; Goldman JM; D'Arcangelo E; Schattenberg A; Nardi A; Apperley JF; Frassoni F; Aversa F; et alPrentice HG; Ljungman P. (15 Nov 1993). Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group. Blood. 82:3211-3219.
• ARCESE W; GOLDMAN JM; DARCANGELO E; SCHATTENBERG A; NARDI A; APPERLEY JF; FRASSONI F; AVERSA F; et alPRENTICE HG; LJUNGMAN P; FERRANT A; MAROSI C; SAYER H; NIEDERWIESER D; ARNOLD R; BANDINI G; CERRERAS E; PARKER A; FRAPPAZ D; MANDELLI F; GRATWOHL A. (15 Nov 1993). OUTCOME FOR PATIENTS WHO RELAPSE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA. BLOOD. 82:A345-A345. Author weblink.
• GRATWOHL A; HERMANS J; NIEDERWIESER D; FRASSONI F; ARCESE W; GAHRTON G; BANDINI G; CARRERAS E; et alVERNANT JP; BOSI A; DEWITTE T; FIBBE WE; ZWAAN F; MICHALLET M; RUUTU T; DEVERGIE A; IRIONDO A; APPERLEY J; REIFFERS J; SPECK B; GOLDMAN J. (1 Nov 1993). BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA - LONG-TERM RESULTS. BONE MARROW TRANSPLANTATION. 12:509-516.
• HEALY L; NIRSIMLOO N; SCOTT M; APPERLEY J; GORDON M. (1 Aug 1993). THE CHARACTERIZATION OF MOBILIZED STEM-CELLS IN LIQUID CULTURE SYSTEMS. EXPERIMENTAL HEMATOLOGY. 21:1141-1141.
• Apperley JF. (Mar 1993). Bone marrow transplant for the haemoglobinopathies: past, present and future. Baillieres Clin Haematol. 6:299-325.
• SCOTT MA; JESTICE HK; TOLLIDAY BH; HEALY L; GORDON MY; MARCUS RE; APPERLEY JF. (1 Jan 1993). PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION (PBSCT) FOLLOWED BY ALPHA-INTERFERON IN MULTIPLE-MYELOMA. BRITISH JOURNAL OF HAEMATOLOGY. 84:44-44. Author weblink.
• APPERLEY JF. (1 Jan 1993). BONE-MARROW TRANSPLANT ACTIVITY IN GREAT-BRITAIN AND THE REPUBLIC-OF-IRELAND IN 1991. BRITISH JOURNAL OF HAEMATOLOGY. 84:49-49. Author weblink.
• Craddock CF; Apperley JF; Wright EG; Healy LE; Bennett CA; Evans M; Grimsley PG; Gordon MY. (1 Jul 1992). Circulating stem cells in mice treated with cyclophosphamide. Blood. 80:264-269.
• MARKS DI; HUGHES TP; SZYDLO R; KELLY S; CULLIS JO; SCHWARER AP; MACKINNON S; APPERLEY J; et alBARRETT AJ; HOWS JM; GOLDMAN JM. (1 Jul 1992). HLA-IDENTICAL SIBLING DONOR BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA IN 1ST CHRONIC PHASE - INFLUENCE OF GVHD PROPHYLAXIS ON OUTCOME. BRITISH JOURNAL OF HAEMATOLOGY. 81:383-390. Author weblink DOI.
• Richards EM; Apperley JF; Marcus RE. (1992). Successful use of liposome encapsulated amphotericin to treat invasive aspergillosis following failure of conventional amphotericin. Clin Lab Haematol. 14:127-130.
• Apperley JF; Luskey BD; Williams DA. (15 Jul 1991). Retroviral gene transfer of human adenosine deaminase in murine hematopoietic cells: effect of selectable marker sequences on long-term expression. Blood. 78:310-317.
• NACHEVA E; FISCHER P; APPERLEY J; KARPAS A. (1 Jul 1991). INVOLVEMENT OF B-CELL SPECIFIC CHROMOSOMAL SITES IN 6 MYELOMA CELL-LINES. EXPERIMENTAL HEMATOLOGY. 19:545-545.
• Apperley JF; Luskey BD; Williams DA. (Apr 1991). Retroviral-mediated gene transfer of human adenosine deaminase into murine hematopoietic cells. Semin Hematol. 28:170-176.
• GRANT JW; OCONNOR S; APPERLEY JF; ARNO J; LYNN R; BLOXHAM D; ATKIN J; MARCUS RE. (1 Feb 1991). COMBINED HISTOLOGICAL, IMMUNOPHENOTYPIC AND GENOTYPIC ANALYSIS OF LYMPHORETICULAR BIOPSIES. JOURNAL OF PATHOLOGY. 163:A172-A172. Author weblink.
• Luskey BD; Lim B; Apperley JF; Orkin SH; Williams DA. (1990). Gene transfer into murine hematopoietic stem cells and bone marrow stromal cells. Ann N Y Acad Sci. 612:398-406.
• Apperley JF; Williams DA. (Jun 1990). Gene therapy: current status and future directions. Br J Haematol. 75:148-155.
• Mackinnon S; Hows JM; Goldman JM; Arthur CK; Hughes T; Apperley JF; Jones L; Batchelor JR; et alBrookes P; Catovsky D. (Jun 1990). Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors. Exp Hematol. 18:421-425.
• Hughes TP; Economou K; Mackinnon S; Vlitos M; Arthur CK; Guo AP; Rassool F; Apperley JF; et alHows J; Goldman JM. (Dec 1989). Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow. Br J Haematol. 73:462-467.
• Lim B; Apperley JF; Orkin SH; Williams DA. (Nov 1989). Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells. Proc Natl Acad Sci U S A. 86:8892-8896.
• BRITOBABAPULLE F; BOWCOCK SJ; MARCUS RE; APPERLEY J; THNG KH; DOWDING C; RASSOOL F; GUO AP; et alCATOVSKY D; GALTON DAG; MCCARTHY D; GOLDMAN JM. (1 Sep 1989). AUTOGRAFTING FOR PATIENTS WITH CHRONIC MYELOID-LEUKEMIA IN CHRONIC PHASE - PERIPHERAL-BLOOD STEM-CELLS MAY HAVE A FINITE-CAPACITY FOR MAINTAINING HEMATOPOIESIS. BRITISH JOURNAL OF HAEMATOLOGY. 73:76-81. Author weblink DOI.
• James ND; Apperley JF; Kam KC; MacKinnon S; Goldman JM; Goolden AW; Sikora K. (Mar 1989). Total lymphoid irradiation preceding bone marrow transplantation for chronic myeloid leukaemia. Clin Radiol. 40:195-198.
• Apperley JF; Dowding C; Hibbin J; Buiter J; Matutes E; Sissons PJ; Gordon M; Goldman JM. (Jan 1989). The effect of cytomegalovirus on hemopoiesis: in vitro evidence for selective infection of marrow stromal cells. Exp Hematol. 17:38-45.
• JAMES ND; APPERLEY JF; KAM KC; MACKINNON S; GOLDMAN JM; GOOLDEN AWG; SIKORA K. (1 Dec 1988). TOTAL LYMPHOID IRRADIATION PRECEDING BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA. BRITISH JOURNAL OF RADIOLOGY. 61:1195-1195. Author weblink.
• APPERLEY JF. (1 Oct 1988). CORRECTION. BRITISH JOURNAL OF HAEMATOLOGY. 70:261-261. Author weblink.
• MACKINNON S; HOWS JM; ARTHUR CK; APPERLEY JF; BATCHELOR J; BROOKES P; HALE G; WALDMANN H; et alGOLDMAN JM. (1 Jul 1988). BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC MYELOID-LEUKEMIA (CML) USING MATCHED UNRELATED DONORS. EXPERIMENTAL HEMATOLOGY. 16:500-500. Author weblink.
• Apperley JF; Goldman JM. (Jul 1988). Cytomegalovirus: biology, clinical features and methods for diagnosis. Bone Marrow Transplant. 3:253-264.
• Apperley JF; Mauro FR; Goldman JM; Gregory W; Arthur CK; Hows J; Arcese W; Papa G; et alMandelli F; Wardle D. (Jun 1988). Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol. 69:239-245.
• MACKINNON S; ARTHUR CK; JONES L; APPERLEY JF; NEWLAND AC; GOLDMAN JM. (1 May 1988). FAILURE OF ALPHA-INTERFERON (AIFN) TO REDUCE THE NUMBER OF PHILADELPHIA (PH) POSITIVE METAPHASES IN PATIENTS WITH RECURRENT CHRONIC MYELOID-LEUKEMIA (CML) AFTER BONE-MARROW TRANSPLANT (BMT). BRITISH JOURNAL OF HAEMATOLOGY. 69:132-132. Author weblink.
• Arthur CK; Apperley JF; Guo AP; Rassool F; Gao LM; Goldman JM. (May 1988). Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase. Blood. 71:1179-1186.
• MACKINNON S; JAMES ND; APPERLEY JF; ARTHUR CK; SIKORA K; GOLDMAN JM. (1 May 1988). ADDITION OF TOTAL LYMPHOID IRRADIATION (TLI) AND CHEMOTHERAPY ENSURES ENGRAFTMENT IN T-CELL DEPLETED (TCD) DONOR MARROW IN ALLOGENEIC BONE-MARROW TRANSPLANT (BMT) FOR LEUKEMIA. BRITISH JOURNAL OF HAEMATOLOGY. 69:118-118. Author weblink.
• MACKINNON S; GOLDMAN JM; APPERLEY JF; ARTHUR C; HOWS JM; BATCHELOR J; BROOKES P; HALE G; et alWALDMANN H. (1 Apr 1988). BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC MYELOID-LEUKEMIA (CML) USING MATCHED UNRELATED DONORS. BRITISH JOURNAL OF HAEMATOLOGY. 68:510-510. Author weblink.
• Sutedja TG; Apperley JF; Hughes JM; Aber VR; Kennedy HG; Nunn P; Jones L; Hopper L; et alGoldman JM. (Mar 1988). Pulmonary function after bone marrow transplantation for chronic myeloid leukaemia. Thorax. 43:163-169.
• HUGHES JMB; SUTEDJA TG; APPERLEY JF; ABER VR; GOLDMAN JM. (1 Mar 1988). LONG-TERM PROSPECTIVE-STUDY OF PULMONARY-FUNCTION AFTER BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA. THORAX. 43:P231-P231. Author weblink.
• Min GL; Hibbin J; Arthur C; Apperley J; Jeffreys A; Goldman J. (Feb 1988). Use of minisatellite DNA probes for recognition and characterization of relapse after allogeneic bone marrow transplantation. Br J Haematol. 68:195-201.
• MACKINNON S; APPERLEY JF; ARTHUR CK; JONES L; HOWS JM; HALE G; WALDMANN H; GOLDMAN JM. (1 Jan 1988). BONE-MARROW TRANSPLANTATION FOR CHRONIC PHASE CML - THE ROLE OF T-CELL DEPLETION IN 1988. BONE MARROW TRANSPLANTATION. 3:150-151. Author weblink.
• MACKINNON S; ARTHUR CK; APPERLEY JF; HOWS JM; BATCHELOR J; BROOKES P; HALE G; WALDMANN H; et alGOLDMAN JM. (1 Jan 1988). HISTOCOMPATIBLE UNRELATED VOLUNTEER DONORS FOR BMT IN PATIENTS WITH CHRONIC MYELOID-LEUKEMIA. BONE MARROW TRANSPLANTATION. 3:176-177. Author weblink.
• MACKINNON S; ARTHUR CK; APPERLEY JF; JAMES ND; SIKORA K; GOLDMAN JM. (1 Jan 1988). INCREASED PRETRANSPLANT IMMUNOSUPPRESSION AIDS ENGRAFTMENT IN T-CELL-DEPLETED (TCD) DONOR MARROW IN ALLOGENEIC BMT. BONE MARROW TRANSPLANTATION. 3:225-225. Author weblink.
• ARTHUR CK; APPERLEY JF; JONES L; GUO AP; RASSOOL F; HALE G; WALDMANN H; GOLDMAN JM. (1 Aug 1987). BONE-MARROW TRANSPLANTATION FOR CHRONIC GRANULOCYTIC-LEUKEMIA (CGL) IN CHRONIC PHASE (CP) USING T-CELL DEPLETED MARROW - REDUCED INCIDENCE OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) BUT INCREASED INCIDENCE OF RELAPSE. BRITISH JOURNAL OF HAEMATOLOGY. 66:572-573. Author weblink.
• Jones L; Thein SL; Jeffreys AJ; Apperley JF; Catovsky D; Goldman JM. (Aug 1987). Identical twin marrow transplantation for 5 patients with chronic myeloid leukaemia: role of DNA finger-printing to confirm monozygosity in 3 cases. Eur J Haematol. 39:144-147.
• APPERLEY JF; DOWDING C; GORDON MY; GOLDMAN JM. (1 Aug 1987). INHIBITION OF HEMATOPOIETIC BLAST COLONY PRODUCTION IN SHORT-TERM CULTURES BY CYTOMEGALOVIRUS (CMV) INFECTION OF BONE-MARROW STROMAL LAYERS. BRITISH JOURNAL OF HAEMATOLOGY. 66:574-574. Author weblink.
• Apperley JF; Rice SJ; Hewitt P; Rombos Y; Barbara J; Gabriel FG; Goldman JM. (Aug 1987). HIV infection due to a platelet transfusion after allogeneic bone marrow transplantation. Eur J Haematol. 39:185-189.
• THOMAS AMK; ARTHUR C; APPERLEY JF; GOOLDEN AWG; GOLDMAN JM; LAVENDER JP. (1 Aug 1987). FOCAL AND GENERALIZED PNEUMONITIS FOLLOWING BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA. BRITISH JOURNAL OF RADIOLOGY. 60:809-809. Author weblink.
• APPERLEY JF; DOWDING C; HIBBIN JA; BUITER J; GORDON MY; GOLDMAN JM. (1 Jun 1987). THE INHIBITORY EFFECT OF CYTOMEGALOVIRUS (CMV) ON COLONY PRODUCTION IN SHORT-TERM CULTURES. EXPERIMENTAL HEMATOLOGY. 15:576-576. Author weblink.
• APPERLEY JF; MAURO F; GOLDMAN JM. (1 Jun 1987). RISK-FACTORS FOR RELAPSE AFTER BMT FOR CHRONIC MYELOID-LEUKEMIA (CML) IN 1ST CHRONIC PHASE (CP). EXPERIMENTAL HEMATOLOGY. 15:535-535. Author weblink.
• Jones L; Ball J; Apperley JF; Ginsberg L; Goldman JM. (Apr 1987). Subacute thyroiditis after bone marrow transplant for chronic granulocytic leukaemia. Bone Marrow Transplant. 1:411-412.
• Cohen J; Moore RH; Al Hashimi S; Jones L; Apperley JF; Aber VR. (3 Jan 1987). Antibody titres to a rough-mutant strain of Escherichia coli in patients undergoing allogeneic bone-marrow transplantation. Evidence of a protective effect against graft-versus-host disease. Lancet. 1:8-11.
• PARREIRA A; SMITH J; HOWS JM; SMITHERS SA; APPERLEY J; ROMBOS Y; GOLDMAN JM; GORDONSMITH EC; et alCATOVSKY D. (1 Jan 1987). IMMUNOLOGICAL RECONSTITUTION AFTER BONE-MARROW TRANSPLANT WITH CAMPATH-1 TREATED BONE-MARROW. CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 67:142-150. Author weblink.
• Apperley JF; Rice SJ; Bishop JA; Chia YC; Krausz T; Gardner SD; Goldman JM. (Jan 1987). Late-onset hemorrhagic cystitis associated with urinary excretion of polyomaviruses after bone marrow transplantation. Transplantation. 43:108-112.
• Brito-Babapulle F; Apperley JF; Rassool F; Guo AP; Dowding C; Goldman JM. (1987). Complete remission after autografting for chronic myeloid leukaemia. Leuk Res. 11:1115-1117.
• APPERLEY JF; SLOCOMBE G; CUTHBERTSON B; BISHOP J; BERRY N; GRIFFITH P; YAP PL; GOLDMAN JM. (1 Dec 1986). SCOTTISH-NATIONAL-BLOOD-TRANSFUSION-SERVICE (SNBTS) HIGH TITER ANTI-CMV HYPERIMMUNE GLOBULIN HALF-LIFE DATA. BRITISH JOURNAL OF HAEMATOLOGY. 64:835-835. Author weblink.
• Hows JM; Yin JL; Marsh J; Swirsky D; Jones L; Apperley JF; James DC; Smithers S; et alBatchelor JR; Goldman JM. (Dec 1986). Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. Blood. 68:1322-1328.
• JONES L; APPERLEY JF; ROMBOS Y; HALE G; WALDMANN H; HOWS J; GORDONSMITH EC; GOOLDEN AWG; et alGOLDMAN JM. (1 Dec 1986). REDUCED INCIDENCE OF GVHD IN MATCHED AND MISMATCHED TRANSPLANTS FOR CHRONIC GRANULOCYTIC-LEUKEMIA (CGL). BRITISH JOURNAL OF HAEMATOLOGY. 64:831-831. Author weblink.
• APPERLEY JF; ROMBOS Y; JONES L; RICE SJ; BISHOP J; TEDDER RA; GARDNER SD; GOLDMAN JM. (1 Dec 1986). UNUSUAL VIRAL-INFECTIONS AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT). BRITISH JOURNAL OF HAEMATOLOGY. 64:821-821. Author weblink.
• JONES L; APPERLEY JF; THEIN SL; ROMBOS Y; HOWS J; GORDONSMITH EC; CATOVSKY D; GOLDMAN JM. (1 Dec 1986). TREATMENT OF 5 PATIENTS WITH CHRONIC GRANULOCYTIC-LEUKEMIA (CGL) BY BONE-MARROW TRANSPLANTATION (BMT) FROM IDENTICAL TWIN - ROLE OF DNA FINGER-PRINTING TO ESTABLISH SYNGENEITY. BRITISH JOURNAL OF HAEMATOLOGY. 64:813-813. Author weblink.
• SUTEDJA T; APPERLEY JF; KENNEDY LJHG; HOPPER L; GOLDMAN JM; HUGHES JMB. (1 Sep 1986). EFFECT OF PRECONDITIONING REGIMENS ON PULMONARY-FUNCTION FOLLOWING BONE-MARROW TRANSPLANTATION. THORAX. 41:726-726. Author weblink.
• Bull BS; Levy WC; Westengard JC; Farr M; Smith PF; Apperley JF; Bacon PA; Stuart J. (16 Aug 1986). Ranking of laboratory tests by consensus analysis. Lancet. 2:377-380.
• GOLDMAN JM; APPERLEY JF; JONES L; HALE G; WALDMANN H; HOWS J; ROMBOS Y; TSATALAS C; et alMARCUS RE; GOOLDEN AWG; GORDONSMITH EC; CATOVSKY D; GALTON DAG. (1 Jul 1986). BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH CHRONIC MYELOID-LEUKEMIA - T-CELL DEPLETION WITH CAMPATH-1 REDUCES THE INCIDENCE OF GRAFT-VERSUS-HOST DISEASE BUT MAY INCREASE THE RISK OF LEUKEMIC RELAPSE. EXPERIMENTAL HEMATOLOGY. 14:447-447. Author weblink.
• PATTERSON J; PRENTICE HG; BRENNER MK; GILMORE M; JANOSSY G; IVORY K; SKEGGS D; MORGAN H; et alLORD J; BLACKLOCK HA; HOFFBRAND AV; APPERLEY JF; GOLDMAN JM; BURNETT A; GRIBBEN J; ALCORN M; PEARSON C; MCVICKERS I; HANN IM; REID C; WARDLE D; GRAVETT PJ; BACIGALUPO A; ROBERTSON AG. (1 Jun 1986). GRAFT-REJECTION FOLLOWING HLA MATCHED LYMPHOCYTE-T DEPLETED BONE-MARROW TRANSPLANTATION. BRITISH JOURNAL OF HAEMATOLOGY. 63:221-230.
• Apperley JF; Rassool F; Parreira A; Geary CG; Harrison C; Stansfield D; Goldman JM. (Jun 1986). Philadelphia-positive metaphases in the marrow after bone marrow transplantation for chronic granulocytic leukemia. Am J Hematol. 22:199-204.
• Apperley JF; Jones L; Hale G; Waldmann H; Hows J; Rombos Y; Tsatalas C; Marcus RE; et alGoolden AW; Gordon-Smith EC. (May 1986). Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant. 1:53-66.
• Goldman JM; Apperley JF; Jones L; Marcus R; Goolden AW; Batchelor R; Hale G; Waldmann H; et alReid CD; Hows J. (23 Jan 1986). Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med. 314:202-207. DOI.
• APPERLEY JF; JONES L; ROMBOS Y; HALE G; WALDMANN H; HOWS J; GORDONSMITH E; GOLDMAN JM. (1 Jan 1986). REDUCED INCIDENCE OF GVHD IN RECIPIENTS OF T-CELL DEPLETED MARROW. LEUKEMIA RESEARCH. 10:122-122. Author weblink DOI.
• Rice SJ; Bishop JA; Apperley J; Gardner SD. (12 Oct 1985). BK virus as cause of haemorrhagic cystitis after bone marrow transplantation. Lancet. 2:844-845.
• Apperley JF; Marcus RE; Goldman JM; Wardle DG; Gravett PJ; Chanas A. (18 May 1985). Foscarnet for cytomegalovirus pneumonitis. Lancet. 1:1151.
• GOLDMAN JM; APPERLEY JF; HOWS J; GORDONSMITH EC; REID CD; CATOVSKY D; GALTON DAG. (1 Jan 1985). BONE-MARROW TRANSPLANTATION (BMT) FOR PATIENTS WITH CHRONIC GRANULOCYTIC-LEUKEMIA (CGL) - LACK OF EARLY RELAPSE IN RECIPIENTS OF T-DEPLETED DONOR MARROW. EXPERIMENTAL HEMATOLOGY. 13:322-322. Author weblink.
• APPERLEY JF; MARCUS RE; GOLDMAN JM; WARDLE DG; GRAVETT PJ; CHANAS A. (1 Jan 1985). FOSCARNET FOR CYTOMEGALO-VIRUS PNEUMONITIS. LANCET. 1:1151-1151. Author weblink.
• APPERLEY JF; HOWS JM; HALE G; WALDMANN H; GORDONSMITH EC; GOLDMAN JM. (1 Jan 1985). RESULTS OF T-CELL DEPLETION WITH CAMPATH-1 IN BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC GRANULOCYTIC-LEUKEMIA (CGL). BRITISH JOURNAL OF CANCER. 52:651-651. Author weblink.
• BRAUDE S; APPERLEY J; KRAUSZ T; GOLDMAN JM; ROYSTON D. (1 Jan 1985). ADULT RESPIRATORY-DISTRESS SYNDROME AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION - EVIDENCE FOR A NEUTROPHIL-INDEPENDENT MECHANISM. LANCET. 1:1239-1242. Author weblink.
• APPERLEY JF; GOLDMAN JM. (1 Jan 1985). BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA. PLASMA THERAPY & TRANSFUSION TECHNOLOGY. 6:207-220. Author weblink.
• PATTERSON J; PRENTICE HG; BRENNER MK; GILMORE M; BLACKLOCK H; HOFFBRAND AV; JANOSSY G; SKEGGS D; et alIVORY K; APPERLEY J; GOLDMAN J; BURNETT A; GRIBBEN J; ALCORN M; PEARSON C; MCVICKERS I; HANN I; REID C; WARDLE D; BACIGALUPO A; ROBERTSON AG. (1 Jan 1985). GRAFT-REJECTION FOLLOWING T-CELL DEPLETED BMT. BRITISH JOURNAL OF HAEMATOLOGY. 61:562-562.
• KENNEDY HG; WYATT SE; APPERLEY J; HOPPER L; GOLDMAN JM; HUGHES JMB. (1 Jan 1985). BONE-MARROW TRANSPLANTATION - PROSPECTIVE-STUDY OF LUNG-FUNCTION. THORAX. 40:233-233.

Books

• Apperley JF. Apperley JF (ed); Carreras E (ed); Gluckman E (ed); Gratwohl A (ed); Masszi T (ed). Haemopoietic Stem Cell Transplantation. European School of Hematology (May 2004).

Conferences

• Loaiza S; Haynes R; Bray E; Finn S; Rezvani K; Apperley J; Davis J. Donor lymphocyte collections using the Spectra Optia MNC version 5. 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), 1 Apr 2012 - 4 Apr 2012. 47:S256-S257. NATURE PUBLISHING GROUP (1 Apr 2012). Author weblink.
• Malard F; Kroger N; Gabriel IH; Huebel K; Apperley JF; Basak GW; Douglas KW; Geraldes C; et alJaksic O; Koristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Duarte R; Mohty M. Plerixafor for autologous peripheral blood stem cell mobilisation in patients previously treated with fludarabine or lenalidomide. 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), 1 Apr 2012 - 4 Apr 2012. 47:S240-S240. NATURE PUBLISHING GROUP (1 Apr 2012). Author weblink.
• Kishore B; Davis J; Rezvani K; Marin D; Chakrabartty J; Szydlo R; Loazia S; Chaidos A; et alGiles C; Kanfer E; Karadimitris A; Macdonald D; Milojkovic D; Rahemtulla A; Goldman J; Apperley J; Pavlu J. Cryopreserved allogeneic peripheral blood stem cells result in outcome equivalent to those of fresh infusions enabling rational scheduling of donations. 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), 1 Apr 2012 - 4 Apr 2012. 47:S253-S254. NATURE PUBLISHING GROUP (1 Apr 2012). Author weblink.
• Salooja N; Patel B; Todd J; Apperley J; Goldman J; Terpos E. Dikkopf-1 is elevated in very long-term survivors of haematopoietic stem cell transplantation. 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), 1 Apr 2012 - 4 Apr 2012. 47:S338-S338. NATURE PUBLISHING GROUP (1 Apr 2012). Author weblink.
• Salooja N; Szydlo R; Apperley J; Goldman J; Todd J. Exercise and cardiovascular risk factors in long-term survivors of transplantation. 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), 1 Apr 2012 - 4 Apr 2012. 47:S337-S337. NATURE PUBLISHING GROUP (1 Apr 2012). Author weblink.
• Chakrabartty J; Pavlu J; Neave EL; Eguialde ML; O'Shea D; Giles C; Goldman J; Kirschke S; et alKanfer E; Kishore B; MacDonald D; Milojkovic D; Marin D; Rahemtulla A; Olavarria E; Apperley J; Rezvani K. Safety and efficacy of two regimens of high-dose liposomal amphotericin B for prophylaxis of invasive fungal infection in allogeneic haematopoietic stem cell transplantation: a comparative retrospective single-centre study. 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), 1 Apr 2012 - 4 Apr 2012. 47:S131-S131. NATURE PUBLISHING GROUP (1 Apr 2012). Author weblink.
• Beckerson J; Sampson B; Kanfer E; Marin D; Milojkovic D; Pavlu J; Rahemtulla A; Rezvani K; et alApperley J; Taylor A. Plasma zinc, copper and selenium in subjects planned for haematopoietic stem cell transplant and their change during treatment. 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), 1 Apr 2012 - 4 Apr 2012. 47:S192-S192. NATURE PUBLISHING GROUP (1 Apr 2012). Author weblink.
• Salooja N; Babb A; Lindsay K; Apperley J. Uptake and outcome of assisted reproductive techniqes in long-term survivors. 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), 1 Apr 2012 - 4 Apr 2012. 47:S8-S9. NATURE PUBLISHING GROUP (1 Apr 2012). Author weblink.
• Pavlu J; Rezvani K; Kishore B; Chakrabartty J; Shah R; Auner HW; Milojkovic D; Marin D; et alRahemtulla A; MacDonald DH; Kanfer EJ; Dazzi F; Goldman JM; Apperley JF; Szydlo RM. Optimising patient selection for allogeneic stem cell transplantation: prediction of non-relapse mortality and survival. 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), 1 Apr 2012 - 4 Apr 2012. 47:S27-S28. NATURE PUBLISHING GROUP (1 Apr 2012). Author weblink.
• Innes AJ; Lurkins J; Szydlo RM; Guerra A; Milojkovic D; Pavlu J; Kanfer EJ; Marin D; et alMacDonald D; Rahemtulla A; Loaiza S; Kirschke S; Rezvani K; Goldman J; Apperley JF; Dazzi F. The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, 10 Dec 2011 - 13 Dec 2011. 118:1752-1752. AMER SOC HEMATOLOGY (18 Nov 2011). Author weblink.
• Fresen MM; Duarte RF; Apperley JF; Basak G; Douglas KW; Gabriel IH; Geraldes C; Jaksic O; et alKoristek Z; Kroeger N; Lanza F; Lemoli RM; Mikala G; Selleslag D; Worel N; Lange F; Mohty M; Hubel K. Stem Cell Mobilization in Poor Mobilizers Using Plerixafor and G-CSF with or without Chemotherapy: A European Perspective. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, 10 Dec 2011 - 13 Dec 2011. 118:1289-1290. AMER SOC HEMATOLOGY (18 Nov 2011). Author weblink.
• Kishore B; Davis J; Rezvani K; Marin D; Szydlo RM; Sandra L; Chrissy G; Chaidos A; et alKanfer EJ; Karadimitris A; MacDonald DH; Milojkovic D; Rahemtulla A; Goldman JM; Apperley JF; Pavlu J. Cryopreserved Allogeneic Peripheral Blood Stem Cells Result in Outcome Equivalent to Those of Fresh Infusions Enabling Rational Scheduling of Donations. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, 10 Dec 2011 - 13 Dec 2011. 118:1730-1731. AMER SOC HEMATOLOGY (18 Nov 2011). Author weblink.
• Cook G; Kirkland K; Lee J; Pearce RM; Apperley JF; Clark RE; Mackinnon S; Marks DI. Allogeneic Stem Cell Transplantation Induces Long Term Survival in Pateitns with Advanced Chronic Myeloid Leukaemia: A Study of the British Society for Blood and Marrow Transplantation. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), 10 Dec 2011 - 13 Dec 2011. 118:1764-1764. AMER SOC HEMATOLOGY (18 Nov 2011). Author weblink.
• O'Donovan EM; Rezvani K; Sargent J; Richardson D; Tharmalingam H; Veys P; Apperley JF; Cooper N. Thrombopoietic Agonists Show Efficacy in ITP Related to Allogeneic Stem Cell Transplantation. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, 10 Dec 2011 - 13 Dec 2011. 118:1415-1416. AMER SOC HEMATOLOGY (18 Nov 2011). Author weblink.
• Milojkovic D; Apperley JF; Ibrahim AR; Bua M; Reid A; Gerrard G; Foroni L; Rezvani K; et alGoldman JM; Marin D. Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, 10 Dec 2011 - 13 Dec 2011. 118:1613-1614. AMER SOC HEMATOLOGY (18 Nov 2011). Author weblink.
• de Lavallade H; Marin D; Hart M; Sekine T; Gabriel I; Alsuliman A; Bazeos A; Khoder A; et alStringaris K; Khorashad J; Cooper N; Milojkovic D; Foroni L; Szydlo RM; Chaidos A; Ibrahim AR; Bua M; Goldman JM; Apperley JF; Kelleher WP; Rezvani K. Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associate with Loss of Discrete Memory B Cell Subsets. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, 10 Dec 2011 - 13 Dec 2011. 118:1602-1602. AMER SOC HEMATOLOGY (18 Nov 2011). Author weblink.
• Cortes JE; Kim D-W; Pinilla-Ibarz J; Le Coutre PD; Chuah C; Nicolini FE; Paquette R; Apperley JF; et alDiPersio JF; Khoury HJ; Rea D; Talpaz M; DeAngelo DJ; Abruzzese E; Baccarani M; Mueller MC; Gambacorti-Passerini C; Wong S; Lustgarten S; Turner CD; Rivera VM; Clackson T; Haluska F; Kantarjian HM. Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), 10 Dec 2011 - 13 Dec 2011. 118:52-53. AMER SOC HEMATOLOGY (18 Nov 2011). Author weblink.
• Pavlu J; Rezvani K; Kishore B; Le Dieu R; Chakrabartty J; Chaidos A; Kanfer EJ; Karadimitris A; et alMacDonald DH; Marin D; Milojkovic D; O'Boyle F; Rahemtulla A; Slade D; Goldman JM; Apperley JF; Szydlo RM. Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, 10 Dec 2011 - 13 Dec 2011. 118:849-849. AMER SOC HEMATOLOGY (18 Nov 2011). Author weblink.
• Milojkovic D; Gerrard G; Paliompeis C; Bua M; Reid A; Alikian M; Khorashad J; Goldman JM; et alMarin D; Foroni L; Apperley JF. The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for 'Stopping' Studies. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, 10 Dec 2011 - 13 Dec 2011. 118:278-278. AMER SOC HEMATOLOGY (18 Nov 2011). Author weblink.
• Marin D; Hedgley C; Clark RE; Apperley JF; Foroni L; Milojkovic D; Pocock C; Goldman JM; et alO'Brien S. The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, 10 Dec 2011 - 13 Dec 2011. 118:357-357. AMER SOC HEMATOLOGY (18 Nov 2011). Author weblink.
• Malard F; Kroeger N; Gabriel IH; Huebel K; Apperley JF; Basak G; Douglas KW; Geraldes C; et alJaksic O; Koristek Z; Lanza F; Lemoli RM; Mikala G; Selleslag D; Worel N; Duarte RF; Mohty M. Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, 10 Dec 2011 - 13 Dec 2011. 118:842-842. AMER SOC HEMATOLOGY (18 Nov 2011). Author weblink.
• Chakrabartty J; Krishna R; Balderamos LG; Hunt C; Januszewski A; Ali S; Gabriel I; Marin D; et alApperley J; Kishore B; Goldman JM; Szydlo R; Busbridge M; Rezvani K. IMPACT OF HEMOCHROMATOSIS GENE (HFE) POLYMORPHISMS AND IRON OVERLOAD ON OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA. BMT Tandem Meeting, 1 Feb 2012 - 5 Feb 2012. 18:S210-S210. ELSEVIER SCIENCE INC (1 Feb 2012). Author weblink.
• Maheswaran M; Szydlo R; Apperley J; Goldman J; Todd JF; Salooja N. Endocrine complications of stem cell transplantation for haematological malignancy. 51st Annual Scientific Meeting of the British-Society-for-Haematology, 4 Apr 2011 - 6 Apr 2011. 153:69-69. WILEY-BLACKWELL (1 Apr 2011). Author weblink.
• Yee C; Szydlo R; Apperley J; Goldman J; Todd J; Salooja N. Cardiovascular risk factors in long-term survivors of stem cell transplantation for haematological malignancy. 51st Annual Scientific Meeting of the British-Society-for-Haematology, 4 Apr 2011 - 6 Apr 2011. 153:18-18. WILEY-BLACKWELL (1 Apr 2011). Author weblink.
• Khorashad SS; Wagner S; Marin D; Reid AG; Milojkovic D; Willimott S; Gerrard G; Foroni L; et alGoldman JM; Apperley JE. EXPRESSION OF H-OCT1 PREDICTS FOR ACHIEVEMENT OF CCYR IN IMATINIB TREATED PATIENTS WHILE THE LEVEL OF PHOSPHO-CRKL INHIBITION IN CD34 POSITIVE CELLS SEEMS TO BE OF LITTLE PROGNOSTIC VALUE. 13th Congress of the European-Hematology-Association, 12 Jun 2008 - 15 Jun 2008. 93:50-50. FERRATA STORTI FOUNDATION (1 Jun 2008). Author weblink.
• Dharmagunawardena RT; Pearce RM; Lee J; Apperley JF; Littlewood T; Wilson KM; Orchard K; Jackson G; et alSnowden JA; Kirkland K; Cook G; Hubbard R; Brown J. A RETROSPECTIVE MULTI-CENTRE STUDY OF THE EFFECTS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION ON PULMONARY FUNCTION. Winter Meeting of the British-Thoracic-Society, 7 Dec 2011 - 9 Dec 2011. 66:A62-A62. B M J PUBLISHING GROUP (1 Dec 2011). Author weblink DOI.
• Chusney GD; Osei-Bimpong A; Apperley J; Cairns T; Lee J; Milojkovic D. Quantitation of imatinib and norimatinib by LC-MS/MS in plasma of patients with chronic myeloid leukaemia. 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, 2 Oct 2011 - 6 Oct 2011. 33:547-547. LIPPINCOTT WILLIAMS & WILKINS (1 Aug 2011).
• Chaidos A; Szydlo RM; Kanfer EJ; Dazzi F; MacDonald DH; Marin D; Milojkovic D; Pavlu J; et alDavis J; Rezvani K; Rahemtulla A; Roberts I; Apperley JF; Karadimitris A. High Frequency and Cell Dose of Invariant NKT Cells In the Graft Are Associated with Lack of Clinically Significant Acute Gvhd In T Cell-Replete Sibling Allografts. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), 4 Dec 2010 - 7 Dec 2010. 116:1051-1052. AMER SOC HEMATOLOGY (19 Nov 2010). Author weblink.
• Schleuning M; Scholten M; van Biezen A; Nagler A; Apperley JF; Michallet M; Grigg A; Silver RT; et alLeitner A; Gratwohl A; Ekblom M; Khoury HJ; de Witte T; Olavarria E. Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia After Prior Treatment with Nilotinib or Dasatinib. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), 4 Dec 2010 - 7 Dec 2010. 116:970-970. AMER SOC HEMATOLOGY (19 Nov 2010). Author weblink.
• Ibrahim AR; Milojkovic D; Bua M; Khorshad JS; Szydlo R; Eliasson L; Foroni L; Reid A; et alde Lavallade H; Rezvani K; Goldman JM; Apperley J; Marin D. Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), 4 Dec 2010 - 7 Dec 2010. 116:1398-1399. AMER SOC HEMATOLOGY (19 Nov 2010). Author weblink.
• Pavlu J; Shah R; Auner HW; Milojkovic D; Marin D; Sargent J; Rahemtulla A; MacDonald DH; et alKanfer EJ; Rezvani K; Dazzi F; Goldman JM; Apperley JF; Szydlo RM. Preconditioning Level of C-Reactive Protein and Disease Stage Are Key Prognostic Factors In Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), 4 Dec 2010 - 7 Dec 2010. 116:1433-1434. AMER SOC HEMATOLOGY (19 Nov 2010). Author weblink.
• Gabriel IH; Marin D; Ahmad S; Foroni L; de Lavallade H; Clark RE; O'Brien S; Sergeant R; et alMilojkovic D; Bua M; Alsuliman A; Khoder A; Stringaris K; Cooper N; Goldman JM; Apperley JF; Rezvani K. KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), 4 Dec 2010 - 7 Dec 2010. 116:388-389. AMER SOC HEMATOLOGY (19 Nov 2010). Author weblink.
• Holroyd A; Phillips E; Szydlo R; Marin D; Foroni L; Khorashad J; Milojkovic D; Kanfer EJ; et alDazzi F; MacDonald DH; Rahemtulla A; McLornan D; Gabriel IH; Pavlu J; Sargent J; Goldman JM; Apperley JF; Rezvani K. Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), 4 Dec 2010 - 7 Dec 2010. 116:1445-1445. AMER SOC HEMATOLOGY (19 Nov 2010). Author weblink.
• Dunwoody R; Szydlo R; Casey L; Davis J; LLoyd S; Gabriel IH; Rezvani K; Apperley JF. Variations In Efficiency of Donor Searches Between International Unrelated Blood and Marrow Donor Registries. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), 4 Dec 2010 - 7 Dec 2010. 116:648-648. AMER SOC HEMATOLOGY (19 Nov 2010). Author weblink.
• Morris CTCM; Scholten M; de Wreede L; van Biezen A; Dickmeiss E; Tmeny M; Apperley JF; Chiusolo P; et alVan Imhoff G; Lenhoff S; Uharek L; Martinelli G; Hentrich M; Sureda A; de Witte TM; Ruutu T. DMSO Reduction Strategies Reduce DMSO Induced Post Autologous Transplant Morbidity In Patients with Lymphoma and Myeloma -Results from an EBMT Non Interventional Prospective Study. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), 4 Dec 2010 - 7 Dec 2010. 116:994-994. AMER SOC HEMATOLOGY (19 Nov 2010). Author weblink.
• Nicolini FE; Morisset S; Hochhaus A; Martinelli G; Kim D-W; Dufva I; Mauro M; Cortes JE; et alChuah C; Apperley J; Guilhot F; Saglio G; Mueller MC; Soverini S; Corm S; Tigaud I; Etienne M; Roche-Lestienne C; Hayette S; Peter S; Zhou W; Michallet M. The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors, Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), 4 Dec 2010 - 7 Dec 2010. 116:1396-1397. AMER SOC HEMATOLOGY (19 Nov 2010). Author weblink.
• Stringaris K; Barrett AJ; Hills R; Linch DC; Gale R; Allen C; Garland P; Sargent R; et alde Lavallade H; Alsuliman A; Khoder A; Gabriel IH; Sekine T; Burnett A; Rezvani K; Apperley JF. A Distinct Signature of Natural Killer Cell KIR Gene Frequencies In Secondary AML Compared with De Novo AML and Normal Controls. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), 4 Dec 2010 - 7 Dec 2010. 116:711-712. AMER SOC HEMATOLOGY (19 Nov 2010). Author weblink.
• de Lavallade H; Garland PL; Sekine T; Hoschler K; Marin D; Stringaris K; Loucaides E; Howe K; et alSzydlo RM; Kanfer EJ; McDonald D; Kelleher P; Cooper N; Khoder A; Gabriel IH; Alsuliman A; Milojkovic D; Pavlu J; Goldman JM; Apperley JF; Rezvani K. 2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), 4 Dec 2010 - 7 Dec 2010. 116:297-298. AMER SOC HEMATOLOGY (19 Nov 2010). Author weblink.
• Ibrahim AR; Bua M; Khorshad JS; Milojkovic D; Eliasson L; Szydlo R; Foroni L; Reid A; et alde Lavallade H; Rezvani K; Goldman JM; Apperley J; Marin D. Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs. ASH Annual Meeting. 116: Abstract 2274. (2010).
• Worel N; Apperley JF; Basak G; Douglas K; Gabriel I; Geraldes C; Huebel K; Jaksic O; et alKoristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Duarte R; Mohty M. Haematopoietic stem cell mobilization with plerixafor in patients with non-haematological diseases. 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 3 Apr 2011 - 6 Apr 2011. 46:S383-S383. NATURE PUBLISHING GROUP (1 Apr 2011). Author weblink.
• Phillips E; Holroyd A; Szydlo R; Marin D; Foroni L; Milojkovic D; de Lavallade H; Gabriel I; et alSargent J; Le Dieu R; Goldman J; Apperley JF; Rezvani K. Staging criteria based on maximal disease stage pre-transplant predicts the outcome of allogeneic stem cell transplantation for chronic myeloid leukaemia in the imatinib era. 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 3 Apr 2011 - 6 Apr 2011. 46:S365-S365. NATURE PUBLISHING GROUP (1 Apr 2011). Author weblink.
• de Lavallade H; Hart M; Sekine T; Gabriel I; Kelleher W; Alsuliman A; Khoder A; Stringaris K; et alKhorashad J; Milojkovic D; Foroni L; Chaidos A; Bua M; Apperley JF; Goldman J; Marin D; Rezvani K. Chronic phase CML patients on tyrosine kinase inhibitors have a normal cellular immune response against influenza but an impaired IgM humoral response against pneumococcus after vaccination: implications for immunotherapy. 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 3 Apr 2011 - 6 Apr 2011. 46:S364-S364. NATURE PUBLISHING GROUP (1 Apr 2011). Author weblink.
• Jaksic O; Apperley JF; Basak G; Douglas K; Gabriel I; Geraldes C; Huebel K; Koristek Z; et alLanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Bojanic I; Mohty M; Duarte R. Autologous haematopoietic stem cell mobilization with plerixafor and G-CSF: impact of apheresis volume. Data from the Plerixafor European Compassionate Use Study. 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 3 Apr 2011 - 6 Apr 2011. 46:S335-S336. NATURE PUBLISHING GROUP (1 Apr 2011). Author weblink.
• Basak G; Wiktor-Jedrzejczak W; Apperley JF; Douglas K; Gabriel I; Geraldes C; Hubel K; Jaksic O; et alKoristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Mohty M; Duarte R. Autologous haematopoietic stem cell mobilization with plerixafor and G-CSF: impact of overweight and obesity. 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 3 Apr 2011 - 6 Apr 2011. 46:S333-S333. NATURE PUBLISHING GROUP (1 Apr 2011). Author weblink.
• Huebel K; Fresen MM; Apperley JF; Basak G; Douglas K; Gabriel I; Geraldes C; Jaksic O; et alKoristek Z; Kroeger N; Lanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Mohty M; Duarte R. Plerixafor for stem cell mobilization in Hodgkin, non-Hodgkin, and multiple myeloma patients: a subgroup analysis from the European Compassionate Use Program. 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 3 Apr 2011 - 6 Apr 2011. 46:S332-S332. NATURE PUBLISHING GROUP (1 Apr 2011). Author weblink.
• Gabriel IH; Apperley JF; Szydlo R; Basak G; Douglas K; Geraldes C; Huebel K; Jaksic O; et alKoristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Wiktor-Jedrzejczak W; Worel N; Mohty M; Duarte R. The role of the CXCR4 antagonist Plerixafor (R) in elderly patients failing autologous stem cell mobilization. Data from the Plerixafor Compassionate Use Study. On behalf of the European Consortium for Stem Cell Mobilization (ECOSM). 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 3 Apr 2011 - 6 Apr 2011. 46:S331-S332. NATURE PUBLISHING GROUP (1 Apr 2011). Author weblink.
• Dunwoody R; Gabriel IH; Szydlo R; Casey L; Davis J; Lloyd S; Rezvani K; Apperley JF. Variations in the efficiency of donor searches between international unrelated blood and marrow donor registries. 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 3 Apr 2011 - 6 Apr 2011. 46:S235-S235. NATURE PUBLISHING GROUP (1 Apr 2011). Author weblink.
• Yee C; Cabrita I; Szydlo R; Apperley JF; Goldman J; Nihoyannopoulos P; Todd J; Salooja N. Echocardiographic findings following 10-14 Gy total body irradiation in long-term survivors of stem cell transplantation for leukaemia. 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 3 Apr 2011 - 6 Apr 2011. 46:S176-S176. NATURE PUBLISHING GROUP (1 Apr 2011). Author weblink.
• Maheswaran M; Szydlo R; Apperley JF; Goldman J; Todd J; Salooja N. Thyroid and parathyroid function in long-term survivors of stem cell transplantation after 10-14Gy total body irradiation. 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 3 Apr 2011 - 6 Apr 2011. 46:S166-S166. NATURE PUBLISHING GROUP (1 Apr 2011). Author weblink.
• Elsey PA; Smith R; Haynes R; Dannie E; Loaiza S; Rezvani K; Apperley JF; Davis J. Haematopoietic progenitor cell collections using the Spectra Optia MNC protocol Version 5. 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 3 Apr 2011 - 6 Apr 2011. 46:S133-S133. NATURE PUBLISHING GROUP (1 Apr 2011). Author weblink.
• Duarte R; Apperley JF; Basak G; Douglas K; Gabriel IH; Geraldes C; Huebel K; Jaksic O; et alKoristek Z; Kroeger N; Lanza F; Lemoli R; Mikala G; Selleslag D; Wiktor-Jedrzejczak W; Worel N; Mohty M. Patient and disease characteristics influencing the outcome of mobilization with plerixafor: large compassionate-use analysis by ECOSM (European Consortium for Stem Cell Mobilization). 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 3 Apr 2011 - 6 Apr 2011. 46:S60-S60. NATURE PUBLISHING GROUP (1 Apr 2011). Author weblink.
• Basak G; Wiktor-Jedrzejczak W; Salooja N; Scholten M; Ganser A; Pavone V; Vitek A; Corral L; et alApperley JF; Ruutu T; de Witte T. Topical tacrolimus in the treatment of cutaneous and mucosal manifestations of chronic GvHD: a noninterventional prospective study by the Complications Subcommittee of the Chronic Leukaemia Working Party of the EBMT. 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 3 Apr 2011 - 6 Apr 2011. 46:S33-S33. NATURE PUBLISHING GROUP (1 Apr 2011). Author weblink.
• Schleuning M; van Biezen A; Hoek J; Apperley JF; Maertens J; Baccarani M; Al Jurf M; Michallet M; et alKuliczowski K; Afanasyev B; Finke J; Olavarria E; de Witte T. Effect of prior therapy with nilotinib or dasatinib on the outcome after allogeneic stem cell transplantation for patients with chronic myeloid leukaemia: a non-interventional prospective study by the CML subcommittee of the Chronic Leukaemia Working Party. 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 3 Apr 2011 - 6 Apr 2011. 46:S31-S31. NATURE PUBLISHING GROUP (1 Apr 2011). Author weblink.
• Morris C; Scholten M; de Wreede L; Brand R; van Biezen A; Dickmeiss E; Trneny M; Apperley JF; et alChiusolo P; van Imhoff G; Lenhoff S; Sureda A; de Witte T; Ruutu T. Final results of the EBMT non-interventional prospective study in DMSO; DMSO reduction lessens side effects. 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 3 Apr 2011 - 6 Apr 2011. 46:S21-S21. NATURE PUBLISHING GROUP (1 Apr 2011). Author weblink.
• Holroyd A; Phillips E; Szydlo R; Mann D; Foroni L; Khorashad J; Milojkovic D; Kanfer EJ; et alDazzi F; MacDonald DH; Rahemtulla A; McLornan D; Gabriel IH; Pavlu J; Sargent J; Goldman JM; Apperley JF; Rezvani K. Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chrome Myeloid Leukemia. 116:1445-1445. (19 Nov 2010).
• Nicolini FE; Morisset S; Hochhaus A; Martinelli G; Kim DW; Dufva I; Mauro M; Cortes JE; et alChuah C; Apperley J; Guilhot F; Saglio G; Muller MC; Soverini S; Corm S; Tigaud I; Etienne M; Lestienne CR; Hayette S; Peter S; Zhou W; Michallet M. The Presence of the BCR ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival Preliminary Results Of a Matched Pair Analysts. 116:1396-1397. (19 Nov 2010).
• Gabriel IH; Marin D; Ahmad S; Foroni L; de Lavallade H; Clark RE; Brien SO; Sergeant R; et alMilojkovic D; Bua M; Alsuliman A; Khoder A; Stringaris K; Cooper N; Goldman JM; Apperley JF; Rezvani K. KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib. 116:388-389. (19 Nov 2010).
• De Lavallade H; Garland PL; Sekine T; Hoschler K; Marin D; Stringaris K; Loucaides E; Howe K; et alSzydlo RM; Kanfer EJ; McDonald D; Kelleher P; Cooper N; Khoder A; Gabriel IH; Alsuliman A; Milojkovic D; Pavlu J; Goldman JM; Apperley JF; Rezvani K. 2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies Requirement for Repeated Dosing to Optimize Seroprotec. 116:297-298. (19 Nov 2010).
• Stringaris K; Barrett AJ; Hills R; Linch DC; Gale R; Allen C; Garland P; Sargent R; et alde Lavallade H; Alsuliman A; Khoder A; Gabriel IH; Sekine T; Burnett A; Rezvani K; Apperley JF. A Distinct Signature of Natural Killer Cell MR Gene Frequencies In Secondary AML Compared with De Novo AML and Normal Controls. 116:711-712. (19 Nov 2010).
• Dunwoody R; Szydlo R; Casey L; Davis J; Lloyd S; Gabriel IH; Rezvani K; Apperley JF. Variations In Efficiency of Donor Searches Between International Unrelated Blood and Marrow Donor Registries. 116:648-648. (19 Nov 2010).
• Rezvani K; Marin D; Goldman JM; Kanfer E; MacDonald D; Dazzi F; Milojkovic D; Rahemtulla A; et alSargeant J; Apperley J; Szydlo R. RISK SCORE PREDICTS OUTCOME OF SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem, 17 Feb 2011 - 21 Feb 2011. 17:S155-S155. ELSEVIER SCIENCE INC (1 Feb 2011). Author weblink DOI.
• Khorashad J; Hu M; Hopmeier D; Daghistani M; May P; Gerrard G; Marin D; Milojkovic D; et alApperley J; Foroni L; Goldman J; Karadimitris A; Reid A. NAMPT, A MEDIATOR OF NORMAL GRANULOCYTIC DIFFERENTIATION, IS DOWN-REGULATED IN CHRONIC MYELOID LEUKAEMIA VIA CHROMATIN MODIFICATION. 15th Annual Meeting of the European-Hematology-Association, 10 Jun 2010 - 13 Jun 2010. 95:49-50. FERRATA STORTI FOUNDATION (1 Jun 2010). Author weblink.
• Gerrard G; Hill S; Khorashad J; Bazeos A; Apperley J; Foroni L. THE TUMOUR SUPPRESSOR PTEN: DIFFERENTIAL EXPRESSION PATTERNS IN CHRONIC MYELOID LEUKAEMIA AND THE ROLE OF PROMOTER METHYLATION. 15th Annual Meeting of the European-Hematology-Association, 10 Jun 2010 - 13 Jun 2010. 95:52-52. FERRATA STORTI FOUNDATION (1 Jun 2010). Author weblink.
• Gerrard G; Hill S; Bazeos A; Khorashad J; De Lavallade H; Apperley J; Foroni L. AURORA KINASE EXPRESSION IN CHRONIC MYELOID LEUKAEMIA: POTENTIAL MARKERS OF DISEASE PROGRESSION. 15th Annual Meeting of the European-Hematology-Association, 10 Jun 2010 - 13 Jun 2010. 95:334-334. FERRATA STORTI FOUNDATION (1 Jun 2010). Author weblink.
• Gabriel IH; Sargent R; de Lavallade H; Szydlo R; Apperley JF; Khodar A; Alsuliman A; Marin D; et alForoni L; Davis J; Giles C; Kanfer E; Rahemtulla A; Rezvani K. KIR genotype is associated with progression free and overall survival following autologous stem cell transplantation for multiple myeloma. 50th Annual Scientific Meeting of the British-Society-for-Haematology, 19 Apr 2010 - 21 Apr 2010. 149:19-19. WILEY-BLACKWELL PUBLISHING, INC (1 May 2010).
• Milojkovic D; De Melo VA; Gerrard G; Goldman JM; Apperley JF; Foroni L; Reid AG. EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib. 50th Annual Scientific Meeting of the British-Society-for-Haematology, 19 Apr 2010 - 21 Apr 2010. 149:22-23. WILEY-BLACKWELL PUBLISHING, INC (1 May 2010).
• Garland P; de Lavallade H; Sekine T; Stringaris K; Loucaides E; Howe K; Kanfer E; Marin D; et alApperley J; Milojkovic D; Macdonald D; Rahemtulla A; Pavlu J; Gabriel I; Khoder A; Alsuliman A; Bazeos A; Szydlo R; Cooper N; Rezvani K. Severe 2009 H1N1 influenza in patients with haematological malignancies. 50th Annual Scientific Meeting of the British-Society-for-Haematology, 19 Apr 2010 - 21 Apr 2010. 149:47-47. WILEY-BLACKWELL PUBLISHING, INC (1 May 2010).
• Patel A; Waheed U; Brett S; Rahemtulla A; Apperley JF; Patel P. Rapid response of myeloma hyperammonaemic encephalopathy to L-ornithine-L-aspartate therapy. 50th Annual Scientific Meeting of the British-Society-for-Haematology, 19 Apr 2010 - 21 Apr 2010. 149:58-58. WILEY-BLACKWELL PUBLISHING, INC (1 May 2010).
• Gabriel IH; Ibrahim M; Szydlo R; de Lavallade H; Apperley JF; Thomas C; Kanfer E; Marin D; et alDoyle A; Rahemtulla A; Rezvani K. KIR genes are associated with incidence and duration of infection following autologous peripheral blood stem cell transplantation for multiple myeloma. 50th Annual Scientific Meeting of the British-Society-for-Haematology, 19 Apr 2010 - 21 Apr 2010. 149:68-68. WILEY-BLACKWELL PUBLISHING, INC (1 May 2010).
• de Lavallade H; Hart M; Gabriel I; Kelleher P; Alsuliman A; Khoder A; Milojkovic D; Stringaris K; et alGarland P; Khorashad JS; Foroni L; Bua M; Apperley JF; Goldman JM; Marin D; Rezvani K. T-cell and B-cell responses after vaccination against influenza virus and pneumococcus in chronic phase CML patients treated with tyrosine kinase inhibitors. 50th Annual Scientific Meeting of the British-Society-for-Haematology, 19 Apr 2010 - 21 Apr 2010. 149:76-76. WILEY-BLACKWELL PUBLISHING, INC (1 May 2010).
• Marin D; Milojkovic D; Bua M; Apperley J; Reid A; Rezvani K; Foroni L; Goldman J; et alMarin D. Adherence to imatinib therapy is the critical factor for achieving molecular responses in patients with chronic myeloid leukaemia. 50th Annual Scientific Meeting of the British-Society-for-Haematology, 19 Apr 2010 - 21 Apr 2010. 149:81-81. WILEY-BLACKWELL PUBLISHING, INC (1 May 2010).
• Milojkovic D; Bua M; Apperley J; Foroni L; Rezvani K; Reid A; Goldman J; Marin D. Imatinib plasma levels do not have prognostic value in determining molecular responses when adherence to therapy is taken in account in CML patients on long term imatinib treatment. 50th Annual Scientific Meeting of the British-Society-for-Haematology, 19 Apr 2010 - 21 Apr 2010. 149:81-81. WILEY-BLACKWELL PUBLISHING, INC (1 May 2010).
• Milojkovic D; Zaiga-Castleton A; Marin D; Reid A; Foroni L; Rezvani K; Bua M; Khorashad J; et alGoldman J; Apperley J. Recurrence of pleural effusion on bosutinib therapy in a dasatinib treated patient with chronic myeloid leukaemia. 50th Annual Scientific Meeting of the British-Society-for-Haematology, 19 Apr 2010 - 21 Apr 2010. 149:83-83. WILEY-BLACKWELL PUBLISHING, INC (1 May 2010).
• Milojkovic D; Aduwa E; Szydlo R; Marin D; Reid A; Foroni L; Bua M; Rezvani K; et alKhorashad J; Goldman J; Apperley J. Significant weight gain in patient with chronic myeloid leukaemia treated with imatinib therapy. 50th Annual Scientific Meeting of the British-Society-for-Haematology, 19 Apr 2010 - 21 Apr 2010. 149:84-84. WILEY-BLACKWELL PUBLISHING, INC (1 May 2010).
• Charif R; Marley S; Gordon M; Tait P; Apperley J; Davis J; Nicholls J; Pusey C; et alHabib N; Taube D; Papalois V. Phase I Clinical Study of Autologous Infusion of Expanded Mobilized Adult Bone Marrow-Derived CD34 Cells into Diabetic Patients with Renal Transplants. 10th American Transplant Congress, 1 May 2010 - 5 May 2010. 10:233-234. WILEY-BLACKWELL PUBLISHING, INC (1 Apr 2010).
• Ibrahim M; Gabriel I; Szydlo R; De Lavallade H; Apperley J; Thomas CP; Kanfer E; Doyle A; et alRahemtulla A; Rezvani K. KIR genes are associated with incidence and duration of infection following autologous peripheral blood stem cell transplantation for multiple myeloma. 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S21-S21. NATURE PUBLISHING GROUP (1 Mar 2010).
• Porkka K; Pavlu J; Contento A; Mustjoki S; Olavarria E; Apperley J. Tyrosine kinase inhibitor therapy is associated with a low risk of cytomegalovirus reactivation after allogeneic haematopoietic stem cell transplantation. 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S38-S38. NATURE PUBLISHING GROUP (1 Mar 2010).
• Patel B; Terpos E; Todd J; Szydlo R; Apperley J; Goldman J; Salooja N. Reduced bone mineral density and high bone turnover in long-term survivors of stem cell transplantation. 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S102-S103. NATURE PUBLISHING GROUP (1 Mar 2010).
• Gabriel I; Sargent R; De Lavallade H; Szydlo R; Apperley J; Khoder A; Alsuliman A; Marin D; et alForoni L; Davis J; Giles C; Kanfer E; Rahemtulla A; Rezvani K. KIR genotype is associated with progression-free and overall survival following autologous stem cell transplantation for multiple myeloma. 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S148-S149. NATURE PUBLISHING GROUP (1 Mar 2010).
• Khoder A; Petrou M; Thomas C; Szydlo R; Kanfer E; Marin D; Rahemtulla A; Luqmani A; et alHung J; MacDonald D; Milojkovic D; Apperley J; Rezvani K. Retrospective study of clinical predictors of positive fungal cultures in recipients of allogeneic and autologous stem cell transplantation. 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S228-S228. NATURE PUBLISHING GROUP (1 Mar 2010).
• Pavlu J; Kew A; Taylor-Roberts B; Auner H; Kanfer E; MacDonald D; Marin D; Milojkovic D; et alRahemtulla A; Rezvani K; Goldman J; Apperley J; Szydlo R. Optimizing patient selection for myeloablative allogeneic haemopoietic cell transplantation in chronic myeloid leukaemia in chronic phase. 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S239-S239. NATURE PUBLISHING GROUP (1 Mar 2010).
• de Lavallade H; Hart M; Gabriel I; Kelleher P; Alsuliman A; Khoder A; Stringaris K; Garland P; et alKhorashad J; Milojkovic D; Foroni L; Bua M; Apperley J; Goldman J; Marin D; Rezvani K. T-cell and B-cell responses after vaccination against influenza virus and pneumococcus in chronic phase CML patients treated with tyrosine kinase inhibitors. 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S243-S243. NATURE PUBLISHING GROUP (1 Mar 2010).
• Lloyd S; Casey L; Sergeant R; Apperley J; Szydlo R. Outcome of unrelated donor searches in a large multicultural transplant centre. 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S310-S310. NATURE PUBLISHING GROUP (1 Mar 2010).
• Dannie E; Auner H; Davis J; Kanfer E; Rahemtulla A; Rezvani K; Apperley J. Single-centre experience on PBSC mobilization using plerixafor. 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S352-S352. NATURE PUBLISHING GROUP (1 Mar 2010).
• Beckerson J; Apperley J; Kanfer E; Rahemtulla A; Rezvani K; Mc Clornan D; Gabriel I. The importance of artificial nutritional support in patients undergoing myeloablative conditioning and essential early dietetic input in the haplo-identical setting. 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S362-S362. NATURE PUBLISHING GROUP (1 Mar 2010).
• Morris TCM; Scholten M; Brand R; van Biezen A; Dickmeiss E; Tmeny M; Apperley J; Chiusolo P; et alvan Imhoff G; Lenhoff S; Uharek L; Martinelli G; Hentrich M; Sureda A; de Witte T; Ruutu T. EBMT non-interventional prospective study on DMSO toxicity in autologous transplantation. 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S34-S34. NATURE PUBLISHING GROUP (1 Mar 2010).
• Thomssen H; van Biezen A; Brand R; Russell N; Apperley J; Foa R; Schots R; Koza V; et alBornhauser M; Olavarria E; de Witte T. The outcome of patients with Philadelphia chromosome negative/bc-abl negative chronic myelogenous leukaemia after allogeneic stem cell transplantation: a restrospective study of the CML subcommittee of the Chronic Leukemia Working Party (EBMT). 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S34-S34. NATURE PUBLISHING GROUP (1 Mar 2010).
• Gratwohl A; Brand R; Niederwieser D; Baldomero H; Chabannon C; de Witte T; McDonald F; McGrath E; et alPassweg J; Peters C; Rocha V; Slapper-Cortenbach I; Sureda A; Tichelli A; Apperley J. Impact of JACIE accreditation on outcome after haematopoietic stem cell transplantation: an EBMT megafile analysis. 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S63-S64. NATURE PUBLISHING GROUP (1 Mar 2010).
• Shaw BE; Apperley J; Russell NH; Craddock C; Liakopoulou E; Potter MN; Wynn R; Gibson B; et alPearce R; Lee J; Kirkland K; Madrigal JA; Cook G; Byrne J. Transplantation using BM or PBSC in adult and paediatric recipients of T-cell depleted myeloablative transplants for standard risk leukaemia results in similar outcomes. 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S160-S160. NATURE PUBLISHING GROUP (1 Mar 2010).
• Schleuning M; Scholten M; van Biezen A; Nagler A; Apperley J; Michallet M; Grigg A; Silver R; et alNiederwieser D; De Witte T; Olavarria E. Effect of prior therapy with nilotinib or dasatinib on the outcome after allogeneic stem cell transplantation for patients with chronic myeloid leukaemia. 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S240-S240. NATURE PUBLISHING GROUP (1 Mar 2010).
• Chalandon Y; Passweg J; Apperley J; Schattenberg A; de Witte T; Kroeger N; Finke J; Guglielmi C; et alOlavarria E. Management relapse of CML after allogeneic stem cell transplantation. No advantage of early administration of donor lymphocyte infusions upon molecular relapse. 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, 21 Mar 2010 - 24 Mar 2010. 45:S241-S241. NATURE PUBLISHING GROUP (1 Mar 2010).
• Ibrahim AR; Milojkovic D; Bua M; Khorshad JS; Szydlo R; Eliasson L; Foroni L; Reid A; et alde Lavallade H; Rezvani K; Goldman JM; Apperley J; Marin D. Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy. ASH Annual Meeting. 116: Abstract 3414. (2010).
• Pavlu J; Kew A; Taylor-Roberts B; Auner H; Goldman J; Apperley J; Szydlo R. Optimizing Patient Selection for Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia. 51st Annual Meeting of the American-Society-of-Hematology, 5 Dec 2009 - 8 Dec 2009. 114:1317-1317. AMER SOC HEMATOLOGY (20 Nov 2009). Author weblink.
• Gabriel IH; Sargent R; de Lavallade H; Szydlo R; Apperley J; Khoder A; Alsuliman A; Marin D; et alForoni L; Davis J; Giles C; Kanfer E; Rahemtulla A; Rezvani K. Presence of the Killer Immunoglobulin-Like Gene KIR3DSI Is Associated with Poor Progression Free and Overall Survival Following Autologous Stem Cell Transplantation in Patients with Myeloma. 51st Annual Meeting of the American-Society-of-Hematology, 5 Dec 2009 - 8 Dec 2009. 114:1109-1109. AMER SOC HEMATOLOGY (20 Nov 2009). Author weblink.
• Bazeos A; Khorashad J; Mahon F-X; Eliasson LL; Milojkovic D; Bua M; Apperley J; Szydlo R; et alKozlowski K; Paliompeis C; Desai R; Foroni L; Reid A; de Lavallade H; Rezvani K; Goldman J; Marin D. Long Term Adherence to Imatinib Therapy is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients. 51st Annual Meeting of the American-Society-of-Hematology, 5 Dec 2009 - 8 Dec 2009. 114:1274-1275. AMER SOC HEMATOLOGY (20 Nov 2009).
• Auner HW; Mazzarella L; Cook L; Szydlo R; Saltarelli F; Pavlu J; Apperley JF; Rahemtulla A. The Combination of Cyclophosphamide and Thalidomide During Induction Therapy for Multiple Myeloma Results in a High Rate of Stem Cell Mobilization Failure. 51st Annual Meeting of the American-Society-of-Hematology, 5 Dec 2009 - 8 Dec 2009. 114:844-844. AMER SOC HEMATOLOGY (20 Nov 2009).
• de Lavallade H; Hart M; Gabriel IH; Kelleher P; Alsuliman A; Khoder A; Milojkovic D; Foroni L; et alBua M; Apperley JF; Goldman JM; Marin D; Rezvani K. T-Cell and B-Cell Responses After Vaccination against Influenza Virus and Pneumococcus in Chronic Phase CML Patients Treated with Tyrosine Kinase Inhibitors. 51st Annual Meeting of the American-Society-of-Hematology, 5 Dec 2009 - 8 Dec 2009. 114:872-873. AMER SOC HEMATOLOGY (20 Nov 2009).
• Bazeos A; Marin D; Gerrard G; Szydlo R; Milojkovic D; Reid A; de Lavallade H; Apperley JF; et alGoldman JM; Foroni L; Khorashad JS. BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML. 51st Annual Meeting of the American-Society-of-Hematology, 5 Dec 2009 - 8 Dec 2009. 114:1258-1258. AMER SOC HEMATOLOGY (20 Nov 2009).
• Babb A; Farah N; Apperley J; Goldman J; Kanfer E; Marin D; Milojkovic D; Rahemtulla A; et alRezvani K; Salooja N. Uptake and Outcome of Artificial Reproductive Techniques Following Allogeneic Stem Cell Tranplantation: A Single Centre Experience. 51st Annual Meeting of the American-Society-of-Hematology, 5 Dec 2009 - 8 Dec 2009. 114:889-890. AMER SOC HEMATOLOGY (20 Nov 2009).
• Auner HW; Owiti H; Giles C; Pavlu J; MacDonald D; Kanfer E; Apperley JF; Rahemtulla A. Ethnic Disparity in Access to Stem Cell Transplantation for Multiple Myeloma. 51st Annual Meeting of the American-Society-of-Hematology, 5 Dec 2009 - 8 Dec 2009. 114:708-709. AMER SOC HEMATOLOGY (20 Nov 2009).
• Chaidos A; Giles C; Auner HW; Bua M; Pavlu J; Smith E; Kanfer E; MacDonald D; et alApperley JF; Rahemtulla A. Second Autologous Stem Cell Transplantation Is Effective Salvage Therapy for Relapsed Multiple Myeloma. 51st Annual Meeting of the American-Society-of-Hematology, 5 Dec 2009 - 8 Dec 2009. 114:507-507. AMER SOC HEMATOLOGY (20 Nov 2009). Author weblink.
• Nicolini FE; Zhou W; Martinelli G; Mauro MJ; Hochhaus A; Su J; Apperley J; Chuah C; et alDufva I; Kim D-W; Giles FJ; Peter S; Cortes J. Impact of Allogeneic Stem Cell Transplantation as Salvage Therapy After T315I Mutation Detection in Chronic Myeloid Leukemia (CML) and Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. 51st Annual Meeting of the American-Society-of-Hematology, 5 Dec 2009 - 8 Dec 2009. 114:268-268. AMER SOC HEMATOLOGY (20 Nov 2009).
• Shaw BE; Apperley J; Russell NH; Craddock CF; Liakopoulou E; Potter MN; Wynn R; Gibson BES; et alPearce R; Kirkland K; Madrigal A; Cook G; Byrne JL. A Comparison of Stem Cell Source in Adult and Paediatric Recipients of T-Cell Depleted Myeloablative Transplants for Standard Risk Leukaemia: No Difference in Mortality Using BM or PBSC. 51st Annual Meeting of the American-Society-of-Hematology, 5 Dec 2009 - 8 Dec 2009. 114:495-496. AMER SOC HEMATOLOGY (20 Nov 2009).
• Apperley JF; Cortes JE; Kim D-W; Roy L; Roboz GJ; Rosti G; Bullorsky EO; Abruzzese E; et alHochhaus A; Heim D; de Souza CA; Larson RA; Lipton JH; Khoury HJ; Kim H-J; Sillaber C; Hughes TP; Erben P; Van Tornout J; Stone RM. Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. 48th Annual Meeting of the American-Society-of-Hematology, 9 Dec 2006 - 12 Dec 2006. 27:3472-3479. AMER SOC CLINICAL ONCOLOGY (20 Jul 2009). Author weblink DOI.
• Guglielmi C; Iacobelli S; Apperley J; Bunjes D; Jacobs P; Kolb H-J; Ljungman P; Olavarria E; et alSchattenberg A; Van Biezen A; Verdonck L; de Witte T. DONOR LYMPHOCYTE INFUSIONS FOR CHRONIC MYELOID LEUKAEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANT: PROGNOSTIC FACTORS FOR A 'PURE' GVL EFFECT ARE DIFFERENT ACCORDING TO THE STAGE OF RELAPSE. 14th Annual Meeting of the European-Hematology-Association, 4 Jun 2009 - 7 Jun 2009. 94:61-61. FERRATA STORTI FOUNDATION (1 Jun 2009). Author weblink.
• Le Coutre PD; Giles F; Hochhaus A; Apperley JF; Ossenkoppele G; Haque A; Gallagher NJ; Baccarani M; et alCortes J; Kantarjian H. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. 45th Annual Meeting of the American-Society-of-Clinical-Oncology, 29 May 2009 - 2 Jun 2009. 27. AMER SOC CLINICAL ONCOLOGY (20 May 2009).
• Auner H; Giles C; Pavlu J; Olavarria E; Macdonald D; Kanfer E; Apperley J; Rahemtulla A. Ethnicity and autologous stem cell transplantation in myeloma. 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, 29 Mar 2009 - 1 Apr 2009. 43:S148-S148. NATURE PUBLISHING GROUP (1 Mar 2009). Author weblink.
• Farah N; Auner H; Kanfer E; Rahemtulla A; Marin D; Apperley J; Salooja N. Uptake and outcome of artificial reproductive techniques following SCT for leukaemia: a single-centre experience. 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, 29 Mar 2009 - 1 Apr 2009. 43:S164-S164. NATURE PUBLISHING GROUP (1 Mar 2009). Author weblink.
• Gabriel I; Sharon-Richman J; Olavarria E; Rahemtulla A; Kanfer E; Marin D; Milojkovic D; Rezvani K; et alMacDonald D; Szydlo R; Apperley J. Efficacy, complication rates, and cost-effectiveness of chemotherapy plus granulocyte-colony-stimulating factor conditioned mobilisation of peripheral blood haematopoietic stem cells in over 150 patients with haematological malignancies. 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, 29 Mar 2009 - 1 Apr 2009. 43:S112-S112. NATURE PUBLISHING GROUP (1 Mar 2009). Author weblink.
• Pavlu J; Auner H; Szydlo R; Olavarria E; Giles C; Klammer M; Kew A; Milojkovic D; et alGabriel I; Rezvani K; Dazzi F; Marin D; Goldman J; Apperley J. Allogeneic myeloablative haematopoietic stem cell transplantation for chronic myeloid leukaemia in the imatinib era. 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, 29 Mar 2009 - 1 Apr 2009. 43:S49-S49. NATURE PUBLISHING GROUP (1 Mar 2009). Author weblink.
• Clare S; Mank A; Stone R; Davies M; Potting C; Apperley J. Management of related donor care: a European survey. 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, 29 Mar 2009 - 1 Apr 2009. 43:S4-S4. NATURE PUBLISHING GROUP (1 Mar 2009).
• Morris C; Drake M; Apperley J; Iacobelli S; Niederwieser D; van Biezen A; Bjorkstrand B; Gahrton G. Autologous transplantation for rare myelomas: an EBMT retrospective analysis. 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, 29 Mar 2009 - 1 Apr 2009. 43:S32-S32. NATURE PUBLISHING GROUP (1 Mar 2009).
• Cordonnier C; Labopin M; Chesnel V; Ribaud P; De La Camara R; Martino R; Ullmann A; Parkkali T; et alLocasciulli A; Yakouben K; Pauksens K; Niederwieser D; Apperley J; Bonnet E; Einsele H; Ljungman P. Immune response to the 23-valent polysaccharide pneumococcal vaccine (PPV23) after the 7-valent conjugate vaccine (PCV7) in allogeneic stem cell transplant (SCT) recipients: results of the EBMT IDWP01 trial. 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, 29 Mar 2009 - 1 Apr 2009. 43:S60-S60. NATURE PUBLISHING GROUP (1 Mar 2009).
• Owiti H; Apperley J. Regional differences in haematopoietic stem cell activity in South East England: a multi-centre investigation of inequalities in utilisation and inequity of access to treatment for multiple myeloma. 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, 29 Mar 2009 - 1 Apr 2009. 43:S150-S150. NATURE PUBLISHING GROUP (1 Mar 2009).
• Owiti H; Apperley J. Inequity in access to bone marrow transplants: an examination of regional differences in haematopoietic stem cell activity between health authorities in South East England. 49th Annual Scientific Meeting of the British-Society-for-Haematology, 27 Apr 2009 - 29 Apr 2009. 145:60-60. WILEY-BLACKWELL PUBLISHING, INC (1 Jan 2009).
• Milojkovic D; Bua M; Apperley JF; Kozlowski K; Sorori J; Foroni L; Reid A; Pavlu J; et alRezvani K; Dazzi F; Olavarria E; Klammer M; Goldman JM; Marin D. Prediction of Cytogenetic Response to Second Generation TKI Therapy in CML Chronic Phase Patients Who Have Failed Imatinib Therapy and Early Identification of Factors That Influence Survival. 50th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2008 - 9 Dec 2008. 112:129-129. AMER SOC HEMATOLOGY (16 Nov 2008). Author weblink.
• Stanghellini MTL; Ciceri F; Bonini C; Bondanza A; Traversari C; Salomoni M; Turchetto L; Colombi S; et alBernardi M; Peccatori J; Pescarollo A; Servida P; Magnani Z; Pema SK; Valtolina V; Crippa F; Callegaro L; Spoldi E; Crocchiolo R; Fleischhauer K; Ponzoni M; Vago L; Santoro A; Todisco E; Apperley J; Olavarria E; Slavin S; Weissinger EM; Hertenstein B; Stadler M; Yannaki E; Fassas A; Anagnostopoulos A; Stampino CG; Bregni M; Bruzzi P; Bordignon C. Early and Effective Immune-Recovery by Gene-Engineered Lymphocytes after Haploidentical Transplantation for Leukemia Abate Late Transplant Mortality. 50th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2008 - 9 Dec 2008. 112:138-138. AMER SOC HEMATOLOGY (16 Nov 2008). Author weblink.
• Pavlu J; Klammer M; Gabriel I; Szydlo R; Olavarria E; Milojkovic D; Kew A; Rezvani K; et alDazzi F; Marin D; Goldman J; Apperley J. Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era. 50th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2008 - 9 Dec 2008. 112:357-357. AMER SOC HEMATOLOGY (16 Nov 2008). Author weblink.
• Nicolini FE; Martinelli G; Kim D-W; Hochhaus A; Mauro MJ; Cortes J; Chuah C; Dufva I; et alApperley JF; Yagasaki F; Pearson J; Peter S; Rodriguez CS; Giles F; Goldman JM; Zhou W. Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph plus Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final Analysis. 50th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2008 - 9 Dec 2008. 112:76-77. AMER SOC HEMATOLOGY (16 Nov 2008). Author weblink.
• Khorashad JS; De Melo VA; Fiegler H; Gerrard G; Brudzevsky D; Marin D; Apperley JF; Goldman JM; et alForoni L; Reid AG. Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia. 50th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2008 - 9 Dec 2008. 112:1067-1068. AMER SOC HEMATOLOGY (16 Nov 2008). Author weblink.
• Klammer M; Giles C; Reid AG; Ross FM; Szydlo RM; Pavlu J; Apperley JF; Rahemtulla A. Incorporating Marrow Plasma Cell Infiltration at Diagnosis and Cytogenetic Features into Prognostic Scoring at Point of Autologous Stem Cell Transplantation for Multiple Myeloma. 50th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2008 - 9 Dec 2008. 112:1140-1140. AMER SOC HEMATOLOGY (16 Nov 2008). Author weblink.
• le Coutre PD; Giles F; Hochhaus A; Apperley JF; Ossenkoppele G; Haque A; Gallagher NJ; Baccarani M; et alCortes J; Kantarjian HM. Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study. 50th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2008 - 9 Dec 2008. 112:1108-1109. AMER SOC HEMATOLOGY (16 Nov 2008). Author weblink.
• Ruutu T; Brand R; van Biezen A; Rocha V; Sureda A; Tichelli A; Einsele H; Dini G; et alBregni M; Garderet L; Apperley J; Gratwohl A; Niederwieser D; de Witte T. Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapse of Malignant Disease: Retrospective Analysis of Outcome and Predictive Factors. 50th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2008 - 9 Dec 2008. 112:132-132. AMER SOC HEMATOLOGY (16 Nov 2008).
• Cordonnier C; Labopin M; Chesnel V; Ribaud P; De La Camara R; Martino R; Ullmann A; Parkkali T; et alLocasciulli A; Yakouben K; Pauksens K; Einsele H; Niederwieser D; Apperley J; Ljungman PT. Immune Response to the 23-Valent Polysaccharide Pneumococcal Vaccine (PPV23) after the 7-Valent Conjugate Vaccine (PCV7) in Allogeneic Stem Cell Transplant (SCT) Recipients: Results of the EBMT IDWP01 Trial. 50th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2008 - 9 Dec 2008. 112:136-137. AMER SOC HEMATOLOGY (16 Nov 2008).
• Khorashad JS; Reid AG; Marin D; Rezvani K; Goldman JM; Apperley JF; Wagner S; Foroni L. Polymorphism in codon 72 of p53 and response to imatinib in chronic myeloid leukaemia. British Human Genetics Conference, 15 Sep 2008 - 17 Sep 2008. 45:S89-S89. B M J PUBLISHING GROUP (1 Sep 2008). Author weblink.
• Bonini C; Ciceri F; Lupo SMT; Bondanza A; Traversari C; Salomoni M; Turchetto L; Colombi S; et alBernardi M; Peccatori J; Magnani Z; Perna SK; Valtolina V; Crippa F; Callegaro L; Spoldi E; Crocchiolo R; Fleischhauer K; Ponzoni M; Vago L; Santoro A; Todisco E; Apperley J; Slavin S; Weissinger EM; Hertenstein B; Bregni M; Gallo SC; Bruzzi P; Bordignon C. SUICIDE GENE TRANSFER INTO DONOR LYMPHOCYTES ALLOWS EARLY AND EFFECTIVE IMMUNE-RECONSTITUTION AFTER FAMILY HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR LEUKEMIAS: RESULTS OF THE TK007 STUDY. 10th Congress of the Italian-Society-of-Experimental-Hematology, 24 Sep 2008 - 26 Sep 2008. 93:S131-S131. FERRATA STORTI FOUNDATION (1 Sep 2008).
• Wong CL; Apperley J; Kanfer E; Marin D; Milojkovic D; Rahemtulla A; Patel K; Olavarria E. CRITERIA FOR INTENSIVE CARE UNIT ADMISSION OF CRITICALLY ILL HAEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS - A SCORING SYSTEM. 13th Congress of the European-Hematology-Association, 12 Jun 2008 - 15 Jun 2008. 93:142-142. FERRATA STORTI FOUNDATION (1 Jun 2008). Author weblink.
• Salooja N; Shankari J; Todd J; Olvarria E; Marin D; Kanfer E; Rahemtulla A; Apperley J. BONE DENSITY IN LONG TERM SURVIVORS OF STEM CELL TRANSPLANTATION FOR HAEMATOLOGICAL MALIGNANCY. 13th Congress of the European-Hematology-Association, 12 Jun 2008 - 15 Jun 2008. 93:569-569. FERRATA STORTI FOUNDATION (1 Jun 2008). Author weblink.
• le Coutre P; Giles FJ; Hochhaus A; Apperley J; Ossenkoppele G; Haque A; Gallagher N; Baccarani M; et alCortes J; Kantarjian HM. NILOTINIB IN IMATINIB-RESISTANT OR -INTOLERANT PATIENTS WITH CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE (CML-AP): UPDATE OF A PHASE 2 STUDY. 13th Congress of the European-Hematology-Association, 12 Jun 2008 - 15 Jun 2008. 93:47-47. FERRATA STORTI FOUNDATION (1 Jun 2008).
• Stanghettini MTL; Ciceri F; Bonini C; Bondanza A; Traversari C; Salomoni M; Turchetto L; Colombi S; et alBernardi M; Peccatori J; Pescarollo A; Servida P; Magnani Z; Perna SK; Valtolina V; Crippa F; Callegaro L; Spoldi E; Crocchiolo R; Fleischhauer K; Ponzoni M; Vago L; Santoro A; Todisco E; Apperley J; Slavin S; Weissinger EM; Hertenstein B; Bregni M; Stampino CG; Bruzzi P. HAPLO-SCT WITH TK plus LYMPHOCYTES PRODUCE LEUKEMIA FREE SURVIVAL COMPARABLE TO UNRELATED BONE MARROW AND CORD BLOOD TRANSPLANTATION IN HIGH RISK ACUTE LEUKEMIA: 'TK007' PHASE II STUDY FINAL ANALYSIS. 13th Congress of the European-Hematology-Association, 12 Jun 2008 - 15 Jun 2008. 93:351-351. FERRATA STORTI FOUNDATION (1 Jun 2008).
• Apperley J; le Coutre P; Giles FJ; Ottmann OG; Larson RA; Haque A; Gallagher N; Baccarani M; et alCortes J; Kantarjian HM. Nilotinib in accelerated phase chronic myelogenous leukaemia (CML-AP) patients with imatinib-resistance or -intolerance: update of a phase 2 study. 48th Annual Scientific Meeting of the British-Society-for-Haematology, 7 Apr 2008 - 9 Apr 2008. 141:38-39. BLACKWELL PUBLISHING (1 Apr 2008).
• Drake MB; Iacobelli S; van Biezen A; Apperley JF; Niederwieser D; Bjorkstrand B; Gahrton G; Morris C. Primary plasma cell leukaemia treated with autologous stem cell transplantation. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EMBT-Data-Management-Group. 41:S38-S38. (Mar 2008).
• Chaidos A; Giles C; Klammer M; Gabriel I; Apperley J; Kanfer E; Olavarria E; Bua M; et alSamson D; Rahemtulla A. Second autologous stem cell transplantation for multiple myeloma in first relapse. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, 30 Mar 2008 - 2 Apr 2008. 41:S180-S180. NATURE PUBLISHING GROUP (1 Mar 2008). Author weblink.
• Mohty M; Young ASM; Szydlo RM; Apperley JF; Goldman JM; Melo JV. Association between the polycomb group BMI-1 gene expression and outcome in chronic myeloid leukaemia patients receiving allogeneic stem cell transplantation. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, 30 Mar 2008 - 2 Apr 2008. 41:S53-S54. NATURE PUBLISHING GROUP (1 Mar 2008). Author weblink.
• Gabriel IH; Chaidos A; Whittaker S; Russell-Jones R; Scarisbrick J; Morris S; Giles C; Apperley JF; et alOlavarria E. Reduced-intensity sibling allogeneic stem cell transplantation and donor lymphocyte infusions in Sezary syndrome and advanced mycosis fungoides result in durable clinical and molecular remissions. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EMBT-Data-Management-Group. 41:S244-S244. (Mar 2008).
• Klammer M; Giles C; Szydlo R; Gabriel I; Naresh K; Samson D; Apperley J; Rahemtulla A. High marrow plasma cell infiltration at diagnosis is associated with shorter time to progression following autologous stem cell transplantation for multiple myeloma. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EMBT-Data-Management-Group. 41:S182-S182. (Mar 2008).
• Klammer M; Giles C; Reid A; Ross F; Szydlo R; Gabriel I; Samson D; Apperley J; et alRahemtulla A. Incorporating cytogenetic features into prognostic scoring at point of autologous stem cell transplantation for multiple myeloma. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, 30 Mar 2008 - 2 Apr 2008. 41:S181-S181. NATURE PUBLISHING GROUP (1 Mar 2008). Author weblink.
• O'Boyle F; Plocki P; Swan N; Szydlo RM; Apperley JF. Survivors of allogeneic stem cell transplants - a telephone survey of long-term hospital outpatient non-attenders. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, 30 Mar 2008 - 2 Apr 2008. 41:S344-S344. NATURE PUBLISHING GROUP (1 Mar 2008).
• Gabriel IH; Avery S; Szydlo R; Salooja N; Olavarria E; Kanfer E; Klammer M; Rahemtulla A; et alGoldman J; Apperley JF. Secondary malignancies in recipients of allografts for chronic myeloid leukaemia in chronic phase using HLA-matched sibling or volunteer donors. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, 30 Mar 2008 - 2 Apr 2008. 41:S8-S8. NATURE PUBLISHING GROUP (1 Mar 2008). Author weblink.
• Gabriel IH; Szydio R; Narat S; Marin D; Klammer M; Olavarria E; Davis J; Goldman J; et alApperley JF. Mobilisation and harvesting of PBSC in patients with CML achieving complete cytogenetic remission on imatinib: a single-centre experience of 133 patients. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, 30 Mar 2008 - 2 Apr 2008. 41:S306-S306. NATURE PUBLISHING GROUP (1 Mar 2008). Author weblink.
• Heim D; Brand R; Olavarria E; Apperley JF; Crawley C; Devergie A; Aljurf A; Holowiecki J; et alRuutu T; Brinch L; Kolb HJ; de Witte T; Hehlmann R; Gratwohl A. Outcome of chronic myeloid leukaemia patients with allogeneic haematopoietic stem cell transplantation and a low risk score in the imatinib era. A report from the EBMT Chronic Leukemia Working Party and the European Leukemia Net. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EMBT-Data-Management-Group. 41:S37-S37. (Mar 2008).
• Shankari J; Olavarria E; Kanfer E; Marin D; Rahemtulla A; Apperley JF; Salooja N. Hyperferritinaemia and the metabolic syndrome in long-term survivors of stem cell transplantation. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, 30 Mar 2008 - 2 Apr 2008. 41:S90-S90. NATURE PUBLISHING GROUP (1 Mar 2008). Author weblink.
• Gabriel IH; Chaidos A; Klammer M; Olavarria E; Kanfer E; Rahemtulla A; Miljokovic D; Apperley JF. The price of survival: are all patients and transplants equal?. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EMBT-Data-Management-Group. 41:S337-S337. (Mar 2008).
• Szydlo R; Gabriel I; Olavarria E; Apperley J. Sign of the Zodiac as a predictor of survival for recipients of an allogeneic stem cell transplant for chronic myeloid leukaemia. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EMBT-Data-Management-Group. 41:S348-S348. (Mar 2008).
• Cordonnier C; Labopin M; Chesnel V; Ribaud P; Da La Camara R; Martino R; Ullmann A; Parkkali T; et alLocasciulli A; Yakouben K; Paukksen K; Niederwieser D; Apperley J; Bonnet E; Einsele H; Ljungman P. Influence of immunisation timing on the response to conjugate-pneumococcal vaccine after allogeneic stem cell transplant: final results of the EBMT IDWP01 Trial. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, 30 Mar 2008 - 2 Apr 2008. 41:S2-S2. NATURE PUBLISHING GROUP (1 Mar 2008).
• Gratwohl A; Stern M; Apperley J; de Witte T; Passweg J; Rocha V; Sureda A; Brand R; et alNiederwieser D. The EBMT risk score predicts outcome after allogeneic HSCT in all haematological disease categories and is independent of stem cell source or conditioning intensity. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, 30 Mar 2008 - 2 Apr 2008. 41:S3-S3. NATURE PUBLISHING GROUP (1 Mar 2008).
• Stanghellini MTL; Ciceri F; Bonini C; Bondanza A; Traversari C; Toma S; Salomoni M; Turchetto L; et alColombi S; Bernardi M; Peccatori J; Pescarollo A; Servida P; Magnani Z; Perna SK; Valtolina V; Crippa F; Callegaro L; Spoldi E; Fleischhauer K; Ponzoni M; Vago L; Santoro A; Todisco E; Apperley J; Slavin S; Weissinger E; Hertenstein B; Bregni M; Stampino CG; Bruzzi P; Bordignon C. TK007 phase II study final analysis. Genetically modified donor lymphocytes abate transplant related mortality and increase leukaemia-free survival providing early immune reconstitution after haploidentical haematopoietic stem cell transplantation. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, 30 Mar 2008 - 2 Apr 2008. 41:S55-S56. NATURE PUBLISHING GROUP (1 Mar 2008).
• Shaw B; Russell N; Pagliuca A; Apperley J; Cook G; Mackinnon S; Madrigal J; Marks D; et alMorgan G; Pearce R; Peggs K; Potter M; Towlson K; Byrne J. No impact on survival is seen when comparing the use of BM or PBSC as the stem cell source in recipients of T-cell depleted myeloablative transplants for leukaemia and MDS. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, 30 Mar 2008 - 2 Apr 2008. 41:S146-S146. NATURE PUBLISHING GROUP (1 Mar 2008).
• Kottaridis P; Bloor A; Pearce R; Towlson K; Thomson K; Apperley J; McQuaker G; Marks D; et alCraddock C; McCann S; Russell N; Mackinnon S; Cook G. Patients with myelofibrosis below the age of 45 should be considered candidates for TBI based myeloablative regimes, where RIC transplants should be applied in older patients. 34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, 30 Mar 2008 - 2 Apr 2008. 41:S304-S304. NATURE PUBLISHING GROUP (1 Mar 2008).
• Bonini C; Ciceri F; Stanghellini MTL; Bondanza A; Magnani Z; Perna S; Bemardi M; Peccatori J; et alServida P; Crippa F; Kaneko S; Valtolina V; Ferrari M; Provasi E; Salomoni M; Turchetto L; Toma S; Traversari C; Bruzzi P; Castagna L; Santoro A; Apperley J; Slavin S; Colombi S; Stampino CG; Bregni M; Bordignon C. Infusion of suicide gene-modified donor T cells promotes a rapid and effective immune reconstitution and provides long-term survival after haploidentical hemaopoietic cell transplantation for the cure of patients with high-risk leukemia. 4th Conference on Stem Cell Gene Therapy, 13 Sep 2007 - 17 Sep 2007. 40:286-286. ACADEMIC PRESS INC ELSEVIER SCIENCE (1 Mar 2008). DOI.
• De Melo VA; Kotzampaltiris P; Nacheva E; Marin D; Apperley JF; Reid AG. Deletions adjacent to BCR and ABL breakpoints occur in a substantial minority of chronic myeloid leukaemia patients with masked Philadelphia rearrangements. 49th Annual Meeting of the American-Society-of-Hematology. 110:860A-861A. (16 Nov 2007).
• Kew AK; Szydlo RM; Olavarria E; Goldman JM; Apperley JF. C-reactive protein on admission predicts transplat-related mortality in recipients of allogeneic stern cell transplant. 49th Annual Meeting of the American-Society-of-Hematology. 110:882A-883A. (16 Nov 2007).
• De Lavallade H; Khorashad JS; Bua M; Milojkovic D; Olavarria E; Reid A; Kaeda JS; Goldman JM; et alApperley JF; Marin D. Long term durability of major molecular responses for patients treated with imatinib after failure of interferon-alfa is equivalent to that of patients achieving major molecular responses to imatinib as primary therapy. 49th Annual Meeting of the American-Society-of-Hematology, 8 Dec 2007 - 11 Dec 2007. 110:314A-314A. AMER SOC HEMATOLOGY (16 Nov 2007). Author weblink.
• Guilhot F; Apperley JF; Kim DW; Kosti G; Yuan X; Van Tomout JMA; Gutzon FT; Cortes J. Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005). 49th Annual Meeting of the American-Society-of-Hematology. 110:145A-145A. (16 Nov 2007).
• De Lavallade H; Milojkovic D; Khorashad JS; Reid A; Olavarria E; Kaeda J; Goldman JM; Apperley JF; et alMarin D. Outcome, prognostic factors and long-term follow-up in 207 chronic phase CML patients receiving front-line imatinib 400 mg at a single institution. 49th Annual Meeting of the American-Society-of-Hematology. 110:316A-317A. (16 Nov 2007).
• Crawley CR; Brand R; Olavarria E; De Witte TM; Apperley JF; Niederwieserl DW; Guglielmi C; Ljungman PT; et alGratwohl A. Transplant centre experience and patient selection are the key elements associated with outcome of RIC and MAC HSCT for CML. 49th Annual Meeting of the American-Society-of-Hematology, 8 Dec 2007 - 11 Dec 2007. 110:147A-147A. AMER SOC HEMATOLOGY (16 Nov 2007). Author weblink.
• Drake MB; Iacobelli S; van Biezen A; Apperley JF; Niederwieser DW; Bjorkstrand BT; Gharton G; Morris TC. Primary plasma cell leukaemia and autologous stem cell transplantation. 49th Annual Meeting of the American-Society-of-Hematology. 110:224A-224A. (16 Nov 2007).
• Punnialingam S; de Lavallade H; Milojkovic D; Marco B; Khorashad JS; Goldman JM; Apperley JF; Marin D. Pleural effusions associated with use of dasatinib in chronic myeloid leukemia may have an auto-immune pathogenesis. 49th Annual Meeting of the American-Society-of-Hematology, 8 Dec 2007 - 11 Dec 2007. 110:865A-865A. AMER SOC HEMATOLOGY (16 Nov 2007). Author weblink.
• Grace C; Brazma D; Chanalaris A; Howard J; Virgili A; Valganon M; Cross N; Apperley JF; et alNacheva E. Array CGH analysis at 60kb resolution of CML samples at advanced stage of disease. 49th Annual Meeting of the American-Society-of-Hematology, 8 Dec 2007 - 11 Dec 2007. 110:860A-860A. AMER SOC HEMATOLOGY (16 Nov 2007). Author weblink.
• Mohty M; Yong ASM; Szydlo RM; Apperley JF; Goldman JM; Melo JV. Association between the polycomb group (PcG) BMI-1 gene expression and outcome in chronic myeloid leukemia (CML) patients receiving allogeneic stem cell transplantation (allo-SCT). 49th Annual Meeting of the American-Society-of-Hematology, 8 Dec 2007 - 11 Dec 2007. 110:143A-143A. AMER SOC HEMATOLOGY (16 Nov 2007). Author weblink.
• Simoes MS; Score J; Cross NCP; Apperley JF; Melo JV. How cured are CML patients in complete molecular remission (CMR) after stem cell transplantation or imatinib?. 49th Annual Meeting of the American-Society-of-Hematology, 8 Dec 2007 - 11 Dec 2007. 110:306A-306A. AMER SOC HEMATOLOGY (16 Nov 2007). Author weblink.
• Virgili A; Brazma D; Grace C; Chanalaris A; Reid A; Apperley JF; Nacheva EP. Philadelphia negative BCR/ABL1-positive CML: FISH mapping and aCGH reveal breakpoint hotspots. 49th Annual Meeting of the American-Society-of-Hematology. 110:859A-859A. (16 Nov 2007).
• Lavallade H; Khorashad JS; Milojkovic D; Wagner S; Kaeda J; Goldman JM; Apperley JF; Marin D. For CML patients in chronic phase who achieve a cytogenetic response to imatinib the finding of a BCR-ABL mutation predicts for progression to advanced phase but it has no such significance in primary resistance. 49th Annual Meeting of the American-Society-of-Hematology, 8 Dec 2007 - 11 Dec 2007. 110:102A-102A. AMER SOC HEMATOLOGY (16 Nov 2007). Author weblink.
• Shaw BE; Russell NH; Pagliuca A; Apperley J; Cook G; Mackinnon S; Madrigal JA; Marks D; et alMorgan GJ; Peggs K; Potter MN; Towlson K; Byrne JL. A comparison of stem cell source in recipients of T-Cell depleted myeloablative transplants for leukaemia: No difference in mortality using BM or PBSC. 49th Annual Meeting of the American-Society-of-Hematology, 8 Dec 2007 - 11 Dec 2007. 110:22A-22A. AMER SOC HEMATOLOGY (16 Nov 2007).
• Le Coutre P; Giles FJ; Apperley J; Ottmann OG; Gattermann N; O'Brien SG; Kuliczkowski K; Larson RA; et alKim D-W; Haque A; Gallagher N; Baccarani M; Kantarjian HM. Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance. 49th Annual Meeting of the American-Society-of-Hematology, 8 Dec 2007 - 11 Dec 2007. 110:145A-145A. AMER SOC HEMATOLOGY (16 Nov 2007).
• Stanghellini MTL; Bonini C; Provasi E; Bernardi M; Peccatori J; Bondanza A; Magnani Z; Perna SK; et alCrippa F; Valtolina V; Salomoni M; Turchetto L; Toma S; Traversari C; Colombi S; Gallo Stampino C; Bruzzi P; Castagna L; Apperley J; Slavin S; Ciceri F; Bordignon C. Infusions of HSV-TK engineered donor lymphocytes effectively protect patients undergoing haploidentical stem cells trasplantation (HSCT) from infectious mortality. 49th Annual Meeting of the American-Society-of-Hematology, 8 Dec 2007 - 11 Dec 2007. 110:320A-320A. AMER SOC HEMATOLOGY (16 Nov 2007).
• Halter J; Kodera Y; Ispizua AU; Greinix H; Schmitz N; Favre E; Baldomero H; Niederwieser D; et alApperley J; Gratwohl A. Severe, donor events after allogeneic hematopoietic stem cell donation. 49th Annual Meeting of the American-Society-of-Hematology, 8 Dec 2007 - 11 Dec 2007. 110:962A-962A. AMER SOC HEMATOLOGY (16 Nov 2007).
• Rondoni M; Apperley J; Reiter A; Cools J; Cross NCP; Grimwade D; Saglio G; Sureda A; et alAlimena G; Aventin A; Bassan R; Cilloni D; Green AR; Haznedaroglu I; Rivas JMH; Hochhaus A; Mecucci C; Nielsen OJ; Pane F; Porkka K; Preudhomme C; Prin L; Stenke L; Merante S; Baccarani M; Martinelli G. THESIS, treatment of HES: International study hypereosinophilic syndrome (HES): A multicentre, retrospective observational study of european leukemianet, hypereosinophilia study group. 41st Congress of the Italian-Society-of-Hematology, 14 Oct 2007 - 17 Oct 2007. 92:126-127. FERRATA STORTI FOUNDATION (1 Oct 2007).
• de Melo VA; Milojkovic D; Khorashad JS; Marin D; Goldman JM; Apperley JF; Reid A. Philadelphia-negative clonal haematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukaemia. British Human Genetics Conference. 44:S32-S32. (Sep 2007).
• De Melo VAS; Vetter M; Howard J; Betts DR; Mazzullo H; Nacheva EP; Apperley JF; Reid AG. Rearrangement-specific breakpoint clustering at chromosome band 3q26: implications for EVl1 FISH in myeloid malignancy. British Human Genetics Conference. 44:S104-S104. (Sep 2007).
• Chaidos A; Giles C; Gabriel I; Apperley JF; Kanfer E; Olavarria E; Bua M; Samson D; et alRahemtulla A. Second autologous stem cell transplantation for multiple myeloma in first relapse. 12th Congress of the European-Hematology-Association, 7 Jun 2007 - 10 Jun 2007. 92:256-256. FERRATA STORTI FOUNDATION (1 Jun 2007). Author weblink.
• Gabriel I; Chaidos A; Apperley J; Whittaker S; Russell-Jones R; Morris S; Scarisbick J; Olavarria E. Reduced intensity sibling allogeneic stem cell transplantation and donor lymphocyte infusions insezary syndromeand advanced mycosis fungoides resultin durable clinical and molecular remissions. 12th Congress of the European-Hematology-Association. 92:169-170. (Jun 2007).
• Gabriel I; Schenk M; Foster J; Chaidos A; Kanfer F; Marin D; Milojkovic D; Rahemtulla A; et alOlavarria E; Apperley J. The price for survival are all patients equal?. 12th Congress of the European-Hematology-Association. 92:223-223. (Jun 2007).
• Khorashad JS; Mehta P; Milojkovic D; Marin DC; Kaeda JS; Swale B; Stevens D; Goldman JM; et alApperley JF. BCR-ABL kinase mutations in response to dasatinib. 12th Congress of the European-Hematology-Association. 92:202-202. (Jun 2007).
• Gabriel I; Chaidos A; Giles C; Apperley J; Seckl M; Bower M; Kanfer E. The role of high dose chemotherapy and peripheral blood stem cell support in refractory trophoblastic disease and non-gestational choriocarcinoma: A review of eight patients. 12th Congress of the European-Hematology-Association, 7 Jun 2007 - 10 Jun 2007. 92:185-185. FERRATA STORTI FOUNDATION (1 Jun 2007). Author weblink.
• Mohty M; Yong ASM; Szydlo RM; Apperley JF; Melo JV. The polycomb group BMI-1 gene is a molecular marker for predicting prognosis of chronic myeloid leukaemia. 12th Congress of the European-Hematology-Association, 7 Jun 2007 - 10 Jun 2007. 92:196-197. FERRATA STORTI FOUNDATION (1 Jun 2007). Author weblink.
• Brazma D; Grace C; Virgili A; Howard J; Chanalaris A; Melo JV; Apperley JF; Nacheva EP. When is a double Philadelphia not a double Philadelphia. 12th Congress of the European-Hematology-Association. 92:202-202. (Jun 2007).
• Guilhot F; Apperley J; Facon T; Niederwieser D; Gambacorti C; Fischer T; Countouriotis A; Ezzeddine R; et alHochhaus A. Dasatinib induces durable cytogenetic responses in patients with chronic-phase CML with resistance or intolerance to imatinib: Updated results of the CA180013 (START-C) trial. 12th Congress of the European-Hematology-Association, 7 Jun 2007 - 10 Jun 2007. 92:128-128. FERRATA STORTI FOUNDATION (1 Jun 2007).
• Virgili A; Brazma D; Grace C; Reid A; Apperley J; Nacheva EP. Identification of breakpoint hotspots in Philadelphia negative BCR/ABL positive CML. 12th Congress of the European-Hematology-Association, 7 Jun 2007 - 10 Jun 2007. 92:201-201. FERRATA STORTI FOUNDATION (1 Jun 2007).
• Nathwani R; Olavarria E; Kanfer E; Rahemtulla A; Marin D; Todd J; Apperley J; Salooja N. Liver dysfunction in long-term survivors of stem cell transplantation. 33rd Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, 25 Mar 2007 - 28 Mar 2007. 39:S205-S206. NATURE PUBLISHING GROUP (1 Apr 2007). Author weblink.
• Ayto R; Garfield B; Todd J; Kanfer E; Olavaria E; Rahemtulla A; Marin D; Apperley J; et alSalooja N. Echocardiographic findings in long term survivors of allogeneic stem cell transplantation for chronic myeloid leukemia. 47th Annual Scientific Meeting of the British-Society-for-Haematology, 30 Apr 2007 - 2 May 2007. 137:77-78. BLACKWELL PUBLISHING (1 Apr 2007). Author weblink.
• Shaw B; Mufti GJ; Mackinnon S; Cavenagh J; Towlson K; Pearce R; Pagliuca A; Apperley J; et alCraddock C; Kazmi MA; Littlewood T; Milligan D; Thomson K; Marks D; Russell N. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse after an initial allogeneic transplant. 33rd Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, 25 Mar 2007 - 28 Mar 2007. 39:S16-S16. NATURE PUBLISHING GROUP (1 Apr 2007).
• Gratwohl A; Baldomero H; Schwendener A; Gratwohl M; Apperley J; Niederwieser D; Frauendorfer K. Predictability of transplant rates and impact of economic factors on transplant rates in Europe. 33rd Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, 25 Mar 2007 - 28 Mar 2007. 39:S44-S44. NATURE PUBLISHING GROUP (1 Apr 2007).
• Dickinson AM; Pearce K; Norden J; Neylon A; Holler E; Rocha V; Gluckman E; Kolb HJ; et alHromadnikova I; Sedlacek P; Niederwieser D; Brand R; Ruutu T; Apperley J; Goulmy E; Olavarria E; de Witte T; Gratwohl A. A distinct pattern of non-HLA polymorphisms predicts an increased risk for GvHD without benefit of GvL in HLA matched sibling transplants for chronic myeloid leukaemia. 33rd Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, 25 Mar 2007 - 28 Mar 2007. 39:S66-S66. NATURE PUBLISHING GROUP (1 Apr 2007).
• Nadal E; Kaeda J; Apperley JF; Lechler R; Dazzi F. Increased CD4+CD25high+regulatory T-cell are associated with disease relapse after allogeneic stem cell transplantation (SCT) for chronic myeloid leukaemia (CML). Tandem BMT Meeting 2007. 13:15-15. (Feb 2007).
• Greinix HT; Van Besien K; Apperley J; Bacigalupo A; Elmangacli A; Grigg A; Kolb H-J; Bouzas L; et alMichallet M; Reddy VS; Knobler RM; Wang J; Williamson P; Flowers MED. A multicenter prospective randomized phase II study in patients with corticosteroid-refractory/dependent/intolerant chronic cutaneous GVHD given either extracorporeal photoimmune therapy with UVADEX (R) in conjunction with conventional therapy or conventional therapy alone. Tandem BMT Meeting 2007, 8 Feb 2007 - 12 Feb 2007. 13:13-13. ELSEVIER SCIENCE INC (1 Feb 2007). DOI.
• Brazma D; Chanalaris A; Melo J; Virgilli A; Apperley J; Nacheva EP; Grace C. Gains and amplifications of the ABL-NUP214 region in blast stage of CML. 1st Marie Curie-Genome Architecture in Relation to Disease Meeting (MC-GARD), 3 May 2007 - 5 May 2007. 29:106-107. SPRINGER (1 Jan 2007).
• Khorashad JS; Lipton JH; Marin D; Milojkovic D; Cross NCP; Dibb N; Melo JV; Kamel-Reid S; et alGoldman JM; Apperley JF; Kaeda JS. Abnormally small BCR-ABL transcripts in CML patients before and during imatinib treatment. 48th Annual Meeting of the American-Society-of-Hematology, 9 Dec 2006 - 12 Dec 2006. 108:611A-611A. AMER SOC HEMATOLOGY (16 Nov 2006). Author weblink.
• Dickinson AM; Pearce KF; Norden J; Neylor A; Holler E; Rocha V; Gluckman E; Kolb H-J; et alHromadnikova I; Sedlacek P; Niederwieser DW; Brand R; Ruutu T; Apperley J; Goulmy EAJM; Olavarria E; de Witte TM; Roosnek E; Siegert W; Gratwohl A. A distinct pattern of non-HLA polymorphisms predicts an increased risk for GvHD without benefit of GvL in HLA matched sibling transplants for chronic myeloid leukemia (CML). 48th Annual Meeting of the American-Society-of-Hematology, 9 Dec 2006 - 12 Dec 2006. 108:21A-21A. AMER SOC HEMATOLOGY (16 Nov 2006). Author weblink.
• Cortes J; Kim DW; Guilhot F; Rosti G; Silver RT; Gollerkeri A; Agarwal P; Branford S; et alApperley JF. Dasatinib (SPRYCEL (R)) in patients (pts) with chronic myelogenous leukemia in accelerated phase (AP-CML) that is imatinib-resistant (im-r) or -intolerant (im-i): Updated results of the CA180-005 'START-A' phase II study. 48th Annual Meeting of the American-Society-of-Hematology. 108:613A-613A. (16 Nov 2006).
• Martinelli G; Hochhaus A; Coutre S; Apperley JF; Shah N; Gollerkeri A; Agarwal P; Ottmann OG. Dasatinib (SPRYCEL (R)) efficacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (Im-r) or -intolerant (Im-i). 48th Annual Meeting of the American-Society-of-Hematology, 9 Dec 2006 - 12 Dec 2006. 108:224A-224A. AMER SOC HEMATOLOGY (16 Nov 2006). Author weblink.
• Baccarani M; Kantarjian HM; Apperley JF; Lipton JH; Druker B; Countouriotis A; Ezzeddine R; Hochhaus A. Efficacy of dasatinib (SPRYCEL (R)) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib: Updated results of the CA180013 'START C' phase II study. 48th Annual Meeting of the American-Society-of-Hematology. 108:53A-53A. (16 Nov 2006).
• Bonini C; Ciceri F; Stanghellini MTL; Bondanza A; Magnani Z; Perna SK; Bernardi M; Peccatori J; et alServida P; Crippa F; Kaneko S; Valtolina V; Salomoni M; Turchetto L; Toma S; Traversari C; Bruzzi P; Castagna L; Santoro A; Apperley J; Slavin S; Colombi S; Stampino CG; Bregni M; Bordignon C. Rapid and ride immunereconstitution obtained with HSV-TK engineered donor lymphocyte add-backs permits long-term survival after haplo-HSCT. 48th Annual Meeting of the American-Society-of-Hematology, 9 Dec 2006 - 12 Dec 2006. 108:95A-95A. AMER SOC HEMATOLOGY (16 Nov 2006).
• Pye S; Cortes J; Rosti G; Ault P; Oliveto T; Pilot R; Kantarjian HM; Hatfield A; et alApperley J. Imatinib and pregnancy. 48th Annual Meeting of the American-Society-of-Hematology, 9 Dec 2006 - 12 Dec 2006. 108:132A-132A. AMER SOC HEMATOLOGY (16 Nov 2006).
• Flowers MED; Van Besien K; Apperley J; Bacigalupo A; Elmaagacli A; Grigg A; Kolb H-J; Bouzas LF; et alMichallet M; Reddy V; Wang J; Williamson P; Knobler R; Greinix H. A randomized single-blind study of extracorporeal photopheresis with UVADEX (R) plus conventional therapy (CT) compared to CT alone in chronic GVHD. 48th Annual Meeting of the American-Society-of-Hematology, 9 Dec 2006 - 12 Dec 2006. 108:228A-228A. AMER SOC HEMATOLOGY (16 Nov 2006).
• Shaw BE; Mufti GJ; Mackinnon S; Cavenagh J; Towlson K; Pearce R; Pagliuca A; Apperley J; et alCraddock C; Kazmi M; Littlewood T; Milligan D; Marks D; Russell NH. Outcome of second allogeneic transplants using reduced intensity conditioning following relapse after an initial allogeneic transplant. 48th Annual Meeting of the American-Society-of-Hematology, 9 Dec 2006 - 12 Dec 2006. 108:1045A-1046A. AMER SOC HEMATOLOGY (16 Nov 2006).
• Talpaz M; Apperley JF; Kim DW; Silver RT; Bullorsky EO; Cheng S; Iyer M; Guilhot F. Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 'START-A' study. 42nd Annual Meeting of the American-Society-of-Clinical-Oncology. 24:343S-343S. (20 Jun 2006).
• Ciceri F; Bonini C; Stanghellini ML; Santoro A; Slavin S; Apperley J; Bruzzi P; Toma S; et alStampino CG; Bregni M; Bordignon C; San Raffaele H. Infusions of HSV-TK genetically modified donor lymphocytes enable a wider use of partially mismatched allogeneic transplantation by reducing infection related mortality and improving survival in high risk acute leukemia. 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, 2 Jun 2006 - 6 Jun 2006. 24:341S-341S. AMER SOC CLINICAL ONCOLOGY (20 Jun 2006).
• Reddy N; Salooja N; Duffy S; Turner C; Apperley JF; Margara R. Pregnancy after assisted conception following stem cell transplant in women with leukaemia. 22nd Annual Meeting of the European-Society-of-Human-Reproduction-and-Embryology. 21:I131-I131. (Jun 2006).
• Jovanovic J; Score J; Waghorn K; Reiter A; Gottardi E; Saglio G; Apperley J; Martinelli G; et alPreudhomme C; Hehlmann R; Grimwade D; Cross NCP. Low-dose imatinib therapy leads to rapid induction of major molecular responses with achievement of molecular remission in FIP1L1-PDGFRA associated hypereosinophilic syndrome. 46th Annual Scientific Meeting of the British-Society-for-Haematology, 3 Apr 2006 - 5 Apr 2006. 133:13-13. BLACKWELL PUBLISHING (1 Apr 2006).
• Perz JB; Sanz J; Ghorashian S; Chaidos A; Kaeda J; Szydlo RM; Marin DC; Olavarria E; et alApperley JF. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukaemia. 32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group, 19 Mar 2006 - 22 Mar 2006. 37:S227-S227. NATURE PUBLISHING GROUP (1 Mar 2006). Author weblink.
• Dannie E; Apperley J; Olavarria E. A retrospective study to determine the percentage and degree of tetany experienced by patients undergoing peripheral blood stem cell harvest. 32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group. 37:S273-S274. (Mar 2006).
• Shankari J; Perz J; Todd J; Marin D; Rahemtulla A; Goldman J; Kanfer E; Olavarria E; et alApperley J; Salooja N. Bone density in long-term survivors of stem cell transplantation. 32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group, 19 Mar 2006 - 22 Mar 2006. 37:S114-S114. NATURE PUBLISHING GROUP (1 Mar 2006). Author weblink.
• Perz JB; Giles C; Szydlo RM; Wagner S; Sanz J; Chaidos A; Apperley JF; MacDonald D; et alKanfer E. Long-term outcome after LACE (lomustine, ara-C, cyclophosphamide, etoposide) conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma. 32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group, 19 Mar 2006 - 22 Mar 2006. 37:S240-S240. NATURE PUBLISHING GROUP (1 Mar 2006). Author weblink.
• Bonini C; Ciceri F; Lupo-Stanghellini MT; Bondanza A; Magnani Z; Perna SK; Bernardi M; Peccatori J; et alPescarollo A; Servida P; Crippa F; Callegaro L; Vago L; Fleischhauer K; Salomoni M; Turchetto L; Toma S; Traversari C; Bruzzi P; Castagna L; Santoro A; Apperley J; Slavin S; Colombi S; Gallo-Stampino C; Bregni M; Bordignon C. Rapid and effective immune reconstitution with HSV-TK engineered donor lymphocyte add-backs after Haplo-HSCT. 32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group, 19 Mar 2006 - 22 Mar 2006. 37:S23-S23. NATURE PUBLISHING GROUP (1 Mar 2006).
• Knop S; Hebart H; Grathwohl A; Holler E; Apperley J; Kolb H; Niederwieser D; Einsele H. OKT3 and high-dose steroids versus high-dose steroids alone in steroid-resistant acute GvHD - a randomised multicentre EBMT-CLWP trial. 32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group, 19 Mar 2006 - 22 Mar 2006. 37:S50-S50. NATURE PUBLISHING GROUP (1 Mar 2006).
• Chalandon Y; Schmid C; Porkka K; Urbano-Ispizua A; Hertenstein B; Dazzi F; Olavarria E; Apperley J; et alLjungman P; Schattenberg A; Lenhof S; Jacobs P; Finke J; Niederwieser D; Guglielmini C. Outcome of patients developing GVHD after DLI for CML relapse post HSCT: a retrospective study from the CLWP of the EBMT. 32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group, 19 Mar 2006 - 22 Mar 2006. 37:S50-S50. NATURE PUBLISHING GROUP (1 Mar 2006).
• Perz JB; Sergeant R; Szydlo R; Davey N; Olavarria E; Apperley JF. Impact of HLA class I and class II DNA high-resolution HLA typing on outcome in adult unrelated stem cell transplantation after in vivo T-cell depiction with CAMPATH III: A single centre experience in 100 patients. 47th Annual Meeting of the American-Society-of-Hematology. 106:513A-513A. (16 Nov 2005).
• Knop S; Hebart H; Gratwohl A; Holler E; Apperley JF; Kolb HJ; Niederwieser D; Einsele H. Treatment of steroid-resistant acute GvHD with OKT3 and high-dose steroids versus high-dose steroids alone. 47th Annual Meeting of the American-Society-of-Hematology, 10 Dec 2005 - 13 Dec 2005. 106:45A-45A. AMER SOC HEMATOLOGY (16 Nov 2005). Author weblink.
• Perz JB; Rahemtulla A; Giles CM; Szydlo R; Apperley JF. Long term survival analysis after high-dose melphalan chemotherapy followed by autologous stem cell transplantation for treatment of AL amyloidosis: A single centre experience. 47th Annual Meeting of the American-Society-of-Hematology. 106:464B-464B. (16 Nov 2005).
• Guilhot F; Apperley JF; Shah N; Kim DW; Grigg A; Cheng S; Iyer M; Cortes J. A phase II study of dasatinib in patients with accelerated phase chronic myeloid leukemia (CML) who are resistant or intolerant to imatinib: First results of the CA180005 'START-A' study. 47th Annual Meeting of the American-Society-of-Hematology. 106:16A-16A. (16 Nov 2005).
• Perz JB; Giles CM; MacDonald D; Apperley JF; Kanfer EJ. Long-term outcome after LACE (Lomustine, Ara-C, Cyclophosphamide, Etoposide) conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: A single centre experience. 47th Annual Meeting of the American-Society-of-Hematology. 106:464B-464B. (16 Nov 2005).
• Yong ASM; Szydlo RM; Goldman JM; Apperley JF; Melo JV. Molecular profiling of CD34+cells from diagnosis in CML patients identifies low expression of CD7 with high expression of proteinase 3 or elastase as predictors of longer survival. 47th Annual Meeting of the American-Society-of-Hematology. 106:562A-562A. (16 Nov 2005).
• Curtis C; Apperley JF; Dang R; Jeng M; Gotlib J; Cross NCP; Grand FH. The platelet-derived growth factor receptor beta fuses to two distinct loci at 3p21 in imatinib responsive chronic eosinophilic leukemia. 47th Annual Meeting of the American-Society-of-Hematology, 10 Dec 2005 - 13 Dec 2005. 106:909A-909A. AMER SOC HEMATOLOGY (16 Nov 2005). Author weblink.
• Khorashad JS; Anand M; Marin D; Andreasson C; Ghorashian S; Apperley JF; Goldman JM; Kaeda JS. Varying response to imatinib in CML patients with BCR-ABL(M244V) mutation. 47th Annual Meeting of the American-Society-of-Hematology. 106:562A-562A. (16 Nov 2005).
• Ciceri F; Bonini C; Stanghellini MTL; Bondanza A; Magnani Z; Perna S; Bernardi M; Peccatori J; et alPescarollo A; Servida P; Crippa F; Callegaro L; Salomoni M; Turchetto L; Toma S; Bruzzi P; Castagna L; Santoro A; Apperley J; Slavin S; Colombi S; Gallo Stampino C; Bregni M; Bordignon C. HSV-TK engineered donor lymphocytes add-backs reduce late mortality and improve survival of high risk acute leukemia after haplo-HSCT: Results of a phase II multicenter trial. 47th Annual Meeting of the American-Society-of-Hematology, 10 Dec 2005 - 13 Dec 2005. 106:133A-133A. AMER SOC HEMATOLOGY (16 Nov 2005).
• Jovanovic J; Reiter A; Cilloni D; Gottardi E; Score J; Popp H; Metzgeroth G; Walz C; et alHochhaus A; Roche C; Preudhomme C; Rondoni M; Ottaviani E; Rancati F; Solomon E; Apperley J; Martinelli G; Saglio G; Hehlmann R; Cross NCP; Grimwade D. Sensitive detection of FIP1L1-PDGFRA fusion transcripts by real-time quantitative RT-PCR (RQ-PCR) reveals achievement of molecular remission in chronic eosinophilic leukemia treated with low-dose imatinib therapy. 47th Annual Meeting of the American-Society-of-Hematology, 10 Dec 2005 - 13 Dec 2005. 106:145A-145A. AMER SOC HEMATOLOGY (16 Nov 2005).
• Chalandon Y; Schmid C; Porkka K; Urbano-Ispizua A; Hertenstein B; Dazzi F; Olavarria E; Apperley J; et alLjungman PT; Schattenberg AVMB; Lenhoff S; Jacobs P; Finke J; Niederwieser DW; Guglielmi C. Outcome of patients developing GVHD after DLI for CML relapse from HLA-identical sibling or VUD HSCT. 47th Annual Meeting of the American-Society-of-Hematology, 10 Dec 2005 - 13 Dec 2005. 106:517A-517A. AMER SOC HEMATOLOGY (16 Nov 2005).
• Hertenstein B; Dammann E; Eder M; Apperley J; Finke J; Schattenberg AVMB; Porkka K; Bjoerkstrand B; et alNiederwieser DW; Guglielmi C. Donor lymphocyte infusions from unrelated donors for treatment of relapsed chronic myelogenous leukemia: Importance of initial cell dose. 47th Annual Meeting of the American-Society-of-Hematology, 10 Dec 2005 - 13 Dec 2005. 106:581A-581A. AMER SOC HEMATOLOGY (16 Nov 2005).
• Elliot V; Marin D; Horncastle D; Elderfield K; Apperley JF; Lampert IA; Naresh K. Counting CD34+ cells in bone marrow trephines of CML patients - Which method correlates best with aspirate blast count?. 3rd Joint Meeting of the British Division of the International-Academy-of-Pahtology/Meeting of the Pathological-Society-of-Great-Britian-and-Ireland. 207:51-51. (Oct 2005).
• Patel KC; Kaeda J; Dazzi F; O'Shea D; Goldman J; Kanfer E; Marin D; Olavarria E; et alRahemtulla A; Apperley J; Salooja N. Low level BCR-ABL transcript positivity in long term survivors of allogeneic stem cell transplantation for CIVIL. 45th Annual Scientific Meeting of the British-Society-for-Haematology, 11 Apr 2005 - 13 Apr 2005. 129:75-75. BLACKWELL PUBLISHING (1 Apr 2005). Author weblink.
• Dannie E; Subramanian PG; Nallamuthu S; Nichols A; Chaemberlain B; Dovernas AM; Davis JG; Loaiza S; et alOlavarria E; Kanfer E; Apperley JF. An assessment of the optimal use of stem cell collection facility by auditing pheresis scheduling in relation to chemotherapy administration in patients with myeloma. 31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, 20 Mar 2005 - 23 Mar 2005. 35:S320-S320. NATURE PUBLISHING GROUP (1 Mar 2005). Author weblink.
• Terpos E; Sana V; Politou M; Samson D; Giles C; Kanter E; Olavarria E; Apperley JF; et alRahemtulla A. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 190 patients. 31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group. 35:S250-S250. (Mar 2005).
• Patel K; Todd J; Goldman J; Kanfer E; Marin D; Olavarria E; Rahemtulla A; Apperley J; et alSalooja N. Cardiovascular risk factors in long-term survivors of allogeneic SCT for CML. 31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, 20 Mar 2005 - 23 Mar 2005. 35:S352-S353. NATURE PUBLISHING GROUP (1 Mar 2005). Author weblink.
• O'Shea DM; Kaeda J; Szydlo R; Olavarria E; Marin D; Dazzi F; Perz JB; Anand M; et alSaunders S; Goldman JM; Apperley JF. Variable significance of low levels of Bcr-Abl transcripts in the peripheral blood after allogeneic stem cell transplant for chronic myeloid leukaemia in chronic phase. 31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, 20 Mar 2005 - 23 Mar 2005. 35:S68-S69. NATURE PUBLISHING GROUP (1 Mar 2005). Author weblink.
• Perz J; Sergeant R; Szydlo R; O'Shea D; Khan T; Davey N; Olavarria E; Apperley J. Impact of HLA class I and class II DNA high-resolution HLA typing on graft-versus-host disease and survival in adult unrelated stem cell transplantation after in vivo T-cell depletion with CAMPATH: a single transplant centre experience. 31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group. 35:S135-S136. (Mar 2005).
• Cordonnier C; Chesnel V; Ljungman P; Ribaud P; Ullmann A; Pauksen K; Ruutu T; Locasciulli A; et alApperley J; Yakouben K; la Camera RD; Martino R; Rovira M; Einsele H; Reusser P; Engelhard D; Labopin M; Wade A. Comparison between early and late immunisation with three doses of an heptavalent pneumococcal conjugate vaccine in allogeneic stem cell transplant recipients (EBMT IDPW01 trial). 31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, 20 Mar 2005 - 23 Mar 2005. 35:S32-S32. NATURE PUBLISHING GROUP (1 Mar 2005).
• Crawley C; Iacobelli S; Bjorkstrand B; Apperley J; Niederwieser D; Gahrton G. Reduced-intensity conditioning does not improve survival compared to standard conditioning for patients with myeloma. 31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, 20 Mar 2005 - 23 Mar 2005. 35:S48-S48. NATURE PUBLISHING GROUP (1 Mar 2005).
• Samson D; Mc Donald F; McGrath E; Apperley J; Cortenbach IS; Urbano-Ispizua A. The JACIE accreditation programme: experience after the first year of full implementation. 31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, 20 Mar 2005 - 23 Mar 2005. 35:S87-S87. NATURE PUBLISHING GROUP (1 Mar 2005).
• Abhyankar S; Shaughnessy P; Bolwell B; van Besien K; Mistrik M; Ihan O; Grigg A; Prince H; et alDodds A; Machado A; Wang J; Thienel U; Peters C; Foss F; Apperley J. Extracorporeal photoimmune therapy with UVADEX for the prevention of acute graft-versus-host disease in patients undergoing standard myeloablative conditioning and allogeneic haematopoetic stem cell transplantation. 31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, 20 Mar 2005 - 23 Mar 2005. 35:S132-S132. NATURE PUBLISHING GROUP (1 Mar 2005).
• Bourhis JH; Bouko Y; Koscielny S; Bakkus M; Greinix H; Derigs G; Salles G; Feremans W; et alApperley J; Samson D; Bjorkstrand B; Niederwieser D; Gahrton G; Pico J; Goldschmidt H. CD34+selection does not improved outcome of autologous haematopoietic progenitors cells transplantation in myeloma and relapse risk is not correlated with infused tumour cell load. Long-term follow-up of an EBMT phase III randomised study. 31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, 20 Mar 2005 - 23 Mar 2005. 35:S246-S247. NATURE PUBLISHING GROUP (1 Mar 2005).
• Abhyankar S; Shaughnessy PJ; Bolwell BJ; van Besien K; Mistrik M; Grigg A; Dodds A; Prince HM; et alMachado A; Thienel U; Wang J; Foss F; Apperley J. A multi-institutional study of extracorporeal photoimmune therapy (ECP) with UVADEX (R) for the prevention of acute gvhd in patients (PTS) undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation (AHCT). Joint Meeting of the American-Society-for-Blood-and-Marrow-Transplantation/Center-for-International-Blood-and-Marrow-Transplant-Research, 10 Feb 2005 - 14 Feb 2005. 11:37-37. CARDEN JENNINGS PUBL CO LTD (1 Feb 2005). DOI.
• Anand M; Kaeda JS; Szydlo R; Khorshad JS; Marin D; Swale B; Saunders S; Olavarria E; et alGoldman JM; Apperley JF. How best to express the results of serial RQ-PCR studies to measure minimal residual disease in treated leukaemia patients?. 46th Annual Meeting of the American-Society-of-Hematology, 4 Dec 2004 - 7 Dec 2004. 104:314A-314A. AMER SOC HEMATOLOGY (16 Nov 2004). Author weblink.
• Marin D; Horncastle D; Andreasson C; Elliot V; Goldman JM; Apperley JF; Naresh K; Lampert IA. Prognostic impact of percentage CD34 expression in bone marrow trephines of patients with chronic myeloid leukaemia in chronic phase treated with imatinib. 46th Annual Meeting of the American-Society-of-Hematology, 4 Dec 2004 - 7 Dec 2004. 104:291A-291A. AMER SOC HEMATOLOGY (16 Nov 2004). Author weblink.
• Marin D; Horncastle D; Howard J; Andreasson C; Elliot V; Goldman JM; Apperley JF; Naresh K; et alLampert I. High levels of CD34 expression in bone marrow trephines predicts for loss of cytogenetic response in patients with in chronic phase who have achieved complete cytogenetic remission on imatinib therapy. 46th Annual Meeting of the American-Society-of-Hematology, 4 Dec 2004 - 7 Dec 2004. 104:550A-550A. AMER SOC HEMATOLOGY (16 Nov 2004). Author weblink.
• Le Dieu R; Bua M; Andreasson C; Olavarria E; Goldman JM; Apperley JF; Maria D. Homoharringtonine in combination with imatinib for patients with CML who have achieved partial or complete cytogenetic responses. 46th Annual Meeting of the American-Society-of-Hematology, 4 Dec 2004 - 7 Dec 2004. 104:289A-289A. AMER SOC HEMATOLOGY (16 Nov 2004). Author weblink.
• Politou M; Naresh K; Terpos E; Crowley D; Lambert I; Apperley JF; Rahemtulla A. Anti-angiogenic effect of bortezomib in multiple myeloma patients. 46th Annual Meeting of the American-Society-of-Hematology, 4 Dec 2004 - 7 Dec 2004. 104:310B-310B. AMER SOC HEMATOLOGY (16 Nov 2004). Author weblink.
• Bourhis JH; Bouko Y; Koscielny S; Greinix H; Derigs G; Salles G; Feremans W; Bakkus M; et alApperley J; Samson D; Bjorkstrand B; Niederwieser D; Gahrton G; Pico JL; Goldschmidt H. Long term follow-up shows no clinical benefit for CD34(+) selection of autologous transplants following myeloablative therapy in patients with newly diagnosed myeloma: An EBMT phase III randomized study. 46th Annual Meeting of the American-Society-of-Hematology, 4 Dec 2004 - 7 Dec 2004. 104:264A-264A. AMER SOC HEMATOLOGY (16 Nov 2004).
• Bonini C; Ciceri F; Lupo-Stanghellini MT; Bondanza A; Magnani Z; Perna SK; Bernardi M; Peccatori J; et alPescarollo A; Crippa F; Callegaro L; Salomoni M; Turchetto L; Toma S; Aversa F; Apperley J; Slavin S; Colombi S; Stampino CG; Bregni M; Bordignon C. A phase II multicenter trial of HSV-TK engineered donor lymphocytes after haplo-identical HSCT: Early immune reconstitution and abrogation of GvHD. 46th Annual Meeting of the American-Society-of-Hematology, 4 Dec 2004 - 7 Dec 2004. 104:128A-128A. AMER SOC HEMATOLOGY (16 Nov 2004).
• Shaughnessy PJ; Bolwell BJ; Abhyankar S; van Besien K; Mistrik M; Grigg A; Dodds A; Prince HM; et alMachado A; Thienel U; Wang J; Foss F; Apperley J. A multi-institutional study of extracorporeal photoimmune therapy with UVADEX (R) for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. 46th Annual Meeting of the American-Society-of-Hematology, 4 Dec 2004 - 7 Dec 2004. 104:347A-347A. AMER SOC HEMATOLOGY (16 Nov 2004).
• Martinelli G; Apperley J; Reiter A; Cross NP; Cilloni D; Grimwade D; Hochhaus A; Ottaviani E; et alCools J; Prin L; Malagola M; Walz C; Preudhomme C; Messa F; Rondoni M; Gottardi E; Rosti G; Mecucci C; Pane F; Testoni N; Soverini S; Merante S; Alimena G; Baccarani M; Hehlmann R; Aventin A; Sureda A; Gomez JR; Duyster J; Verhoef G; Saglio G. European multicenter experience on idiopathic hypereosinophilic syndrome (HES) with FIP1L1-PDGFRA rearrangement treated with Imatinib. 46th Annual Meeting of the American-Society-of-Hematology, 4 Dec 2004 - 7 Dec 2004. 104:422A-422A. AMER SOC HEMATOLOGY (16 Nov 2004).
• Walz C; Cilloni D; Soverini S; Roche C; Ottaviani E; Martinelli G; Saglio G; Preudhomme C; et alPaschka P; Apperley J; Hochhaus A; Hehlmann R; Cross NCP; Grimwade D; Reiter A. Molecular heterogeneity of the FIP1L1-PDGFRA fusion gene in chronic eosinophilic leukemia (CEL) and systemic mastocytosis with eosinophilia (SME): A study of 43 cases. 46th Annual Meeting of the American-Society-of-Hematology, 4 Dec 2004 - 7 Dec 2004. 104:667A-667A. AMER SOC HEMATOLOGY (16 Nov 2004).
• Wain EM; Olavarria E; Apperley JF; Orchard GE; Whittaker SJ; Russell-Jones R. Autologous stem cell transplantation in tumour-stage mycosis fungoides: histological and immunophenotypic features as predictors of outcome. 84th Annual Meeting of the British-Association-of-Dermatologists. 151:4-5. (Jul 2004).
• Zino E; Frumento G; Di Terlizzi S; Ferrara GB; Sergeant R; Martinetti M; Bontadini A; Bandini G; et alLocatelli F; Apperley J; Bacigalupo A; Fleischhauer K. A T cell epitope encoded by a subset of HLA-DPB1 alleles determines non-permissive mismatches for hematological stem cell transplantation. 18th European Histocompatibility Conference, 8 May 2004 - 11 May 2004. 5:S4-S4. NATURE PUBLISHING GROUP (1 May 2004).
• Nadal E; Davis J; Loaiza S; Marin D; Avery S; Dannie E; Apperley J. Circulating absolute number of CD34+cells remain the best predictor of successful mobilisation in cytogenetic responders to imatinib. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group. 33:S125-S125. (Mar 2004).
• Terpos E; Politou M; Szydlo R; Nadal E; Avery S; Olavarria E; Kanfer E; Goldman JM; et alApperley JF; Rahemtulla A. The combination of sRANKL/osteoprotegerin ratio, beta2-microglobulin and CRP predicts survival in patients with multiple myeloma post autologous stem cell transplantation. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, 28 Mar 2004 - 31 Mar 2004. 33:S9-S9. NATURE PUBLISHING GROUP (1 Mar 2004). Author weblink.
• Burton C; Thomson E; Kanfer E; Rogers T; Goldman J; Apperley J. Tuberculosis post stem cell transplantation. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group. 33:S207-S207. (Mar 2004).
• Nadal E; Fowler A; Avery S; Kanfer E; Apperley J; Goldman J; Dazzi F. Adjuvant IL-2 in the treatment of relapse after allogeneic transplant refractory to donor lymphocyte infusions: clinical and biological effects. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, 28 Mar 2004 - 31 Mar 2004. 33:S80-S80. NATURE PUBLISHING GROUP (1 Mar 2004). Author weblink.
• Avery S; Szydlo R; Salooja N; Nadal E; Olavarria E; Kanfer E; Rahemtulla A; Goldman J; et alApperley J. Secondary malignancies in recipients of allogeneic stem cell transplantation for CML in chronic phase using HLA-identical sibling or HLA-compatible unrelated donors. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group. 33:S52-S53. (Mar 2004).
• Nadal E; Marktel S; Szydlo R; Olavarria E; Kanter E; Rahemtulla A; Apperley J; Goldman J; et alDazzi F. Impact of GvHD in long-term remission after escalated donor lymphocyte infusions. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group. 33:S178-S178. (Mar 2004).
• Drake M; Morris C; Hagman A; Lopponen T; Bjorkstrand B; Gahrton G; Apperley J. Outcome after autologous transplantation in primary plasma cell leukaemia. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, 28 Mar 2004 - 31 Mar 2004. 33:S8-S9. NATURE PUBLISHING GROUP (1 Mar 2004).
• Morris C; Drake M; Hagman A; Lopponen T; Bjorkstrand B; Gahrton G; Apperley J. Outcome of autologous transplantation in rare and common-type multiple myeloma. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, 28 Mar 2004 - 31 Mar 2004. 33:S9-S9. NATURE PUBLISHING GROUP (1 Mar 2004).
• Apperley J; Boque C; Carella A; Champion K; Goldman J; Hasford J; Hehlmann R; Labopin M; et alLazarus H; Niederwieser D; O'Brien S; Olavarria E; Perreau; Reiffers J; Rowe J; Richards S. Autografting in chronic myeloid leukaemia: a meta-analysis of six randomised trials. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, 28 Mar 2004 - 31 Mar 2004. 33:S28-S28. NATURE PUBLISHING GROUP (1 Mar 2004).
• Shaughnessy PJ; Bolwell BJ; van Besien K; Abhyankar S; Mistrik M; Ilhan O; Grigg A; Prince HM; et alDodds T; Machado A; Wang J; Thienel U; Foss F; Apperley J. Extracorporeal photoimmune therapy with uvadex (R) for the prevention of acute graft-versus-host disease in patients undergoing standard myeloablative conditioning and allogeneic haematopoietic stem cell transplantation. 30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, 28 Mar 2004 - 31 Mar 2004. 33:S189-S189. NATURE PUBLISHING GROUP (1 Mar 2004).
• Terpos E; Politou M; Szydlo R; Nadal E; Avery S; Olavarria E; Kanfer E; Goldman JM; et alApperley JF; Rahemtulla A. The combination of autologous stem cell transplantation with zoledronic acid normalises abnormal bone remodelling in multiple myeloma. Workshop on What is New in Bisphosphonates. 34:S89-S90. (Jan 2004).
• Burton CH; Ranger A; Nadal E; Avery S; Nathan I; Apperley JF; Goldman JM; Marin D. Semi-synthetic homoharringtonine (Myelostat (R)) for chronic myeloid leukemia in accelerated phase after imatinib failure. 45th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:908A-909A. AMER SOC HEMATOLOGY (16 Nov 2003). Author weblink.
• Terpos E; Politou M; Szydlo R; Nadal E; Avery S; Olavarria E; Kanfer E; Goldman JM; et alApperley JF; Rahemtulla A. Autologous stem cell transplantation normalises abnormal bone resorption through the reduction of RANKL/OPG ratio in multiple myeloma. 45th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:983A-983A. AMER SOC HEMATOLOGY (16 Nov 2003). Author weblink.
• Nadal E; Marley S; Davis JH; Avery S; Apperley J; Goldman J; Marin D. CFU-GM assays confirm adequate collections from CML patients subjected to stem cell mobilisation after achieving complete cytogenetic response on imatinib. 45th Annual Meeting of the American-Society-of-Hematology. 102:461A-461A. (16 Nov 2003).
• Pye SM; Ford JM; Clark RE; Goldman JM; Silberman S; Apperley JF. Recommendations for treatment before and during pregnancy in chronic myeloid leukaemia (CML). 45th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:908A-908A. AMER SOC HEMATOLOGY (16 Nov 2003). Author weblink.
• Payne EM; Rahemtulla A; Kanfer E; Olavarria E; Apperley JF; Goldman JM. Favourable outcome with long term follow-up of recipients of solid organ transplants following complications after allogeneic bone marrow transplantation. 45th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:468B-468B. AMER SOC HEMATOLOGY (16 Nov 2003). Author weblink.
• Avery S; Nadal E; Whiteway A; Burton CH; Moule SP; Sohal M; Rahemtulla A; Kanfer E; et alApperley JF; Craddock C; Goldman JM; Olavarria E. Combining immunotherapy and BCR-ABL tyrosine kinase inhibition: Reduced intensity conditioning stem cell transplantation followed by imatinib in patients with chronic myeloid leukemia in chronic phase. 45th Annual Meeting of the American-Society-of-Hematology. 102:969A-969A. (16 Nov 2003).
• Franceschino A; Nathan I; Lampert I; Avery S; Burton CH; Nadal E; Olavarria E; Apperley JF; et alGoldman JM; Marin D. Morphological changes masquerading as residual leukemia in CML patients responding well to imatinib. 45th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:907A-908A. AMER SOC HEMATOLOGY (16 Nov 2003). Author weblink.
• Politou M; Terpos E; Szydlo R; Laffan M; Layton M; Voskaridou E; Apperley JF; Goldman JM; et alRahemtulla A. Role of RankL, osteoprotegerin and macrophage inflammatory protein-1 alpha in monoclonal gammopathy of undetermined significance (MGUS). 45th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:442A-442A. AMER SOC HEMATOLOGY (16 Nov 2003). Author weblink.
• Avery S; Nadal E; Apperley JF; Olavarria E; Kanfer E; Rahemtulla A; Marin D; Dazzi F; et alSzydlo RM; Goldman JM. Survival beyond 10 years after allogeneic stem cell transplantation (SCT) for CML in chronic phase using HLA-identical sibling or HLA-matched unrelated donors. 45th Annual Meeting of the American-Society-of-Hematology. 102:980A-980A. (16 Nov 2003).
• Schultheis B; Fidanis E; Mahon FX; Apperley JF; Goldman JM; Melo JV. Development of a test to predict resistance to imatinib mesylate in the treatment of chronic myeloid leukemia. 45th Annual Meeting of the American-Society-of-Hematology. 102:71A-72A. (16 Nov 2003).
• Marin D; Ranger A; Kaeda J; Avery S; Nadal E; Nathan I; Burton CH; Apperley JF; et alGoldman JM. Phase I/II trial of adding semi-synthetic homoharringtonine (HHT, Myelostat (R)) in CML patients who have achieved complete cytogenetic response on imatinib. 45th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:908A-908A. AMER SOC HEMATOLOGY (16 Nov 2003). Author weblink.
• Avery S; Nadal E; Davis J; Apperley JF; Goldman JM; Marin D. Infusion of peripheral blood stem cells collected at diagnosis can improve the level of cytogenetic response in CML patients on imatinib whose treatment is limited by cytopenia. 45th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:318B-318B. AMER SOC HEMATOLOGY (16 Nov 2003). Author weblink.
• Burton CH; Avery S; Ranger A; Nadal E; Nathan I; Olavarria E; Apperley JF; Goldman JM; et alMarin D. Use of RT-PCR to monitor the possible benefit of adding interferon-alpha to imatinib for patients with CML in chronic phase. 45th Annual Meeting of the American-Society-of-Hematology. 102:908A-908A. (16 Nov 2003).
• Terpos E; Politou M; Armstrong L; Henderson C; Kanfer E; Apperley JF; Goldman JM; Rahemtulla A. The effect of bortezomib (VELCADE) on bone disease in multiple myeloma. 45th Annual Meeting of the American-Society-of-Hematology. 102:390B-390B. (16 Nov 2003).
• Bourhis JH; Bouko Y; Koscielny S; Greinix H; Derigs G; Salles G; Feremans W; Bakkus M; et alApperley J; Samson D; Gahrton G; Pico JL; Goldschmidt H. CD34(+) selection of autologous transplants following myeloablative therapy in patients with newly diagnosed myeloma shows no significant clinical benefit at 4 years: An EBMT phase III randomized study. 45th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:988A-988A. AMER SOC HEMATOLOGY (16 Nov 2003).
• Bonini C; Ciceri F; Apperley J; Slavin S; Marktel S; Bondanza A; Magnani Z; Perna SK; et alZappone E; Pescarollo A; Callegaro L; Bernardi M; Gallo-Stampino C; Salomoni M; Turchetto L; Servida P; Bregni M; Bordignon C. Hsv-Tk engineered donor lymphocytes provide early immune reconstitution and control of Gvhd after haplo-identical hemopoietic stem cell transplantation. 45th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:155A-155A. AMER SOC HEMATOLOGY (16 Nov 2003).
• Hunter HM; Peggs K; Powles R; Apperley J; Mahendra P; Cavenagh J; Littlewood T; Potter M; et alHunter A; Pagliuca A; Williams C; Cook G; Towlson K; Marks D; Russell NH. A comparison of outcome for patients undergoing non-myeloablative stem cell transplantation compared to conventional conditioning for multiple myeloma. 45th Annual Meeting and Exhibition of the American-Society-of-Hematology, 6 Dec 2003 - 9 Dec 2003. 102:732A-732A. AMER SOC HEMATOLOGY (16 Nov 2003).
• Terpos E; Szydlo R; Politou M; Hatjiharissi E; Goldman JM; Apperley JF; Rahemtulla A. Impact of nuclear factor kB ligand/osteoprotegerin pathway and macrophage inflammatory protein-1 alpha on bone disease in multiple myeloma. 32nd Annual Scientific Meeting of the International-Society-for-Experimental-Hematology. 31:192-192. (Jul 2003).
• Bonini C; Grez M; Traversari C; Ciceri F; Marktel S; Ferrari G; Dinauer M; Aiuti A; et alHagenbeek A; Apperley J; Kolb HJ; Weber M; Weissinger E; Bueren JA; Falkenburg JHF; Austin T; Kornblau S; Introna M; Slavin S; Greenberg PD; Bregni M; Mavilio E; Bordignon C. Safety of retroviral gene marking with a truncated NGF receptor. 6th Annual Meeting of the American-Society-of-Gene-Therapy, 4 Jun 2003 - 8 Jun 2003. 7:S171-S171. ACADEMIC PRESS INC ELSEVIER SCIENCE (1 May 2003).
• Dazzi F; Marktel S; Nadal E; Szydlo R; Olavarria E; Rahemtulla A; Kanfer E; Apperley J; et alGoldman J. Factors influencing the incidence of GVHD after donor lymphocyte infusions in escalating doses for chronic myeloid leukemia. 29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, 23 Mar 2003 - 26 Mar 2003. 31:S42-S42. NATURE PUBLISHING GROUP (1 Mar 2003). Author weblink.
• Terpos E; de la Fuente J; Szydlo R; Karadimitris A; Crawley C; Kanfer E; Olavarria E; Goldman JM; et alApperley JF; Rahemtulla A. Effect of autologous stem cell transplantation on bone remodelling in multiple myeloma. 29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group. 31:S83-S83. (Mar 2003).
• Crawley C; Szydlo R; Lalanacette M; Bacigalupo A; Lange A; Juliusson G; Shimoni A; Nagler A; et alGratwohl A; Mayer J; Ringden O; Boiron JM; Smith G; Niederwiesser D; Apperley J; Chronic Leukaemia Working Party EB. Sibling and unrelated reduced-intensity conditioned allogeneic transplantation for chronic myeloid leukemia. 29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group. 31:S56-S56. (Mar 2003).
• Dazzi F; Marktel S; Szydlo R; Crawley C; Olavarria E; Kanfer E; Rahemtulla A; Apperley J; et alGoldman J. Donor lymphocyte infusions for chronic myeloid leukemia: factors influencing the effective cell dose. 29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, 23 Mar 2003 - 26 Mar 2003. 31:S37-S37. NATURE PUBLISHING GROUP (1 Mar 2003). Author weblink.
• Crawley C; Szydlo R; Lalancette M; Juliusson G; Shimoni A; Nagler A; Ruutu T; Ades L; et alMichallet M; Urbano-Ispizua A; Einsele H; Chopra R; Zander A; Greinix H; Cavenagh J; Garban F; Niederwiesser D; Gahrton G; Apperley J; Chronic Leukaemia Working Party EB. Sibling and unrelated reduced-intensity conditioned allogeneic transplantation for multiple myeloma. 29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group. 31:S57-S57. (Mar 2003).
• Schmitz N; Beksac M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley JF; et alSzer J; Bradstock K; Buzyn A; Matcham J; Gratwohl A; European Grp Blood Marrow Transpla. Comparison of mobilized peripheral blood progenitor cells and bone marrow transplantation to HLA-identical siblings with standard-risk leukaemia: long term follow-up. 29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group. 31:S62-S62. (Mar 2003).
• Russell N; Szydlo R; Towlson K; Apperley J; BSBMT. Use of a national transplant registry to benchmark transplant outcome against the EBMT database. 29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group. 31:S217-S217. (Mar 2003).
• Bourhis JH; Bouko Y; Koscielny S; Greinix H; Derigs G; Salles G; Feremans W; Bakkus M; et alApperley J; Samson D; Gahrton G; Pico J; Goldschmidt H. CD34+selection of autologous transplants in patients with newly diagnosed myeloma: final report of an EBMT phase III randomized study. 29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, 23 Mar 2003 - 26 Mar 2003. 31:S8-S8. NATURE PUBLISHING GROUP (1 Mar 2003).
• Drake M; Morris C; Hagman A; Lopponen T; Bjorkstrand B; Gahrton G; Apperley J. Autologous transplantation in primary plasma cell leukemia. 29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, 23 Mar 2003 - 26 Mar 2003. 31:S9-S9. NATURE PUBLISHING GROUP (1 Mar 2003).
• Morris C; Drake M; Hagman A; Lopponen T; Bjorkstrand B; Gahrton G; Apperley J. Outcome of autologous transplantation in rare myelomas. 29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, 23 Mar 2003 - 26 Mar 2003. 31:S80-S81. NATURE PUBLISHING GROUP (1 Mar 2003).
• Feng L; Drummond MW; Byrne J; Shepherd PCA; Apperley JF; O'Brien SG; Craddock CF; Clark RE; et alCervantes F; Lennard AL; Holyoake TL; Szydlo RM; Goldman JM; Kaeda JS. Molecular monitoring of complete cytogenetic responders following treatment with imatinib (STI571, Gleevec) for CML: A report from the UKSTI571 study group. 44th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2002 - 10 Dec 2002. 100:368A-368A. AMER SOC HEMATOLOGY (16 Nov 2002). Author weblink.
• Crawley C; Lalanacette M; Szydlo R; Gilleece M; Juliusson G; Michallet M; Mackinnon S; Einsele H; et alReiffers J; Zander AR; Carreras E; Carella A; Gratwohl A; Sotto JJ; Cavenagh JD; Niederweiser D; Ciceri F; Apperley JF. Reduced intensity conditioned allografts for myeloma: A study from the Chronic Leukaemia Working Party of the EBMT. 44th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2002 - 10 Dec 2002. 100:144A-144A. AMER SOC HEMATOLOGY (16 Nov 2002). Author weblink.
• Guglielmi C; Arcese W; Dazzi F; Brand R; Bunjes D; Verdonck LF; Schattenberg A; Kolb HJ; et alLjungman P; Devergie A; Bacigalupo A; Gomez M; Michallet M; Elmaagacli A; Gratwohl A; Apperley J; Niederwieser D; Chronic Leukemia Working Party. Low initial cell dose and escalating dose regimen is the best method of administering unmanipulated donor lymphocytes for relapsed chronic myelogenous leukemia. 44th Annual Meeting of the American-Society-of-Hematology. 100:635A-635A. (16 Nov 2002).
• Marktel S; Crawley C; Szydlo R; Rahemtulla A; Kanfer E; Olavarria E; Marin D; Apperley JF; et alGoldman JM. Donor lymphocyte infusions for chronic myeloid leukemia: Factors influencing the effective cell dose. 44th Annual Meeting of the American-Society-of-Hematology. 100:785A-785A. (16 Nov 2002).
• Marin D; Marktel S; Foot N; Bua M; Olavarria E; Goldman J; Apperley J. G-CSF reverses cytopenia and may increase cytogenetic responses in patients with CML treated with imatinib mesylate. 44th Annual Meeting of the American-Society-of-Hematology. 100:782A-782A. (16 Nov 2002).
• Terpos E; Hatziharissi E; Szydlo R; de la Fuente J; Karadimitris A; Kanfer E; Olavarria E; Goldman JM; et alApperley JF; Rahemtulla A. Autologous stem cell transplantation improves abnormal bone turnover in multiple myeloma. 44th Annual Meeting of the American-Society-of-Hematology. 100:434A-434A. (16 Nov 2002).
• Marktel S; Marin D; Foot N; Szydlo R; Bua M; Olavarria E; Goldman J; Apperley J. Chronic myeloid leukemia in chronic phase responding to imatinib: The occurrence of additional cytogenetic abnormalities predicts disease progression. 44th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2002 - 10 Dec 2002. 100:785A-785A. AMER SOC HEMATOLOGY (16 Nov 2002). Author weblink.
• Crawley CR; Lalancette M; Szydlo R; Bacigalupo A; Lange A; Juliusson G; Ringden O; Gratwohl A; et alMayer J; Hansz J; Zander AR; Vitek A; Brune ML; Urbano-Ispizua A; Niederwieser D; Mufti G; Apperley JF. Reduced intensity conditioned allografts for chronic myeloid leukaemia: A study from the chronic leukaemia working party of the EBMT. 44th Annual Meeting of the American-Society-of-Hematology. 100:781A-781A. (16 Nov 2002).
• Terpos E; Szydlo R; Hatziharissi E; de la Fuente J; Viniou N; Meletis J; Yataganas X; Apperley JF; et alGoldman JM; Rahemtulla A. Prognostic value of markers of bone turnover in multiple myeloma. 44th Annual Meeting of the American-Society-of-Hematology. 100:372B-373B. (16 Nov 2002).
• Marin D; Marktel S; O'Brien S; Olavarria E; Apperley J; Goldman J. Use of imatinib mesylate in patients with CML in chronic phase resistant to interferon-alfa: Factors defined at start of therapy that predict disease progression and survival. 44th Annual Meeting of the American-Society-of-Hematology, 6 Dec 2002 - 10 Dec 2002. 100:326B-326B. AMER SOC HEMATOLOGY (16 Nov 2002). Author weblink.
• Elliston DJ; Miller-Reynolds AR; Melo JV; Apperley JF. The use of suicide genes in the treatment of chronic myeloid leukemia. 44th Annual Meeting of the American-Society-of-Hematology. 100:486B-486B. (16 Nov 2002).
• Marin D; Marktel S; Szydlo R; Olavarria E; Sepherd P; Goldman J; Apperley J. Case-match study of patients with CML in chronic phase resistant to or intolerant of IFN treated with imatinib and comparable patients continuing treatment with IFN: Patients achieving cytogenetic responses after 6 months on imatinib survive longer than controls. 44th Annual Meeting of the American-Society-of-Hematology. 100:782A-783A. (16 Nov 2002).
• Russell-Jones R; Child F; Olavarria E; Whittaker S; Spittle M; Apperley J. Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: Predictors of disease-free survival. Conference on Basic and Clinical Relevant Biology of Cutaneous T Cell Lymphoma. 941:147-154. (2001).
• Abusedra A; Vulliamy T; Gilmore JD; Bybee A; Hawkins PN; Laffan M; Apperley JF. Immunoglobulin gene rearrangement in AL amyloidosis. VIIIth International Symposium on Amyloidosis, 7 Aug 1998 - 11 Aug 1998. 124-126. PARTHENON PUBLISHING GROUP LTD (1 Jan 1999). Author weblink.
• Gillmore JD; Apperley JF; Craddock C; Madhoo S; Pepys MB; Hawkins PN. High-dose melphalan and stem cell rescue for AL amyloidosis. VIIIth International Symposium on Amyloidosis. 102-104. (1999).
• DEWITTE T; OBERG G; OR R; GRATWOHL A; NIEDERWISER D; VANBEIZEN A; HERMANS J; RUNDE V; et alMELONI G; MORGAN G; APPERLEY J; VERNANT J; KOLB H; VOSSEN J; LJUNGMAN P; BEELEN D; FERRANT A; ARNOLD R; CAHN J; BACIGALUPO A; FIBBE W; GORIN N. AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR LEUKEMIA FOLLOWING MDS - A SURVEY FOR THE WORKING PARTIES ON CHRONIC AND ACUTE-LEUKEMIA OF THE EUROPEAN-SOCIETY FOR BONE-MARROW TRANSPLANTATION. International Symposium on Current Problems of Childhood Panmyelopathies - Focus on Myelodysplastic Syndrome, 8 Sep 1994 - 12 Sep 1994. 40:15-15. MINISTERSTVO ZDRAVOOKHRANENIYA (1 Mar 1995).
• Apperley JF; Roberts IAG. The current status of bone marrow transplantation and gene therapy in the management of the haemoglobinopathies. 19th International Symposium on Blood Transfusion - Hereditary Diseases and Blood Transfusion, 1994. 30:71-80. KLUWER ACADEMIC PUBL (1 Jan 1995). Author weblink.
• REIFFERS J; GOLDMAN J; MELONI G; CAHN JY; FABERES C; APPERLEY J. AUTOLOGOUS TRANSPLANTATION IN CHRONIC MYELOGENOUS LEUKEMIA - EUROPEAN RESULTS. 2nd International Symposium on Autografting for Chronic Myeloid Leukaemia, 26 Jun 1994 - 27 Jun 1994. 14:S51-S54. STOCKTON PRESS (1 Jan 1994).
• APPERLEY J; BANDINI G. CHRONIC LEUKEMIA-(I). 19th Annual Meeting of the EBMT/9th Meeting of the Nurses-Group, 17 Jan 1993 - 21 Jan 1993. 12:S24-S26. STOCKTON PRESS (1 Jan 1993).
• GORDON MY; HEALY LE; CRADDOCK CF; APPERLEY JF. EXPERIMENTAL-MODELS FOR PERIPHERAL-BLOOD STEM-CELL AUTOGRAFTING. 2ND INTERNATIONAL SYMP ON PERIPHERAL BLOOD STEM CELL AUTOGRAFTS, 29 Sep 1991 - 2 Oct 1991. 10:2-5. ALPHAMED PRESS (1 Jan 1992). Author weblink.
• LUSKEY BD; BING L; APPERLEY JF; ORKIN SH; WILLIAMS DA. GENE-TRANSFER INTO MURINE HEMATOPOIETIC STEM-CELLS AND BONE-MARROW STROMAL CELLS. 6TH SYMP ON COOLEYS ANEMIA, 13 Mar 1990 - 15 Mar 1990. 612:398-406. NEW YORK ACAD SCIENCES (1 Jan 1990). Author weblink.

Patents

• Vectors for gene therapy. Patent number: WO 01/79502 (PCT - International Patent Application). Garin M. Filed: 25 Oct 2001.